

# CITATION REPORT

List of articles citing

## Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

DOI: 10.1016/j.cell.2020.03.045  
Cell, 2020, 181, 894-904.e9.

**Source:** <https://exaly.com/paper-pdf/77535098/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #    | Paper  | IF | Citations |
|------|--|----|-----------|
| 2004 | Predicting susceptibility to SARS-CoV-2 infection based on structural differences in ACE2 across species. <b>2020</b> , 34, 15946-15960  |    | 24        |
| 2003 | Flexible, Functional, and Familiar: Characteristics of SARS-CoV-2 Spike Protein Evolution. <b>2020</b> , 11, 2112  |    | 18        |
| 2002 | Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses. <b>2020</b> , 7, 226  |    | 8         |
| 2001 | The management of allergic diseases in children during the SARS-CoV-2 pandemic. <b>2020</b> , 7, 153-161   |    | 0         |
| 2000 | Drug Weaponry to Fight Against SARS-CoV-2. <b>2020</b> , 7, 204  |    | 2         |
| 1999 | SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors. <b>2020</b> , 289, 198154   |    | 10        |
| 1998 | ACE2 enhance viral infection or viral infection aggravate the underlying diseases. <b>2020</b> , 18, 2100-2106   |    | 4         |
| 1997 | Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain. <b>2020</b> , 21, 100451 |    | 11        |
| 1996 | Syncytia formation by SARS-CoV-2-infected cells. <b>2020</b> , 39, e106267   |    | 167       |
| 1995 | Nicotinic Receptor Subunits Atlas in the Adult Human Lung. <b>2020</b> , 21,   |    | 4         |
| 1994 | PI3K inhibition as a Potential Therapeutic Target in COVID-19. <b>2020</b> , 11, 2094  |    | 15        |
| 1993 | Repurposing anticancer drugs for the management of COVID-19. <b>2020</b> , 141, 40-61  |    | 30        |
| 1992 | Nucleic acid-based therapy for coronavirus disease 2019. <b>2020</b> , 6, e05007   |    | 17        |
| 1991 | The Immune Nature of Platelets Revisited. <b>2020</b> , 34, 209-220  |    | 26        |
| 1990 | Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors. <b>2020</b> , 13,  |    | 8         |
| 1989 | The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression. <b>2020</b> , 18, 2438-2444  |    | 18        |
| 1988 | Computational biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and implications for infectivity. <b>2020</b> , 18, 2573-2582  |    | 26        |

|      |  |          |
|------|--|----------|
| 1987 | Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. <b>2020</b> , 130, 215-217  | 18       |
| 1986 | Cardiac inflammation in COVID-19: Lessons from heart failure. <b>2020</b> , 260, 118482  | 40       |
| 1985 | The influence of ABO blood groups on COVID-19 susceptibility and severity: A molecular hypothesis based on carbohydrate-carbohydrate interactions. <b>2020</b> , 144, 110155   | 30       |
| 1984 | Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , <b>2020</b> , 183, 1024-1042.e21   | 56.2 601 |
| 1983 | Identification of twenty-five mutations in surface glycoprotein (Spike) of SARS-CoV-2 among Indian isolates and their impact on protein dynamics. <b>2020</b> , 21, 100891   | 10       |
| 1982 | Identifying pathophysiological bases of disease in COVID-19. <b>2020</b> , 5, 15   | 4        |
| 1981 | Thermodynamics of the Interaction between the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus-2 and the Receptor of Human Angiotensin-Converting Enzyme 2. Effects of Possible Ligands. <b>2020</b> , 11, 9272-9281 | 18       |
| 1980 | Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor. <b>2020</b> , 8,   | 9        |
| 1979 | Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. <b>2020</b> , 50, 2025-2040  | 111      |
| 1978 | Strategies and Advances in Combating COVID-19 in China. <b>2020</b> , 6, 1076-1084   | 8        |
| 1977 | 2020 update on human coronaviruses: One health, one world. <b>2020</b> , 8, 100043   | 12       |
| 1976 | Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2. <b>2020</b> , 27, 905-919.e10   | 92       |
| 1975 | The epigenetic implication in coronavirus infection and therapy. <b>2020</b> , 12, 156   | 29       |
| 1974 | Identifying Pathways and Networks Associated With the SARS-CoV-2 Cell Receptor ACE2 Based on Gene Expression Profiles in Normal and SARS-CoV-2-Infected Human Tissues. <b>2020</b> , 7, 568954                                     | 14       |
| 1973 | Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <b>2020</b> , 33, 108322  | 35       |
| 1972 | Targeting Proteases for Treating COVID-19. <b>2020</b> , 19, 4316-4326   | 36       |
| 1971 | Engineered ACE2 receptor traps potentially neutralize SARS-CoV-2. <b>2020</b> , 117, 28046-28055   | 110      |
| 1970 | An aberrant STAT pathway is central to COVID-19. <b>2020</b> , 27, 3209-3225   | 95       |

|      |  |     |
|------|--|-----|
| 1969 | Furin: A Potential Therapeutic Target for COVID-19. <b>2020</b> , 23, 101642   | 86  |
| 1968 | Molecular dynamics analysis predicts ritonavir and nalmefegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. <b>2020</b> , 1-10  | 7   |
| 1967 | Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. <b>2020</b> , 41, 1006-1022   | 46  |
| 1966 | Fighting COVID-19 Using Molecular Dynamics Simulations. <b>2020</b> , 6, 1654-1656   | 27  |
| 1965 | Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. <b>2020</b> , 6,   | 44  |
| 1964 | The potential of lactoferrin, ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-19. <b>2020</b> , 15, 609-624   | 13  |
| 1963 | Potential Therapeutic Effect of Traditional Chinese Medicine on Coronavirus Disease 2019: A Review. <b>2020</b> , 11, 570893   | 5   |
| 1962 | Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach. <b>2020</b> , 320, 114493            | 46  |
| 1961 | Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. <b>2020</b> , 155, 105522  | 17  |
| 1960 | Porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines. <b>2020</b> , 149, 104553   | 10  |
| 1959 | Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. <b>2020</b> , 288, 198141   | 59  |
| 1958 | Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins. <b>2020</b> , 19, 4587-4608  | 26  |
| 1957 | Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. <b>2020</b> , 6, 68   | 69  |
| 1956 | Correlation analysis of coagulation dysfunction and liver damage in patients with novel coronavirus pneumonia: a single-center, retrospective, observational study. <b>2020</b> , 125, 293-296 | 8   |
| 1955 | Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines. <b>2020</b> , 19, 781-784   |     |
| 1954 | Atomistic simulation reveals structural mechanisms underlying D614G spike glycoprotein-enhanced fitness in SARS-COV-2. <b>2020</b> , 41, 2158-2161   | 30  |
| 1953 | Natural derivatives with dual binding potential against SARS-CoV-2 main protease and human ACE2 possess low oral bioavailability: a brief computational analysis. <b>2021</b> , 39, 5819-5830  | 9   |
| 1952 | Distinct conformational states of SARS-CoV-2 spike protein. <b>2020</b> , 369, 1586-1592   | 552 |

|      |   |     |
|------|---|-----|
| 1951 | Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection. <b>2020</b> , 319, C500-C509                               | 4   |
| 1950 | Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. <b>2020</b> , 8, 384  | 7   |
| 1949 | The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. <b>2020</b> , 15, 359-386  | 199 |
| 1948 | Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. <b>2020</b> , 58, 102890   | 15  |
| 1947 | SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes. <b>2020</b> , 69, 1875-1886   | 35  |
| 1946 | AGTR2, One Possible Novel Key Gene for the Entry of SARS-CoV-2 Into Human Cells. <b>2021</b> , 18, 1230-1233  | 26  |
| 1945 | Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. <b>2020</b> , 12, 1647-1656  | 33  |
| 1944 | The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. <b>2020</b> , 510, 186-190   | 19  |
| 1943 | The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. <i>Cell</i> , <b>2020</b> , 182, 1284-1294.e8  | 199 |
| 1942 | Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients. <b>2020</b> , 53, 685-696.e3                                   | 148 |
| 1941 | Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. <b>2020</b> , 11, 3618  | 89  |
| 1940 | New strategies for treatment of COVID-19 and evolution of SARS-CoV-2 according to biodiversity and evolution theory. <b>2020</b> , 7, 226-232   | 3   |
| 1939 | ACE2, the Receptor that Enables Infection by SARS-CoV-2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators. <b>2020</b> , 15, 1682-1690               | 17  |
| 1938 | Current and Future Direct-Acting Antivirals Against COVID-19. <b>2020</b> , 11, 587944  | 10  |
| 1937 | Profile of SARS-CoV-2. <b>2020</b> , 132, 635-644   | 2   |
| 1936 | SSSCPreds: Deep Neural Network-Based Software for the Prediction of Conformational Variability and Application to SARS-CoV-2. <b>2020</b> , 5, 30556-30567  | 3   |
| 1935 | Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity. <b>2020</b> , 26, 341 | 17  |
| 1934 | Natural Products Database Screening for the Discovery of Naturally Occurring SARS-Cov-2 Spike Glycoprotein Blockers. <b>2020</b> , 5, 13309-13317   | 11  |

|      |  |     |
|------|--|-----|
| 1933 | Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. <b>2020</b> , 7, 608259   | 14  |
| 1932 | Computational Analysis of Targeting SARS-CoV-2, Viral Entry Proteins ACE2 and TMPRSS2, and Interferon Genes by Host MicroRNAs. <b>2020</b> , 11,                                     | 22  |
| 1931 | Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection. <b>2021</b> , 421, 127742  | 44  |
| 1930 | Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. <b>2020</b> , 28, 867-879.e5 | 168 |
| 1929 | SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. <b>2020</b> , 10, 587269   | 199 |
| 1928 | SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. <b>2020</b> , 11, 6013   | 450 |
| 1927 | Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses. <b>2020</b> , 8,  | 10  |
| 1926 | Molecular docking and dynamic simulations of some medicinal plants compounds against SARS-CoV-2: an in silico study. <b>2020</b> , 14, 1563-1570                                     | 10  |
| 1925 | Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. <b>2020</b> , 21, 1311-1329                            | 16  |
| 1924 | A comprehensive review of the impact of COVID-19 on human reproductive biology, assisted reproduction care and pregnancy: a Canadian perspective. <b>2020</b> , 13, 140              | 39  |
| 1923 | Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. <b>2020</b> , 7, 605236  | 60  |
| 1922 | Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development. <b>2020</b> , 9,  | 0   |
| 1921 | Rare case of COVID-19 presenting as acute abdomen and sepsis. <b>2020</b> , 38, 100818   | 4   |
| 1920 | Investigation of the Effect of Temperature on the Structure of SARS-CoV-2 Spike Protein by Molecular Dynamics Simulations. <b>2020</b> , 7, 583523                                   | 21  |
| 1919 | Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Protease. <b>2020</b> , 25,   | 23  |
| 1918 | Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. <b>2020</b> , 28, 880-891.e8  | 70  |
| 1917 | Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. <b>2020</b> ,   | 57  |
| 1916 | Identifying the Zoonotic Origin of SARS-CoV-2 by Modeling the Binding Affinity between the Spike Receptor-Binding Domain and Host ACE2. <b>2020</b> , 19, 4844-4856                  | 15  |

|      |   |     |
|------|---|-----|
| 1915 | Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. <b>2020</b> , 11, 6122  | 141 |
| 1914 | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. <b>2020</b> , 588, 682-687   | 651 |
| 1913 | SARS-CoV2 infectivity is potentially modulated by host redox status. <b>2020</b> , 18, 3705-3711  | 12  |
| 1912 | In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. <b>2020</b> , 25,  | 8   |
| 1911 | COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. <b>2020</b> , 11, 588409  | 11  |
| 1910 | ACE2 partially dictates the host range and tropism of SARS-CoV-2. <b>2020</b> , 18, 4040-4047   | 14  |
| 1909 | Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). <b>2020</b> , 4, 121-131   |     |
| 1908 | Efforts at COVID-19 Vaccine Development: Challenges and Successes. <b>2020</b> , 8,   | 47  |
| 1907 | Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2. <b>2020</b> , 3, 2000156  | 9   |
| 1906 | A Hydrophobic-Interaction-Based Mechanism Triggers Docking between the SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2. <b>2020</b> , 4, 2000067         | 9   |
| 1905 | Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. <b>2020</b> , 329                            | 4   |
| 1904 | Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. <b>2020</b> , 12,  | 20  |
| 1903 | Peptide and peptide-based inhibitors of SARS-CoV-2 entry. <b>2020</b> , 167, 47-65  | 63  |
| 1902 | Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization. <b>2020</b> , 18, 3402-3414 | 36  |
| 1901 | Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor. <b>2020</b> , 18, 3518-3527       | 30  |
| 1900 | Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Reveals Mosaic Pattern of Phylogeographical Distribution. <b>2020</b> , 5,                        | 35  |
| 1899 | COVID-19 and Obesity: Dangerous Liaisons. <b>2020</b> , 9,  | 64  |
| 1898 | Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer. <b>2020</b> , 11, 5289-5292                  | 17  |

|      |   |     |
|------|---|-----|
| 1897 | Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning. <b>2020</b> , 40, 603-614   | 7   |
| 1896 | Elucidating the microscopic and computational techniques to study the structure and pathology of SARS-CoVs. <b>2020</b> , 83, 1623-1638   | 5   |
| 1895 | Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. <b>2020</b> , 130, 104572   | 49  |
| 1894 | Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. <b>2020</b> , 27, 942-949   | 89  |
| 1893 | [Tracing the origins of SARS-COV-2 in coronavirus phylogenies]. <b>2020</b> , 36, 783-796   | 7   |
| 1892 | Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review. <b>2020</b> , 13, 2657-2665  | 40  |
| 1891 | The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting. <b>2020</b> , 17,  | 25  |
| 1890 | Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. <b>2020</b> , 29, 1-15   | 21  |
| 1889 | Geographic and Genomic Distribution of SARS-CoV-2 Mutations. <b>2020</b> , 11, 1800   | 333 |
| 1888 | Quantitative determination of mechanical stability in the novel coronavirus spike protein. <b>2020</b> , 12, 16409-16413  | 13  |
| 1887 | Analysis of ACE2 Gene-Encoded Proteins Across Mammalian Species. <b>2020</b> , 7, 457   | 5   |
| 1886 | A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0. <b>2020</b> , 21, | 17  |
| 1885 | COVID-19 and SARS-CoV-2. Modeling the present, looking at the future. <b>2020</b> , 869, 1-51   | 90  |
| 1884 | A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <b>2020</b> , 584, 120-124   | 844 |
| 1883 | Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike. <b>2020</b> , 18, 2117-2131   | 17  |
| 1882 | SARS-CoV-2 and cancer: Are they really partners in crime?. <b>2020</b> , 89, 102068   | 42  |
| 1881 | Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System. <b>2020</b> , 8, 862  | 49  |
| 1880 | Coronaviruses and the central nervous system. <b>2020</b> , 26, 459-473   | 24  |



|      |   |          |
|------|---|----------|
| 1879 | Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. <b>2020</b> , 39, 268-284 | 27       |
| 1878 | The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. <b>2020</b> , 11, 1991  | 56       |
| 1877 | In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy. <b>2020</b> , 26, 663-669  | 36       |
| 1876 | An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection. <b>2020</b> , 181, 104882   | 25       |
| 1875 | In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2. <b>2020</b> , 886, 173448          | 51       |
| 1874 | Crystal structure of SARS-CoV-2 nsp10/nsp16 2'-O-methylase and its implication on antiviral drug design. <b>2020</b> , 5, 131   | 46       |
| 1873 | Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. <b>2020</b> , 41, 1141-1149  | 739      |
| 1872 | Vascular inflammation and endothelial injury in SARS-CoV-2 infection: The overlooked regulatory cascades implicated by the ACE2 gene cluster. <b>2020</b> ,                               | 10       |
| 1871 | "Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. <b>2020</b> , 8,                             | 12       |
| 1870 | SARS-CoV-2-specific ELISA development. <b>2020</b> , 484-485, 112832  | 45       |
| 1869 | Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. <b>2020</b> , 584, 450-456  | 848      |
| 1868 | Impact of COVID-19 and other viruses on reproductive health. <b>2020</b> , 52, e13791   | 29       |
| 1867 | COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. <b>2020</b> , 17, 22   | 24       |
| 1866 | Emerging Pandemic Diseases: How We Got to COVID-19. <i>Cell</i> , <b>2020</b> , 182, 1077-1092  | 56.2 198 |
| 1865 | Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors. <b>2020</b> , 9,  | 4        |
| 1864 | Antiviral Polymers: Past Approaches and Future Possibilities. <b>2020</b> , 53, 9158-9186   | 40       |
| 1863 | Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods. <b>2020</b> , 45, 1  | 24       |
| 1862 | The Perfect Storm: COVID-19 Health Disparities in US Blacks. <b>2021</b> , 8, 1153-1160   | 27       |

|      |   |     |
|------|---|-----|
| 1861 | Targeting the glycan of receptor binding domain with jacalin as a novel approach to develop a treatment against COVID-19. <b>2020</b> , 7, 200844   | 2   |
| 1860 | Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. <b>2020</b> , 11,   | 69  |
| 1859 | Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity. <b>2020</b> , 9, e1189 | 23  |
| 1858 | ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. <b>2020</b> , 7, 588618  | 49  |
| 1857 | Genetic Spectrum and Distinct Evolution Patterns of SARS-CoV-2. <b>2020</b> , 11, 593548  | 23  |
| 1856 | Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology. <b>2021</b> , 21, 13-127  | 16  |
| 1855 | Probing infectious disease by single-cell RNA sequencing: Progresses and perspectives. <b>2020</b> , 18, 2962-2971  | 8   |
| 1854 | A graph-based approach identifies dynamic H-bond communication networks in spike protein S of SARS-CoV-2. <b>2020</b> , 212, 107617   | 19  |
| 1853 | Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations. <b>2020</b> , 124, 10034-10047   | 39  |
| 1852 | High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein. <b>2020</b> , 1-14   | 16  |
| 1851 | Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach. <b>2020</b> , 38, 100786   | 30  |
| 1850 | Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. <b>2020</b> , 19, 4291-4315  | 36  |
| 1849 | ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients. <b>2020</b> , 29, 963689720968749  | 14  |
| 1848 | Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. <b>2020</b> , 11, 5413   | 105 |
| 1847 | Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19. <b>2020</b> , 120, 1629-1641   | 25  |
| 1846 | High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. <b>2020</b> , 295, 18579-18588   | 47  |
| 1845 | The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. <b>2020</b> , 11, 576622  | 137 |
| 1844 | COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Relevance. <b>2020</b> , 9,   | 61  |

|      |   |      |     |
|------|---|------|-----|
| 1843 | Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , <b>2020</b> , 183, 1367-1382.e17                              | 56.2 | 217 |
| 1842 | Coronavirus disease 2019 and the pancreas. <b>2020</b> , 20, 1567-1575  |      | 28  |
| 1841 | Quantifying the adhesive strength between the SARS-CoV-2 S-proteins and human receptor and its effect in therapeutics. <b>2020</b> , 10, 17538  |      | 7   |
| 1840 | Comparative ACE2 variation and primate COVID-19 risk. <b>2020</b> , 3, 641  |      | 83  |
| 1839 | The past, present and future of RNA respiratory viruses: influenza and coronaviruses. <b>2020</b> , 78,   |      | 5   |
| 1838 | An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. <b>2020</b> , 11, 4420  |      | 151 |
| 1837 | Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients. <b>2020</b> , 40, 321-330  |      | 15  |
| 1836 | Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. <b>2020</b> , 11, 4417   |      | 195 |
| 1835 | (SARS-CoV-2) Exhibits High Predicted Binding Affinity to ACE2 from Lagomorphs (Rabbits and Pikas). <b>2020</b> , 10,  |      | 10  |
| 1834 | The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS-CoV-2 targets. <b>2020</b> , 34, 3420-3433   |      | 17  |
| 1833 | Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. <b>2020</b> , 6, 1722-1734  |      | 340 |
| 1832 | Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <b>2020</b> , 370, 950-957   |      | 314 |
| 1831 | Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. <b>2020</b> , 5, 212   |      | 59  |
| 1830 | Molecular Architecture of the SARS-CoV-2 Virus. <i>Cell</i> , <b>2020</b> , 183, 730-738.e13  | 56.2 | 385 |
| 1829 | Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. <i>Cell</i> , <b>2020</b> , 183, 1013-1023.e13 | 56.2 | 145 |
| 1828 | Bioactive Virus-Mimicking Nanovesicles From Dendrimersomes: A Novel Approach to Understanding SARS-CoV-2 Host-Interactions to Better Design Therapeutics. <b>2020</b> , 7, 188              |      | 4   |
| 1827 | Nanoparticle-Based Strategies to Combat COVID-19. <b>2020</b> , 3, 8557-8580  |      | 90  |
| 1826 | Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. <b>2020</b> , 10, 14214  |      | 117 |

|      |   |     |
|------|---|-----|
| 1825 | Is periodontal disease a risk factor for developing severe Covid-19 infection? The potential role of Galectin-3. <b>2020</b> , 245, 1425-1427   | 15  |
| 1824 | Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. <b>2020</b> , 76, 1339-1349                              | 86  |
| 1823 | Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic Targets. <b>2020</b> , 11, 1821  | 33  |
| 1822 | Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). <b>2020</b> , 46, 3-16  | 178 |
| 1821 | Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant. <b>2020</b> , 32, e2004210   | 26  |
| 1820 | Human animal interface of SARS-CoV-2 (COVID-19) transmission: a critical appraisal of scientific evidence. <b>2020</b> , 44, 119-130  | 34  |
| 1819 | Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. <b>2020</b> , 295, 15174-15182  | 19  |
| 1818 | Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. <b>2020</b> , 14, 29   | 27  |
| 1817 | Nanotechnology-Based Approaches for the Detection of SARS-CoV-2. <b>2020</b> , 2,   | 13  |
| 1816 | Mass Spectrometry and Structural Biology Techniques in the Studies on the Coronavirus-Receptor Interaction. <b>2020</b> , 25,   | 6   |
| 1815 | Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System. <b>2020</b> , 8, 559841  | 23  |
| 1814 | Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. <b>2020</b> , 8, 572885                    | 32  |
| 1813 | The Wide Spectrum of COVID-19 Clinical Presentation in Children. <b>2020</b> , 9,   | 17  |
| 1812 | A Concise Review of Baseline Facts of SARS-CoV-2 for Interdisciplinary Research. <b>2020</b> , 5, 10897-10923   | 4   |
| 1811 | Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia. <b>2020</b> , 1-11  | 35  |
| 1810 | Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective. <b>2020</b> , 11, 570018 | 23  |
| 1809 | Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity?. <b>2020</b> , 3, 1023-1026   | 36  |
| 1808 | De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. <b>2020</b> , 370, 426-431   | 219 |

|      |   |     |
|------|---|-----|
| 1807 | An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. <b>2020</b> , 10, 13866  | 61  |
| 1806 | Comparison of nonhuman primates identified the suitable model for COVID-19. <b>2020</b> , 5, 157  | 122 |
| 1805 | COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. <b>2020</b> , 16, e1008762  | 96  |
| 1804 | COVID-19 diagnostic testing: Technology perspective. <b>2020</b> , 10, e158   | 38  |
| 1803 | Plasmin Cascade Mediates Thrombotic Events in SARS-CoV-2 Infection via Complement and Platelet-Activating Systems. <b>2020</b> , 1, 220-227   | 1   |
| 1802 | Structural basis for the multimerization of nonstructural protein nsp9 from SARS-CoV-2. <b>2020</b> , 1, 5  | 10  |
| 1801 | Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. <b>2020</b> , 21, | 39  |
| 1800 | Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. <b>2020</b> , 14, 11821-11830   | 33  |
| 1799 | COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. <b>2020</b> , 6, 18   | 66  |
| 1798 | SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure. <b>2020</b> , 9,  | 16  |
| 1797 | Comparative molecular dynamics study of the receptor-binding domains in SARS-CoV-2 and SARS-CoV and the effects of mutations on the binding affinity. <b>2020</b> , 1-20                              | 16  |
| 1796 | identification of SARS-CoV-2 spike (S) protein-ACE2 complex inhibitors from eight species and cultivars analyzed by LC-MS.. <b>2020</b> , 10, 43103-43108   | 8   |
| 1795 | Humoral Responses and Serological Assays in SARS-CoV-2 Infections. <b>2020</b> , 11, 610688   | 90  |
| 1794 | Design, Expression, Purification, and Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain Construct. <b>2020</b> , 8, 618615   | 3   |
| 1793 | Surveying the Side-Chain Network Approach to Protein Structure and Dynamics: The SARS-CoV-2 Spike Protein as an Illustrative Case. <b>2020</b> , 7, 596945  | 4   |
| 1792 | Characterization of Structural and Energetic Differences between Conformations of the SARS-CoV-2 Spike Protein. <b>2020</b> , 13,   | 33  |
| 1791 | Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses. <b>2020</b> , 11,                              | 45  |
| 1790 | Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients. <b>2020</b> , 9,  | 12  |

|      |   |     |
|------|---|-----|
| 1789 | Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. <b>2020</b> , 1, 100142  | 76  |
| 1788 | Interpretation of SARS-CoV-2 behaviour on different substrates and denaturation of virions using ethanol: an atomic force microscopy study.. <b>2020</b> , 10, 44079-44086                        | 5   |
| 1787 | COVID-19;-The origin, genetics,and management of the infection of mothers and babies. <b>2020</b> , 7, 371-388  |     |
| 1786 | Chasing COVID-19 through SARS-CoV-2 spike glycoprotein. <b>2020</b> , 31, 1-9   | 7   |
| 1785 | Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation. <b>2020</b> , 1-11   | 22  |
| 1784 | Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2. <b>2020</b> , 7, 591873   | 30  |
| 1783 | Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. <b>2020</b> , 9,                                      | 57  |
| 1782 | The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. <b>2020</b> , 21,  | 10  |
| 1781 | Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. <b>2020</b> , 13,   | 12  |
| 1780 | A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19. <b>2020</b> , 11, 556335                               |     |
| 1779 | Structures and distributions of SARS-CoV-2 spike proteins on intact virions. <b>2020</b> , 588, 498-502   | 461 |
| 1778 | Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection and Inhibition. <b>2020</b> , 11, 2098  | 5   |
| 1777 | Carcinoembryonic Antigen: A Potential Biomarker to Evaluate the Severity and Prognosis of COVID-19. <b>2020</b> , 7, 579543   | 3   |
| 1776 | Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2. <b>2020</b> , 21, | 14  |
| 1775 | Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches. <b>2020</b> , 1-17  | 13  |
| 1774 | Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. <b>2020</b> , 370, 1479-1484  | 138 |
| 1773 | An Early Pandemic Analysis of SARS-CoV-2 Population Structure and Dynamics in Arizona. <b>2020</b> , 11,  | 18  |
| 1772 | Man-Specific, GalNAc/T/Tn-Specific and Neu5Ac-Specific Seaweed Lectins as Glycan Probes for the SARS-CoV-2 (COVID-19) Coronavirus. <b>2020</b> , 18,  | 10  |

|      |  |     |
|------|--|-----|
| 1771 | Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. <b>2020</b> , 8,  | 26  |
| 1770 | SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution. <b>2020</b> , 6, 2238-2249   | 82  |
| 1769 | Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. <b>2020</b> , 11, 5588  | 73  |
| 1768 | Emerging of composition variations of SARS-CoV-2 spike protein and human ACE2 contribute to the level of infection: approaches. <b>2020</b> , 1-12   | 2   |
| 1767 | De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. <b>2020</b> , 370, 1208-1214   | 98  |
| 1766 | An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. <b>2020</b> , 370, 1473-1479   | 166 |
| 1765 | Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus. <b>2020</b> , 112, 5331-5342  | 13  |
| 1764 | Docking and QSAR of Aminothiourreas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface. <b>2020</b> , 25,   | 4   |
| 1763 | Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy. <b>2020</b> , 3, 95-100                                   | 43  |
| 1762 | Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIOa Living Working Document. <b>2020</b> , 13, e007175   | 27  |
| 1761 | The Novel Coronavirus - Latest Findings. <b>2020</b> , 13, 819-828   | 4   |
| 1760 | Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank. <b>2020</b> , 287, 3703-3718   | 25  |
| 1759 | Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps. <b>2020</b> , 11, 1076-1078   | 25  |
| 1758 | Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. <b>2020</b> , 8,  | 31  |
| 1757 | The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. <b>2020</b> , 15, 759-766 | 66  |
| 1756 | The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor. <b>2020</b> , 12,   | 94  |
| 1755 | COVID-19: The first documented coronavirus pandemic in history. <b>2020</b> , 43, 328-333  | 254 |
| 1754 | Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review. <b>2020</b> , 14, 509-512  | 9   |



|      |   |     |
|------|---|-----|
| 1753 | Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. <b>2020</b> , 9,                         | 285 |
| 1752 | From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. <b>2020</b> , 22, 245-253   | 28  |
| 1751 | A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. <b>2020</b> , 368, 1274-1278  | 682 |
| 1750 | Glycemic control of type 2 diabetic patients with coronavirus disease during hospitalization: a proposal for early insulin therapy. <b>2020</b> , 318, E835-E837                                | 7   |
| 1749 | SARS-CoV-2, More than a Respiratory Virus: Its Potential Role in Neuropathogenesis. <b>2020</b> , 11, 1887-1899   | 22  |
| 1748 | SARS-CoV-2 immunogenicity at the crossroads. <b>2020</b> , 75, 1822-1824  | 15  |
| 1747 | Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts. <b>2020</b> , 94,        | 90  |
| 1746 | Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? <b>2020</b> , 16, e1008421  | 224 |
| 1745 | Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. <b>2020</b> , 190, 1680-1690  | 185 |
| 1744 | [COVID-19: Pathogenesis of a multi-faceted disease]. <b>2020</b> , 41, 375-389  | 12  |
| 1743 | A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). <b>2020</b> , 158, 104929  | 53  |
| 1742 | Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens. <b>2020</b> , 84, 104382            | 20  |
| 1741 | Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system. <b>2020</b> , 529, 257-262  | 22  |
| 1740 | Early-Morning vs Spot Posterior Oropharyngeal Saliva for Diagnosis of SARS-CoV-2 Infection: Implication of Timing of Specimen Collection for Community-Wide Screening. <b>2020</b> , 7, ofaa210 | 19  |
| 1739 | A compendium answering 150 questions on COVID-19 and SARS-CoV-2. <b>2020</b> , 75, 2503-2541  | 58  |
| 1738 | Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <b>2020</b> , 369, 643-650  | 724 |
| 1737 | Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. <b>2020</b> , 369, 1014-1018  | 794 |
| 1736 | ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. <b>2020</b> , 18, 537-544  | 170 |



|      |   |     |
|------|---|-----|
| 1735 | Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19. <b>2021</b> , 39, 4582-4593             | 41  |
| 1734 | A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. <b>2020</b> , 369, 650-655   | 854 |
| 1733 | COVID-19 and the endothelium. <b>2020</b> , 75, 7-11  | 58  |
| 1732 | Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach. <b>2021</b> , 39, 4594-4609                                       | 36  |
| 1731 | In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. <b>2020</b> , 32, 176-187.e4   | 271 |
| 1730 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review. <b>2020</b> , 19, 100   | 45  |
| 1729 | Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. <b>2020</b> , 75, 2829-2845 | 269 |
| 1728 | The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?. <b>2020</b> , 11, 699  | 27  |
| 1727 | Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. <b>2020</b> , 117, 13967-13974   | 200 |
| 1726 | Broad neutralization of SARS-related viruses by human monoclonal antibodies. <b>2020</b> , 369, 731-736   | 376 |
| 1725 | Vaccines and Therapies in Development for SARS-CoV-2 Infections. <b>2020</b> , 9,   | 31  |
| 1724 | Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. <b>2020</b> , 1, 100040   | 268 |
| 1723 | Cryo-EM structures of HKU2 and SARS-CoV spike glycoproteins provide insights into coronavirus evolution. <b>2020</b> , 11, 3070   | 20  |
| 1722 | ACE2, Much More Than Just a Receptor for SARS-COV-2. <b>2020</b> , 10, 317  | 144 |
| 1721 | Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <b>2020</b> , 28, 445-454.e6  | 187 |
| 1720 | Natural compounds from spp. as possible therapeutic candidates against SARS-CoV-2: An investigation. <b>2021</b> , 39, 4774-4785  | 25  |
| 1719 | Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection. <b>2020</b> , 11, 730  | 23  |
| 1718 | Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane. <b>2020</b> , 124, 7128-7137  | 131 |

|      |  |     |
|------|--|-----|
| 1717 | Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): From Bench to Bedside. <b>2020</b> , 8, 476  | 12  |
| 1716 | Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. <b>2020</b> , 11, 707-722  | 45  |
| 1715 | Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. <b>2020</b> , 14, 6383-6406  | 290 |
| 1714 | Rationale for targeting complement in COVID-19. <b>2020</b> , 12, e12642   | 67  |
| 1713 | A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. <i>Cell</i> , <b>2020</b> , 182, 722-733.e127   | 127 |
| 1712 | Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy. <b>2020</b> , 11, 1576  | 20  |
| 1711 | Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor. <b>2020</b> , 5, 16292-16298                                       | 73  |
| 1710 | SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets. <b>2020</b> , 1866, 165889   | 38  |
| 1709 | Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. <b>2020</b> , 85, 104445   | 108 |
| 1708 | Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. <b>2020</b> , 146, 285-299  | 28  |
| 1707 | Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. <b>2020</b> , 32, 107915  | 68  |
| 1706 | Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections. <b>2020</b> , 21,  | 46  |
| 1705 | SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. <b>2020</b> , 9,                             | 29  |
| 1704 | Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design. <b>2020</b> , 8,  | 29  |
| 1703 | High prevalence for obesity in severe COVID-19: Possible links and perspectives towards patient stratification. <b>2020</b> , 179, 257-265   | 19  |
| 1702 | Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). <b>2020</b> , 75, 2445-2476 | 81  |
| 1701 | SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. <b>2020</b> , 8,  | 29  |
| 1700 | A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <b>2020</b> , 205, 915-922  | 126 |

|      |   |      |
|------|---|------|
| 1699 | Extrapulmonary manifestations of COVID-19. <b>2020</b> , 26, 1017-1032  | 1253 |
| 1698 | Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response. <b>2020</b> , 11, | 48   |
| 1697 | The hypothesis that SARS-CoV-2 affects male reproductive ability by regulating autophagy. <b>2020</b> , 143, 110083   | 15   |
| 1696 | A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. <b>2020</b> , 28, 486-496.e6   | 116  |
| 1695 | Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy. <b>2020</b> , 144, 109976   | 0    |
| 1694 | Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. <b>2020</b> , 257, 118056   | 89   |
| 1693 | Antibody therapies for the treatment of COVID-19. <b>2020</b> , 3, 101-108  | 7    |
| 1692 | Emerging genetic diversity among clinical isolates of SARS-CoV-2: Lessons for today. <b>2020</b> , 84, 104330   | 45   |
| 1691 | Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India. <b>2020</b> , 728, 138914  | 118  |
| 1690 | Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. <b>2020</b> , 297, E216-E222                   | 172  |
| 1689 | scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells. <b>2020</b> , 9,                           | 312  |
| 1688 | High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2. <b>2021</b> , 141, 206-209.e1   | 43   |
| 1687 | Structural Basis of SARS-CoV-2- and SARS-CoV-Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. <b>2021</b> , 61, 465-493  | 19   |
| 1686 | Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. <b>2021</b> , 78, 1501-1522  | 56   |
| 1685 | Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. <b>2021</b> , 16, 4-23  | 30   |
| 1684 | In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain. <b>2021</b> , 890, 173701   | 6    |
| 1683 | Human coronavirus spike protein-host receptor recognition. <b>2021</b> , 161, 39-53   | 15   |
| 1682 | Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. <b>2021</b> , 296, 100025   | 24   |

|      |  |    |
|------|--|----|
| 1681 | Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19. <b>2021</b> , 538, 92-96                        | 10 |
| 1680 | In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking. <b>2021</b> , 40, e2000115   | 67 |
| 1679 | Risk Factors for Severity in Children with Coronavirus Disease 2019: A Comprehensive Literature Review. <b>2021</b> , 68, 321-338  | 40 |
| 1678 | A hybrid model integrating warm heat and ultraviolet germicidal irradiation might efficiently disinfect respirators and personal protective equipment. <b>2021</b> , 49, 309-318 | 11 |
| 1677 | The use of mechanistic reasoning in assessing coronavirus interventions. <b>2021</b> , 27, 684-693   | 3  |
| 1676 | Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity. <b>2021</b> , 22, 1239-1253                                     | 52 |
| 1675 | DockCoV2: a drug database against SARS-CoV-2. <b>2021</b> , 49, D1152-D1159  | 17 |
| 1674 | Effect of different human tissue processing techniques on SARS-CoV-2 inactivation-review. <b>2021</b> , 22, 1-10   | 4  |
| 1673 | Binding of SARS-CoV-2 to Cell Receptors: A Tale of Molecular Evolution. <b>2021</b> , 22, 724-732  | 15 |
| 1672 | Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. <b>2021</b> , 44, 1085-1090                                      | 77 |
| 1671 | A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2). <b>2021</b> , 171, 112715  | 79 |
| 1670 | Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. <b>2021</b> , 53, 153-157  | 29 |
| 1669 | Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens. <b>2021</b> , 59,                                   | 36 |
| 1668 | N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects. <b>2021</b> , 41, 335-344  | 9  |
| 1667 | New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein. <b>2021</b> , 18, 243-244  | 6  |
| 1666 | One year update on the COVID-19 pandemic: Where are we now?. <b>2021</b> , 214, 105778   | 70 |
| 1665 | Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. <b>2021</b> , 93, 1967-1982                             | 5  |
| 1664 | Intermolecular $\pi$ -Stacking Interactions Made Visible. <b>2021</b> , 98, 540-545  | 3  |

|      |  |     |
|------|--|-----|
| 1663 | The flexibility of ACE2 in the context of SARS-CoV-2 infection. <b>2021</b> , 120, 1072-1084   | 52  |
| 1662 | Occurrence, fate and removal of SARS-CoV-2 in wastewater: Current knowledge and future perspectives. <b>2021</b> , 9, 104870   | 30  |
| 1661 | Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein. <b>2021</b> , 180, 143-148                                   | 28  |
| 1660 | Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. <b>2021</b> , 40, 108-125   | 24  |
| 1659 | Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. <b>2021</b> , 320, L301-L330   | 11  |
| 1658 | Review of COVID-19 and male genital tract. <b>2021</b> , 53, e13914  | 8   |
| 1657 | Structural insights into SARS-CoV-2 proteins. <b>2021</b> , 433, 166725  | 78  |
| 1656 | The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. <b>2021</b> , 538, 104-107                                       | 52  |
| 1655 | Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. <b>2021</b> , 538, 108-115  | 36  |
| 1654 | SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals. <b>2021</b> , 206, 109-117  | 55  |
| 1653 | COVID-19: A review of therapeutic strategies and vaccine candidates. <b>2021</b> , 222, 108634   | 109 |
| 1652 | Structural investigations, quantum mechanical studies on proton and metal affinity and biological activity predictions of selipercatinib. <b>2021</b> , 325, 114765                            | 10  |
| 1651 | Immunohistochemical expression of angiotensin-converting enzyme 2 in minor salivary glands during SARS-CoV-2 infection. <b>2021</b> , 93, 1905-1906  | 5   |
| 1650 | Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. <b>2021</b> , 169, 100-117   | 25  |
| 1649 | Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. <b>2021</b> , 169, 168-189                                       | 35  |
| 1648 | [The early phase of the COVID-19 pandemic in Bavaria, Germany]. <b>2021</b> , 146, e1-e9   | 3   |
| 1647 | Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19. <b>2021</b> , 70, 759-771 | 10  |
| 1646 | Hidden in plain sight: The effects of BCG vaccination in the COVID-19 pandemic. <b>2021</b> , 93, 1950-1966  | 4   |

|      |  |     |
|------|--|-----|
| 1645 | Identification and computational analysis of mutations in SARS-CoV-2. <b>2021</b> , 129, 104166  | 11  |
| 1644 | Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails. <b>2021</b> , 16, 385-397   | 13  |
| 1643 | COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. <b>2021</b> , 20, 139-153  | 6   |
| 1642 | Structural basis of severe acute respiratory syndrome coronavirus 2 infection. <b>2021</b> , 16, 74-81   | 3   |
| 1641 | Dynamic anti-spike protein antibody profiles in COVID-19 patients. <b>2021</b> , 103, 540-548  | 11  |
| 1640 | Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. <b>2021</b> , 7,  | 132 |
| 1639 | Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein. <b>2021</b> , 7, 156-163  | 21  |
| 1638 | The role of NO in COVID-19 and potential therapeutic strategies. <b>2021</b> , 163, 153-162  | 47  |
| 1637 | Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. <b>2021</b> , 538, 137-144           | 8   |
| 1636 | Kidney Function Indicators Predict Adverse Outcomes of COVID-19. <b>2021</b> , 2, 38-48.e2   | 17  |
| 1635 | SARS-CoV-2 replicates in respiratory ex vivo organ cultures of domestic ruminant species. <b>2021</b> , 252, 108933  | 24  |
| 1634 | Sex-dependent immune response and lethality of COVID-19. <b>2020</b> , 50, 102116  | 8   |
| 1633 | Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. <b>2021</b> , 296, 100135 | 28  |
| 1632 | Translating bioactive peptides for COVID-19 therapy. <b>2021</b> , 890, 173661   | 6   |
| 1631 | A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2. <b>2021</b> , 552, 107-111   | 18  |
| 1630 | Comprehensive annotations of the mutational spectra of SARS-CoV-2 spike protein: a fast and accurate pipeline. <b>2021</b> , 68, 1625-1638                                       | 16  |
| 1629 | Evaluation of SARS-CoV-2 in Tears of Patients with Moderate to Severe COVID-19. <b>2021</b> , 128, 494-503   | 47  |
| 1628 | COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. <b>2021</b> , 49, 199-213  | 46  |

|      |   |    |
|------|---|----|
| 1627 | Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms. <b>2021</b> , 93, e12967   | 40 |
| 1626 | Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia. <b>2021</b> , 224, 298.e1-298.e8 | 35 |
| 1625 | CoV3D: a database of high resolution coronavirus protein structures. <b>2021</b> , 49, D282-D287  | 29 |
| 1624 | Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies. <b>2021</b> , 236, 2364-2392   | 43 |
| 1623 | Origin-independent analysis links SARS-CoV-2 local genomes with COVID-19 incidence and mortality. <b>2021</b> , 22, 905-913   | 0  |
| 1622 | Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophectoderm and placenta. <b>2021</b> , 57, 248-256  | 30 |
| 1621 | Computational Investigation of Increased Virulence and Pathogenesis of SARS-CoV-2 Lineage B.1.1.7.  | 1  |
| 1620 | The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. <b>2021</b> , 26, 961-971  | 2  |
| 1619 | The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?. <b>2021</b> , 17, 1476-1485   | 11 |
| 1618 | Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides. <b>2020</b> , 12, 197-202   | 8  |
| 1617 | Correlative Multi-scale Cryo-imaging Unveils SARS-CoV-2 Assembly and Egress. <b>2021</b> ,  | 1  |
| 1616 | Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals. <b>2020</b> , 11, 618097   | 8  |
| 1615 | Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species. <b>2021</b> , 296, 100435  | 16 |
| 1614 | Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. <b>2021</b> , 534, 374-380   | 29 |
| 1613 | Single point mutations can potentially enhance infectivity of SARS-CoV-2 revealed by affinity maturation and SPR assay.. <b>2021</b> , 11, 14737-14745  | 5  |
| 1612 | Nucleic Acid-Based Diagnostic Tests for the Detection SARS-CoV-2: An Update. <b>2021</b> , 11,  | 37 |
| 1611 | Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides. <b>2021</b> , 57, 3283-3286   | 11 |
| 1610 | Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes. <b>2021</b> ,  | 7  |

|      |  |    |
|------|--|----|
| 1609 | Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy. <b>2021</b> , 17, 2957-2969 | 4  |
| 1608 | A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization. <b>2021</b> , 59,   | 10 |
| 1607 | Topography, Spike Dynamics, and Nanomechanics of Individual Native SARS-CoV-2 Virions. <b>2021</b> , 21, 2675-2680   | 15 |
| 1606 | Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates. <b>2021</b> ,  | 4  |
| 1605 | Possible impact of plasma oxidation on the structure of the C-terminal domain of SARS-CoV-2 spike protein: a computational study. <b>2021</b> , 14, 027002                               | 7  |
| 1604 | Exploring G protein-coupled receptors and yeast surface display strategies for viral detection in baker's yeast: SARS-CoV-2 as a case study. <b>2021</b> , 21,                           | 2  |
| 1603 | Coronavirus Pneumonia and Pulmonary Thromboembolism. <b>2021</b> , 1, 178-184  | 1  |
| 1602 | Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. <b>2021</b> , 12, 469   | 74 |
| 1601 | Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis. <b>2021</b> , 12, 1209-12265   |    |
| 1600 | Structure of SARS-CoV-2 Proteins. <b>2021</b> , 91-120   |    |
| 1599 | Gene Expression of Angiotensin-Converting Enzyme 2 Receptor in Skin and the Implications for COVID-19. <b>2021</b> , 34, 31-35   | 4  |
| 1598 | A quantitative exploration of symptoms in COVID-19 patients: an observational cohort study. <b>2021</b> , 18, 1082-1095  | 4  |
| 1597 | Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. <b>2021</b> , 19, 3799-3809  | 12 |
| 1596 | Acute treatment with monoclonal antibodies: their design and their use. <b>2021</b> , 42, 39   |    |
| 1595 | Structural determinants driving the binding process between PDZ domain of wild type human PALS1 protein and SLiM sequences of SARS-CoV E proteins. <b>2021</b> , 19, 1838-1847           | 3  |
| 1594 | Possible mechanisms of cholesterol elevation aggravating COVID-19. <b>2021</b> , 18, 3533-3543   | 4  |
| 1593 | Computational Modeling of ACE2-Mediated Cell Entry Inhibitors for the Development of Drugs Against Coronaviruses. <b>2021</b> , 495  | 0  |
| 1592 | Receptors   Angiotensin Receptors. <b>2021</b> , 110-121   |    |



|      |   |    |
|------|---|----|
| 1591 | Effect of mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion function. <b>2021</b> ,  | 1  |
| 1590 | Insight into the origin of SARS-CoV-2 through structural analysis of receptor recognition: a molecular simulation study.. <b>2021</b> , 11, 8718-8729                                       | 1  |
| 1589 | Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning. <b>2021</b> , 19, 3133-3148  | 5  |
| 1588 | Carbon nanotubes for rapid capturing of SARS-COV-2 virus: revealing a mechanistic aspect of binding based on computational studies.. <b>2021</b> , 11, 5785-5800                            | 7  |
| 1587 | Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. <b>2021</b> , 12, 264  | 41 |
| 1586 | Interaction analyses of SARS-CoV-2 spike protein based on fragment molecular orbital calculations.. <b>2021</b> , 11, 3272-3279   | 11 |
| 1585 | Molecular recognition of SARS-CoV-2 spike glycoprotein: quantum chemical hot spot and epitope analyses.. <b>2021</b> , 12, 4722-4739  | 22 |
| 1584 | Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. <b>2021</b> , 296, 100701  | 31 |
| 1583 | Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. <b>2021</b> , 13, 1953683                                    | 8  |
| 1582 | Noneffect of SARS-CoV-2 spike glycoprotein Y217N mutation on affinity between the virus and ACE2. <b>2021</b> , 296, 100725   |    |
| 1581 | Underpinning the Rudimentary/Underlying Mechanisms Involved in the Pathogenesis of SARS-CoV-2 (COVID-19) in Human Lung Cells. <b>2021</b> , 537-557   | 1  |
| 1580 | Furin cleavage sites naturally occur in coronaviruses. <b>2020</b> , 50, 102115   | 25 |
| 1579 | Toward Rapid and Sensitive Detection of SARS-CoV-2 with Functionalized Magnetic Nanoparticles. <b>2021</b> , 6, 976-984   | 31 |
| 1578 | A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection. <b>2021</b> , 26, 100714  | 1  |
| 1577 | SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. <b>2021</b> , 4, 129  | 46 |
| 1576 | Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA. <b>2021</b> , 12, 1597-1609  | 17 |
| 1575 | Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?. <b>2021</b> , 22,   | 45 |
| 1574 | A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. <b>2021</b> , 12, 542 | 86 |

|      |  |    |
|------|--|----|
| 1573 | Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. <b>2021</b> , 13,   | 30 |
| 1572 | Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. <b>2021</b> , 15, 2738-2752  | 57 |
| 1571 | Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. <b>2021</b> , 538, 97-103   | 14 |
| 1570 | Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach. <b>2020</b> , 11, 621099   | 11 |
| 1569 | Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development. <b>2021</b> , 195, 221-229  | 6  |
| 1568 | HVIDB: a comprehensive database for human-virus protein-protein interactions. <b>2021</b> , 22, 832-844  | 13 |
| 1567 | A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics. <b>2021</b> , 166, 697-714  | 8  |
| 1566 | Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. <b>2021</b> , 10, 1227-1240  | 3  |
| 1565 | Minerals in biology and medicine.. <b>2021</b> , 11, 1939-1951   | 4  |
| 1564 | Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2). <b>2021</b> , 16, e0245258                   | 9  |
| 1563 | Molecular characterization of COVID-19 therapeutics: luteolin as an allosteric modulator of the spike protein of SARS-CoV-2.   | 4  |
| 1562 | Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations. <b>2021</b> , 166, 801-812 | 30 |
| 1561 | Unraveling the molecular basis of host cell receptor usage in SARS-CoV-2 and other human pathogenic ECoVs. <b>2021</b> , 19, 759-766   | 1  |
| 1560 | Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. <b>2021</b> , 10, 1097-1111   | 6  |
| 1559 | In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19. <b>2021</b> , 32, 1-9  | 19 |
| 1558 | design of peptides with binding to the receptor binding domain (RBD) of the SARS-CoV-2 and their utility in bio-sensor development for SARS-CoV-2 detection.. <b>2021</b> , 11, 3816-3826                                | 8  |
| 1557 | Rapid antibody diagnostics for SARS-CoV-2 adaptive immune response. <b>2021</b> , 13, 4019-4037  | 0  |
| 1556 | Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. <b>2021</b> , 23, 14  | 93 |

|      |   |     |
|------|---|-----|
| 1555 | Autoimmune Processes Involved in Organ System Failure Following Infection with SARS-CoV-2. <b>2021</b> , 1318, 355-368  |     |
| 1554 | Viral pathogenesis of SARS-CoV-2 infection and male reproductive health. <b>2021</b> , 11, 200347   | 15  |
| 1553 | Immune response to COVID-19 infection: a double-edged sword. <b>2021</b> , 44, 187-196  | 7   |
| 1552 | A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. <b>2021</b> , 12, 288  | 108 |
| 1551 | Stereotypic neutralizing V antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals. <b>2021</b> , 13,               | 36  |
| 1550 | SARS-CoV-2 Fusion Peptide has a Greater Membrane Perturbating Effect than SARS-CoV with Highly Specific Dependence on Ca <sup>2+</sup> .  |     |
| 1549 | SARS-CoV-2 spike protein N501Y mutation causes differential species transmissibility and antibody sensitivity: a molecular dynamics and alchemical free energy study.             | 4   |
| 1548 | study of the inhibition of SARS-COV-2 viral cell entry by neem tree extracts.. <b>2021</b> , 11, 26524-26533  | 4   |
| 1547 | SARS-CoV-2 receptor binding mutations and antibody mediated immunity.   | 3   |
| 1546 | Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages. <b>2021</b> , 11,   | 11  |
| 1545 | Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat RBD of SARS-CoV-2 spike protein protects mice against COVID-19.   |     |
| 1544 | COR-101, ein menschlicher Antikörper gegen COVID-19. <b>2021</b> , 27, 46-48  | 0   |
| 1543 | Variation in predicted COVID-19 risk among lemurs and lorises. <b>2021</b> ,  |     |
| 1542 | Computational insights into differential interaction of mamalian ACE2 with the SARS-CoV-2 spike receptor binding domain.  |     |
| 1541 | Seguimiento de los pacientes con secuelas no respiratorias de la COVID-19. <b>2021</b> , 28, 81-89  | 2   |
| 1540 | Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2. <b>2021</b> , 9,  | 9   |
| 1539 | SARS-CoV-2 spike protein-, main protease- and papain-like-protease-targeting peptides from seed proteins following gastrointestinal digestion: An study.. <b>2021</b> , 1, 100016 | 7   |
| 1538 | Tetracycline as an inhibitor to the SARS-CoV-2. <b>2021</b> , 122, 752-759  | 3   |

|      |   |    |
|------|---|----|
| 1537 | A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. <b>2021</b> ,  | 38 |
| 1536 | A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. <b>2021</b> , 12, 776   | 26 |
| 1535 | Animal Coronaviruses and SARS-COV-2 in Animals, What Do We Actually Know?. <b>2021</b> , 11,  | 11 |
| 1534 | Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. <b>2020</b> , 11, 583914   | 4  |
| 1533 | Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex. <b>2021</b> , 1-11   | 21 |
| 1532 | Retrained Generic Antibodies Can Recognize SARS-CoV-2. <b>2021</b> , 12, 1438-1442  | 1  |
| 1531 | Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library. <b>2021</b> , 30, 716-727  | 8  |
| 1530 | Targeting Lipid Rafts as a Strategy Against Coronavirus. <b>2020</b> , 8, 618296  | 15 |
| 1529 | Acute Ischemic Colitis in a Covid-19 Patient. <b>2021</b> , 4, 60-65  | 1  |
| 1528 | Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. <b>2021</b> , 31, 395-403   | 63 |
| 1527 | SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets. <b>2021</b> , 10,   | 34 |
| 1526 | A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2. <b>2021</b> , 147, 106361  | 5  |
| 1525 | A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation. <b>2021</b> , 12, 637654 | 9  |
| 1524 | Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro. <b>2021</b> , 86, 243-247   | 8  |
| 1523 | Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. <b>2021</b> , 100, 1  | 26 |
| 1522 | Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. <b>2021</b> , 17, e1009352   | 24 |
| 1521 | Molecular Recognition. <b>2021</b> , 22, 433-434  | 0  |
| 1520 | Comparison of the binding characteristics of SARS-CoV and SARS-CoV-2 RBDs to ACE2 at different temperatures by MD simulations. <b>2021</b> , 22, 1122-1136  | 13 |

|      |   |     |
|------|---|-----|
| 1519 | In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. <b>2021</b> , 22,   | 54  |
| 1518 | Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies. <b>2021</b> , 26,   | 37  |
| 1517 | Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. <b>2021</b> , 17, e1009165  | 20  |
| 1516 | Axial Chiral Binaphthoquinone and Perylenequinones from the Stromata of Are SARS-CoV-2 Entry Inhibitors. <b>2021</b> , 84, 436-443  | 8   |
| 1515 | Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. <b>2021</b> , 17, e1009282  | 23  |
| 1514 | Receptor Binding Domain (RBD) Structural Susceptibility in the SARS-CoV-2 Virus Spike Protein Exposed to a Pulsed Electric Field. <b>2021</b> , 8, 177-182  | 2   |
| 1513 | SARS-CoV-2 infection: Understanding the immune system abnormalities to get an adequate diagnosis. <b>2021</b> , 21, 503-514   | 2   |
| 1512 | SARS-CoV-2, Covid-19, and the debunking of conspiracy theories. <b>2021</b> , 31, e2222   | 11  |
| 1511 | Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides. <b>2021</b> , 61, 1226-1243   | 11  |
| 1510 | Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. <b>2021</b> ,   | 13  |
| 1509 | COVID-19 mRNA vaccines. <b>2021</b> , 48, 107-114   | 24  |
| 1508 | Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. <b>2021</b> , 371,   | 149 |
| 1507 | Impact of coronavirus disease 2019 on reproductive health: An update. 2, 65-71  |     |
| 1506 | Immunopathogenesis and perspectives for immunotherapy of coronavirus infection. <b>2021</b> , 12, 7-22  | 0   |
| 1505 | A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. <b>2020</b> , 11, 590154   | 6   |
| 1504 | Digital PCR for high sensitivity viral detection in false-negative SARS-CoV-2 patients. <b>2021</b> , 11, 4310  | 10  |
| 1503 | Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19. <b>2021</b> , 12, 598925 | 7   |
| 1502 | Tracing the origins of SARS-COV-2 in coronavirus phylogenies: a review. <b>2021</b> , 19, 1-17  | 31  |

|      |  |    |
|------|--|----|
| 1501 | Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection. <b>2021</b> ,  | 3  |
| 1500 | Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?. <b>2021</b> , 134, 111143                    | 2  |
| 1499 | Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment. <b>2021</b> , 1-14   | 6  |
| 1498 | Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study. <b>2021</b> , 45, 35-41   | 4  |
| 1497 | Looking beyond pulmonary disease in COVID-19: A lesson from patients with cystic fibrosis. <b>2021</b> , 147, 110481   | 3  |
| 1496 | A rapid and cost-effective multiplex ARMS-PCR method for the simultaneous genotyping of the circulating SARS-CoV-2 phylogenetic clades. <b>2021</b> , 93, 2962-2970                        | 8  |
| 1495 | An overview of Covid-19 pandemic: immunology and pharmacology. <b>2021</b> , 42, 493-512   |    |
| 1494 | COVID-19: The Heart of the Matter-Pathological Changes and a Proposed Mechanism. <b>2021</b> , 26, 217-224   | 5  |
| 1493 | Discovery of Clloquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction. <b>2021</b> , 7, e06426 | 7  |
| 1492 | Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. <b>2021</b> , 476, 2917-2942                       | 10 |
| 1491 | Ca-dependent mechanism of membrane insertion and destabilization by the SARS-CoV-2 fusion peptide. <b>2021</b> , 120, 1105-1119  | 21 |
| 1490 | The polybasic insert, the RBD of the SARS-CoV-2 spike protein, and the feline coronavirus - evolved or yet to evolve. <b>2021</b> , 25, 100907   | 2  |
| 1489 | The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. <b>2021</b> , 213, 113157   | 15 |
| 1488 | Insights into biological therapeutic strategies for COVID-19. <b>2021</b> , 1, 166-178   | 2  |
| 1487 | A study on non-synonymous mutational patterns in structural proteins of SARS-CoV-2. <b>2021</b> , 64, 665-678  | 6  |
| 1486 | Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations. <b>2021</b> , 894, 173836   | 22 |
| 1485 | Docking and toxicity assessment of compounds as potential antiviral agents against SARS-CoV-2. <b>2021</b> , 33, 1-24  | 12 |
| 1484 | Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain. <b>2021</b> ,  | 19 |

|      |  |    |
|------|--|----|
| 1483 | ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species. <b>2021</b> , 5, 600-608   | 30 |
| 1482 | as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines. <b>2021</b> , 9,  | 7  |
| 1481 | A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <b>2021</b> , 895, 173890  | 41 |
| 1480 | Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. <b>2021</b> , 12, 635677 | 3  |
| 1479 | Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. <b>2021</b> , 11, 5639    | 1  |
| 1478 | <del>ES</del> SARS-CoV-2 in vitro <del>ES</del><br><b>2021</b> , 86, 291-296   |    |
| 1477 | Percutaneous microwave ablation applications for liver tumors: recommendations for COVID-19 patients. <b>2021</b> , 7, e06454  | 3  |
| 1476 | Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes. <b>2021</b> , 7,  | 6  |
| 1475 | A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection. <b>2021</b> ,  | 6  |
| 1474 | Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutant receptor-binding domain with ACE2. <b>2021</b> , 104, 491-500                             | 3  |
| 1473 | Spiking dependence of SARS-CoV-2 pathogenicity on TMPRSS2. <b>2021</b> , 93, 4205-4218   | 10 |
| 1472 | Should we discount the laboratory origin of COVID-19?. <b>2021</b> , 19, 1-15  | 16 |
| 1471 | Atrial Arrhythmias in Patients with Severe COVID-19. <b>2021</b> , 2021, 8874450   | 1  |
| 1470 | SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack. <b>2021</b> , 13, 361-375   | 3  |
| 1469 | Failla Memorial Lecture: The Many Facets of Heavy-Ion Science. <b>2021</b> , 195, 403-411  | 2  |
| 1468 | A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2. <b>2021</b> , 17, e1009328  | 17 |
| 1467 | Identification of ACE2 mutations that modulate SARS-CoV-2 spike binding across multiple mammalian species. <b>2021</b> ,   |    |
| 1466 | A Review of the Progress of COVID-19 Vaccine Development.  | 1  |

|      |  |     |
|------|--|-----|
| 1465 | Binding of SARS-CoV-2/SARS-CoV spike protein with human ACE2 receptor. <b>2021</b> , 5, 035010   | 4   |
| 1464 | Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. <b>2021</b> , 82, 399-406   | 54  |
| 1463 | Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry. <b>2021</b> , 12, 1299-1312   | 9   |
| 1462 | SARS-CoV-2 Spike receptor-binding domain with a G485R mutation in complex with human ACE2.   | 2   |
| 1461 | Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution. <b>2021</b> , 12, 1607  | 31  |
| 1460 | Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. <b>2021</b> , 118,  | 73  |
| 1459 | Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <b>2021</b> ,  | 12  |
| 1458 | A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <b>2021</b> , 12, 1951   | 25  |
| 1457 | Identifying Primate ACE2 Variants That Confer Resistance to SARS-CoV-2. <b>2021</b> , 38, 2715-2731  | 7   |
| 1456 | Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data. <b>2021</b> , 236, 7045-7057                    | 151 |
| 1455 | Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein. <b>2021</b> , 7, e06564  | 13  |
| 1454 | Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus. <b>2021</b> , 20, 350-356   | 9   |
| 1453 | Comparison of Clinical Features and Outcomes of Medically Attended COVID-19 and Influenza Patients in a Defined Population in the 2020 Respiratory Virus Season. <b>2021</b> , 9, 587425 | 4   |
| 1452 | Herbal Medicine in Fighting Against COVID-19: New Battle with an Old Weapon. <b>2021</b> ,   | 2   |
| 1451 | Why Does SARS-CoV-2 Infection Induce Autoantibody Production?. <b>2021</b> , 10,   | 1   |
| 1450 | An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2. <b>2021</b> , 125, 2533-2550  | 7   |
| 1449 | SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. <b>2021</b> , 12, 1577                                     | 28  |
| 1448 | Covid-19 and blood groups: ABO antibody levels may also matter. <b>2021</b> , 104, 242-249   | 19  |



|      |  |     |
|------|--|-----|
| 1447 | Comparative research on nucleocapsid and spike glycoprotein as the rapid immunodetection targets of COVID-19 and establishment of immunoassay strips. <b>2021</b> , 131, 6-12  | 8   |
| 1446 | SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. <b>2021</b> , 27, 622-625  | 670 |
| 1445 | In silico identification of compounds from seed oil as potential inhibitors of SARS-CoV-2 targets. <b>2021</b> , 45, 57  | 7   |
| 1444 | Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment. <b>2021</b> , 16, 205-209   | 7   |
| 1443 | Human Rhinovirus Infection Blocks Severe Acute Respiratory Syndrome Coronavirus 2 Replication Within the Respiratory Epithelium: Implications for COVID-19 Epidemiology. <b>2021</b> , 224, 31-38  | 32  |
| 1442 | Frontrunners in the race to develop a SARS-CoV-2 vaccine. <b>2021</b> , 67, 189-212  | 6   |
| 1441 | In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase. <b>2021</b> , 1   | 6   |
| 1440 | The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. <b>2021</b> , 10,   | 11  |
| 1439 | Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry. <b>2021</b> , 17, e1009392   | 16  |
| 1438 | Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence. <b>2021</b> , 15, 6929-6948  | 18  |
| 1437 | Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. <b>2021</b> , 120, 1011-1019  | 26  |
| 1436 | Neurological manifestations of COVID-19: with emphasis on Iranian patients. <b>2021</b> , 27, 217-227  | 1   |
| 1435 | Human cardiosphere-derived stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression. <b>2021</b> , 117, 1557-1566 | 10  |
| 1434 | Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. <b>2021</b> , 31, 517-525  | 20  |
| 1433 | Severe covid-19 pneumonia: pathogenesis and clinical management. <b>2021</b> , 372, n436   | 79  |
| 1432 | Production of high-quality SARS-CoV-2 antigens: Impact of bioprocess and storage on glycosylation, biophysical attributes, and ELISA serologic tests performance. <b>2021</b> , 118, 2202-2219   | 8   |
| 1431 | Perspectives and Challenges in the Fight Against COVID-19: The Role of Genetic Variability. <b>2021</b> , 11, 598875   | 6   |
| 1430 | Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage. <b>2021</b> , 10,   | 38  |

|      |   |         |
|------|---|---------|
| 1429 | SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. <b>2021</b> , 22,  | 15      |
| 1428 | SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.  | 2       |
| 1427 | COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays. <b>2021</b> , 1-14                   | 8       |
| 1426 | ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. <b>2021</b> , 224, S631-S641 | 1       |
| 1425 | Development of a Novel Human CD147 Transgenic NSG Mouse Model to test SARS-CoV-2 Infection and Immune Responses. <b>2021</b> ,  | 1       |
| 1424 | The COVID-19 Vaccines: Recent Development, Challenges and Prospects. <b>2021</b> , 9,   | 34      |
| 1423 | Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. <b>2021</b> , 35, 108950  | 38      |
| 1422 | Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. <b>2021</b> , 24, 102367   | 34      |
| 1421 | Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. <i>Cell</i> , <b>2021</b> , 184, 1821-1835.e16  | 56.2 90 |
| 1420 | Can ketone bodies inactivate coronavirus spike protein? The potential of biocidal agents against SARS-CoV-2. <b>2021</b> , 43, e2000312   | 2       |
| 1419 | Identification and Characterization of Species-Specific Severe Acute Respiratory Syndrome Coronavirus 2 Physicochemical Properties. <b>2021</b> , 20, 2942-2952                                 | 2       |
| 1418 | Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase. <b>2021</b> , 16, 881-895      | 2       |
| 1417 | The Up state of the SARS-COV-2 Spike homotrimer favors an increased virulence for new variants.   | 0       |
| 1416 | The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response. <b>2021</b> , 39, 2500-2503   | 2       |
| 1415 | In Silico Identification of Multi-target Anti-SARS-CoV-2 Peptides from Quinoa Seed Proteins. <b>2021</b> , 27, 1-11   | 6       |
| 1414 | Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. <b>2021</b> , 125, 4596-4619   | 16      |
| 1413 | Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. <b>2021</b> , 133, 13014-13020                    | 1       |
| 1412 | Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. <b>2021</b> , 7, 21  | 8       |

|      |  |    |
|------|--|----|
| 1411 | Tackling Covid-19 using disordered-to-order transition of residues in the spike protein upon angiotensin-converting enzyme 2 binding. <b>2021</b> , 89, 1158-1166  | 5  |
| 1410 | Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. <b>2021</b> , 379, 23  | 2  |
| 1409 | Interplay of Opposing Effects of the WNT/ $\beta$ Catenin Pathway and PPAR $\alpha$ and Implications for SARS-CoV2 Treatment. <b>2021</b> , 12, 666693   | 14 |
| 1408 | SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs. <b>2021</b> , 9,   | 13 |
| 1407 | The Association of Subacute Thyroiditis with COVID-19: a Systematic Review. <b>2021</b> , 3, 1-13  | 14 |
| 1406 | Protein Footprinting, Conformational Dynamics, and Core Interface-Adjacent Neutralization "Hotspots" in the SARS-CoV-2 Spike Protein Receptor Binding Domain/Human ACE2 Interaction. <b>2021</b> , 32, 1593-1600 | 4  |
| 1405 | The role of cell surface sialic acids for SARS-CoV-2 infection. <b>2021</b> , 31, 1245-1253  | 25 |
| 1404 | D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect. <b>2021</b> , 26,                                     | 11 |
| 1403 | The Role of the SARS-CoV-2 S-Protein Glycosylation in the Interaction of SARS-CoV-2/ACE2 and Immunological Responses. <b>2021</b> , 34, 165-173  | 22 |
| 1402 | The SARS-unique domain (SUD) of SARS-CoV and SARS-CoV-2 interacts with human Paip1 to enhance viral RNA translation. <b>2021</b> , 40, e102277   | 12 |
| 1401 | Deletion of ER-retention Motif on SARS-CoV-2 Spike Protein Reduces Cell Hybrid During Cell-cell Fusion. <b>2021</b> ,  |    |
| 1400 | Structural insights into SARS-CoV-2 infection and therapeutics development. <b>2021</b> , 52, 102219   | 3  |
| 1399 | Variation in predicted COVID-19 risk among lemurs and lorises. <b>2021</b> , 83, e23255  | 3  |
| 1398 | Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance. <b>2021</b> , 21, 498-503  | 11 |
| 1397 | SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. <b>2021</b> , 12, 638334  | 6  |
| 1396 | Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19. <b>2021</b> , 26,  |    |
| 1395 | Structure-based assortment of herbal analogues against spike protein to restrict COVID-19 entry through hACE2 receptor: An in-silico approach. <b>2021</b> , 64, 159-171   | 2  |
| 1394 | GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein. <b>2021</b> , 12, 2114  | 22 |

|      |   |     |
|------|---|-----|
| 1393 | SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. <b>2021</b> , 58, 1-15  | 28  |
| 1392 | Structural impact on SARS-CoV-2 spike protein by D614G substitution. <b>2021</b> , 372, 525-530   | 147 |
| 1391 | Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <b>2021</b> ,  | 34  |
| 1390 | Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. <b>2021</b> , 7, 757-767  | 24  |
| 1389 | The importance of genomic analysis in cracking the coronavirus pandemic. <b>2021</b> , 21, 547-562  | 7   |
| 1388 | Optical technologies for the detection of viruses like COVID-19: Progress and prospects. <b>2021</b> , 178, 113004  | 28  |
| 1387 | Anticoagulation in COVID-19: current concepts and controversies. <b>2021</b> ,  | 19  |
| 1386 | ACE2 models of frequently contacted animals provide clues of their SARS-CoV-2 S protein affinity and viral susceptibility. <b>2021</b> , 93, 4469-4479  | 6   |
| 1385 | SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. <b>2021</b> , 35, 109017   | 42  |
| 1384 | Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <b>2021</b> , 60, 1459-1484 | 17  |
| 1383 | COVID-19 and Cardiovascular Disease: From Bench to Bedside. <b>2021</b> , 128, 1214-1236  | 57  |
| 1382 | Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. <b>2021</b> , 60, 12904-12910   | 14  |
| 1381 | IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein. <b>2021</b> , 22,   | 7   |
| 1380 | Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options. <b>2021</b> , 14, 1883-1892   | 5   |
| 1379 | The role of mediator complex subunit 19 in human diseases. <b>2021</b> , 246, 1681-1687   |     |
| 1378 | Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2. <b>2021</b> , 93, 5487-5504   | 4   |
| 1377 | Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects. <b>2021</b> , 413, 4137-4159   | 26  |
| 1376 | Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2. <b>2021</b> , 14, 1123-1132  | 5   |

|      |   |    |
|------|---|----|
| 1375 | Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside. <b>2021</b> , 7, 2150-2176   | 13 |
| 1374 | A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. <b>2021</b> , 51, 1774-1784 | 9  |
| 1373 | Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review. <b>2021</b> , 2, 100116  | 15 |
| 1372 | An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2-Spike complex of SARS-CoV-2 using computational methods. <b>2021</b> , 75, 1-24       | 2  |
| 1371 | SARS-CoV-2 cell entry and targeted antiviral development. <b>2021</b> , 11, 3879-3879   | 5  |
| 1370 | Unveiling the Potential Role of Nanozymes in Combating the COVID-19 Outbreak. <b>2021</b> , 11,   | 1  |
| 1369 | Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review. <b>2021</b> , 154, 104809                              | 2  |
| 1368 | Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients. <b>2021</b> , 206, 2393-2401   | 8  |
| 1367 | SARS-CoV-2 Fusion Peptide has a Greater Membrane Perturbating Effect than SARS-CoV with Highly Specific Dependence on Ca. <b>2021</b> , 433, 166946                                 | 20 |
| 1366 | Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the ACE2 Receptor. <b>2021</b> , 9, 661230               | 50 |
| 1365 | The authors respond: Cardiac troponin levels in Covid-19 patients. <b>2021</b> , 43, 250-251  |    |
| 1364 | Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay. <b>2021</b> , 12, 643275                                 | 7  |
| 1363 | Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins. <b>2021</b> , 29, 249-262  | 0  |
| 1362 | Coronavirus Disease 19 and Future Ecological Crises: Hopes from Epigenomics and Unraveling Genome Regulation in Humans and Infectious Agents. <b>2021</b> , 25, 269-278             | 0  |
| 1361 | Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. <b>2021</b> , 125, 5537-5548   | 15 |
| 1360 | Plausible blockers of Spike RBD in SARS-CoV2-molecular design and underlying interaction dynamics from high-level structural descriptors. <b>2021</b> , 27, 191                     | 1  |
| 1359 | The human pandemic coronaviruses on the show: The spike glycoprotein as the main actor in the coronaviruses play. <b>2021</b> , 179, 1-19   | 7  |
| 1358 | Evaluation of the Prognosis of COVID-19 Patients According to the Presence of Underlying Diseases and Drug Treatment. <b>2021</b> , 18,   | 3  |

|      |   |      |     |
|------|---|------|-----|
| 1357 | Identification of potential inhibitors of SARS-CoV-2 S protein-ACE2 interaction by drug repurposing.. <b>2021</b> , 10,   |      |     |
| 1356 | Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. <b>2021</b> , 29, 819-833.e7                      |      | 215 |
| 1355 | Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , <b>2021</b> , 184, 2939-2954.e9   | 56.2 | 281 |
| 1354 | Clinical course and outcome among patients with acute pancreatitis and COVID-19. <b>2021</b> , 33, 695-700  |      | 8   |
| 1353 | Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. <b>2021</b> , 7, 1001-1008  |      | 8   |
| 1352 | In silico binding profile characterization of SARS-CoV-2 spike protein and its mutants bound to human ACE2 receptor. <b>2021</b> , 22,                          |      | 6   |
| 1351 | Evaluation of SARS-CoV-2 Spike S1 Protein Response on PI3K-Mediated IL-8 Release. <b>2021</b> , 9,  |      | 1   |
| 1350 | Identification of T Cell Epitopes in the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 in Rhesus Macaques. <b>2021</b> , 206, 2527-2535 |      | 1   |
| 1349 | The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic. <b>2021</b> , 28, 2852-2886   |      | 9   |
| 1348 | Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction. <b>2021</b> , 6, 198                       |      | 8   |
| 1347 | Current Strategies of Antiviral Drug Discovery for COVID-19. <b>2021</b> , 8, 671263  |      | 24  |
| 1346 | Diferencias entre el SARS-CoV-2 y el coronavirus de la Bronquitis Infecciosa Aviar (IBV). <b>2021</b> , 16, 47-58   |      |     |
| 1345 | Mechanism of Ligand Recognition by Human ACE2 Receptor. <b>2021</b> , 12, 4814-4822   |      | 3   |
| 1344 | Susceptibility to SARS-CoV-2 of Cell Lines and Substrates Commonly Used to Diagnose and Isolate Influenza and Other Viruses. <b>2021</b> , 27, 1380-1392        |      | 4   |
| 1343 | Computational analysis of functional monomers used in molecular imprinting for promising COVID-19 detection. <b>2021</b> , 1199, 113215                         |      | 5   |
| 1342 | SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. <b>2021</b> , 180, 113122             |      | 9   |
| 1341 | Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein. <b>2021</b> , 31, 1080-1092                   |      | 5   |
| 1340 | A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction. <b>2021</b> , 1-14    |      | 0   |

|      |  |     |
|------|--|-----|
| 1339 | Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV. <b>2021</b> , 16, e0251913  | 6   |
| 1338 | The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19. <b>2021</b> , 50, 493-523   | 3   |
| 1337 | NMR Based SARS-CoV-2 Antibody Screening. <b>2021</b> , 143, 7930-7934  | 3   |
| 1336 | Coronavirus disease 2019, allergic diseases, and allergen immunotherapy: Possible favorable mechanisms of interaction. <b>2021</b> , 42, 187-197   | 5   |
| 1335 | SARS-CoV-2-Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis. <b>2021</b> , 10,   | 4   |
| 1334 | The Anti-Infectious Role of Sphingosine in Microbial Diseases. <b>2021</b> , 10,   | 4   |
| 1333 | Possible effects of air temperature on COVID-19 disease severity and transmission rates. <b>2021</b> , 93, 5358-5366   | 4   |
| 1332 | Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases. <b>2021</b> , 17, 2824-2840 | 3   |
| 1331 | Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. <b>2021</b> , 12, 2506   | 132 |
| 1330 | Modulates Immunity against SARS-CoV-2 in Respiratory Epithelial Cells. <b>2021</b> , 10,   | 4   |
| 1329 | Following the Trail of One Million Genomes: Footprints of SARS-CoV-2 Adaptation to Humans.   |     |
| 1328 | Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. <b>2021</b> , 22,   | 1   |
| 1327 | Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients. <b>2021</b> , 15, 29  | 9   |
| 1326 | Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity. <b>2021</b> , 137, 111363   | 18  |
| 1325 | Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein. <b>2021</b> , 16, e0251585  | 5   |
| 1324 | Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19. <b>2021</b> , 11, 9825  | 9   |
| 1323 | Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys. <b>2021</b> , 32, 1034-1046  | 8   |
| 1322 | Vitamin D supplementation for the treatment of COVID-19: a living systematic review. <b>2021</b> , 5, CD015043   | 35  |



|      |   |    |
|------|---|----|
| 1321 | Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?. <b>2021</b> , 27, 2270-2280  | 2  |
| 1320 | The Role of Neuropilin-1 (NRP-1) in SARS-CoV-2 Infection: Review. <b>2021</b> , 10,   | 11 |
| 1319 | Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. <b>2021</b> , 232, 60-74  | 29 |
| 1318 | Molecular biology of the SARS-CoV-2 spike protein: A review of current knowledge. <b>2021</b> , 93, 5729-5741   | 12 |
| 1317 | Interfering Reactive Cysteine Proteome in Covid-19 Disease. <b>2021</b> ,   | 1  |
| 1316 | The Significance of Angiotensin-Converting Enzyme-2 (ACE2) in SARSCov- 2 Infection and COVID-19. <b>2021</b> , 2,   |    |
| 1315 | COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <b>2021</b> , 117, 2148-2160   | 8  |
| 1314 | Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective. <b>2021</b> , 36, e2021010-0  | 1  |
| 1313 | SARS-CoV-2 Host Receptor ACE2 Protein Expression Atlas in Human Gastrointestinal Tract. <b>2021</b> , 9, 659809   | 3  |
| 1312 | Lactoferrin Against SARS-CoV-2: and Evidences. <b>2021</b> , 12, 666600   | 21 |
| 1311 | Immunological imprinting of the antibody response in COVID-19 patients. <b>2021</b> , 12, 3781  | 51 |
| 1310 | The key role of the level of ACE2 gene expression in SARS-CoV-2 infection. <b>2021</b> , 13, 14552-14556  | 5  |
| 1309 | Transport of Aerosols in Underground Mine Workings in Terms of SARS-CoV-2 Virus Threat. <b>2021</b> , 26,   | 0  |
| 1308 | Up State of the SARS-COV-2 Spike Homotrimer Favors an Increased Virulence for New Variants.. <b>2021</b> , 3, 694347  | 4  |
| 1307 | Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants. <b>2021</b> ,   |    |
| 1306 | Virtual screenings of the bioactive constituents of tea, prickly chaff, catechu, lemon, black pepper, and synthetic compounds with the main protease (Mpro) and human angiotensin-converting enzyme 2 (ACE 2) of SARS-CoV-2. <b>2021</b> , 7, 121 | 0  |
| 1305 | The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections. <b>2021</b> , 394, 1589-1593  | 5  |
| 1304 | Molecular basis of cross-species ACE2 interactions with SARS-CoV-2-like viruses of pangolin origin. <b>2021</b> , 40, e107786   | 13 |



|      |   |    |
|------|---|----|
| 1303 | Attractive and repulsive residue fragments at the interface of SARS-CoV-2 and hACE2. <b>2021</b> , 11, 12567  | 1  |
| 1302 | Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms. <b>2021</b> , 12, 698944   | 16 |
| 1301 | A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. <b>2021</b> , 13,   | 0  |
| 1300 | SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <b>2021</b> , 9,   | 2  |
| 1299 | Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease. <b>2021</b> , 12, 695230   | 4  |
| 1298 | COVID-19 Infection and Circulating Microparticles-Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease. <b>2021</b> , 58, 4188-4215  | 5  |
| 1297 | The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2. <b>2021</b> , 17, 3297-3309  | 3  |
| 1296 | FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant. <b>2021</b> ,   | 2  |
| 1295 | The bat ACE2 and multiple animal orthologs are functional receptors for bat coronavirus RaTG13 and SARS-CoV-2. <b>2021</b> , 66, 1215-1227  | 9  |
| 1294 | Therapeutic Potential of Glycosyl Flavonoids as Anti-Coronaviral Agents. <b>2021</b> , 14,  | 7  |
| 1293 | Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature. <b>2021</b> , 126, 1-46   | 3  |
| 1292 | The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?. <b>2021</b> , 9,                                       | 3  |
| 1291 | Landscape-Based Mutational Sensitivity Cartography and Network Community Analysis of the SARS-CoV-2 Spike Protein Structures: Quantifying Functional Effects of the Circulating D614G Variant. <b>2021</b> , 6, 16216-16233 | 3  |
| 1290 | Toward the prevention of coronavirus infection: what role can polymers play?. <b>2021</b> , 10, 100140  | 9  |
| 1289 | RETRACTED ARTICLE: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. <b>2021</b> ,  | 16 |
| 1288 | Photonics of human saliva: potential optical methods for the screening of abnormal health conditions and infections. <b>2021</b> , 13, 1-27   | 3  |
| 1287 | Which species does the virus like most: Binding modes study between SARS-CoV-2 S protein and ACE2 receptor. <b>2021</b> , 105, 107893   | 2  |
| 1286 | Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication. <b>2021</b> , 65, e0009721  | 20 |

|      |   |    |
|------|---|----|
| 1285 | Distinct cytokine profiles associated with COVID-19 severity and mortality. <b>2021</b> , 147, 2098-2107  | 18 |
| 1284 | Sphingolipids as Modulators of SARS-CoV-2 Infection. <b>2021</b> , 9, 689854  | 11 |
| 1283 | SARS-CoV-2 Genetic Variability and Non-Specific Immunity Associated with the Use of Different BCG Strains-A Molecular and Clinical Approach. <b>2021</b> , 9,                                     | 0  |
| 1282 | Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. <b>2021</b> , 12, 697074                              | 5  |
| 1281 | ACE2 Expression Is Upregulated in Inflammatory Corneal Epithelial Cells and Attenuated by Resveratrol. <b>2021</b> , 62, 25   | 1  |
| 1280 | Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction. <b>2021</b> , 188, 114564  | 3  |
| 1279 | SPIKE PROTEIN AND ITS PROTEASES ROLE IN SARS-COV-2 PATHOGENICITY AND TREATMENT; A REVIEW. <b>2021</b> , 64,   | 0  |
| 1278 | Prevention of Viral Effect and Enhancement of Immune System with the help of Herbal Plants and Himalayan Crude Drugs in SAR-COV-2 Patient; A Review..   |    |
| 1277 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. <b>2021</b> , 373, 642-648   | 92 |
| 1276 | Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies. <b>2021</b> , 13,  | 1  |
| 1275 | Deletion of ER-retention motif on SARS-CoV-2 spike protein reduces cell hybrid during cell-cell fusion. <b>2021</b> , 11, 114   | 2  |
| 1274 | Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <b>2021</b> , 6, 233   | 60 |
| 1273 | Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. <b>2021</b> , 12, 3802  | 28 |
| 1272 | Allosteric Cross-Talk among Spike's Receptor-Binding Domain Mutations of the SARS-CoV-2 South African Variant Triggers an Effective Hijacking of Human Cell Receptor. <b>2021</b> , 12, 5987-5993 | 9  |
| 1271 | SARS-CoV-2: An Overview of Virus Genetics, Transmission, and Immunopathogenesis. <b>2021</b> , 18,  | 5  |
| 1270 | Phyllanthin and hypophyllanthin, the isolated compounds of inhibit protein receptor of corona virus (COVID-19) through approach. <b>2021</b> , 32, 809-815  | 0  |
| 1269 | COVID-19 Pain and Comorbid Symptoms. <b>2021</b> , 36, 1-7  | 1  |
| 1268 | A Centenary Tale of Two Pandemics: The 1918 Influenza Pandemic and COVID-19, Part I. <b>2021</b> , 111, 1086-1094   | 9  |

|      |   |      |    |
|------|---|------|----|
| 1267 | Liver injury in COVID-19: Detection, pathogenesis, and treatment. <b>2021</b> , 27, 3022-3036   |      | 3  |
| 1266 | SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. <b>2021</b> , 11, 11998  |      | 2  |
| 1265 | AI-based spectroscopic monitoring of real-time interactions between SARS-CoV-2 and human ACE2. <b>2021</b> , 118,   |      | 2  |
| 1264 | Oral Health In Patients With COVID-19: A Literature Review. <b>2021</b> , 10,   |      |    |
| 1263 | Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection. <b>2021</b> , 21, 754-764  |      | 2  |
| 1262 | Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <b>2021</b> , 10,  |      | 2  |
| 1261 | Nanotraps for the containment and clearance of SARS-CoV-2. <b>2021</b> , 4, 2059-2082   |      | 14 |
| 1260 | SARS-CoV-2 mutation 614G creates an elastase cleavage site enhancing its spread in high AAT-deficient regions. <b>2021</b> , 90, 104760   |      | 18 |
| 1259 | Does the SARS-CoV-2 Spike Protein Receptor Binding Domain Interact Effectively with the DPP4 (CD26) Receptor? A Molecular Docking Study. <b>2021</b> , 22,  |      | 9  |
| 1258 | Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein. <b>2021</b> , 6, 15988-15999   |      | 10 |
| 1257 | Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review. <b>2021</b> , 14, 2259-2268  |      | 5  |
| 1256 | SARS-CoV-2 and hypertension. <b>2021</b> , 9, e14800  |      | 4  |
| 1255 | Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. <i>Cell</i> , <b>2021</b> , 184, 3438-3451.e10   | 56.2 | 30 |
| 1254 | SARS-CoV-2 Spreads through Cell-to-Cell Transmission. <b>2021</b> ,   |      | 9  |
| 1253 | Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?. <b>2021</b> , 188, 114517  |      | 13 |
| 1252 | ACE2 correlates with immune infiltrates in colon adenocarcinoma: Implication for COVID-19. <b>2021</b> , 95, 107568   |      | 1  |
| 1251 | Genetic Control of Human Infection with SARS-CoV-2. <b>2021</b> , 57, 627-641   |      | 2  |
| 1250 | Computational analysis of protein stability and allosteric interaction networks in distinct conformational forms of the SARS-CoV-2 spike D614G mutant: reconciling functional mechanisms through allosteric model of spike regulation. <b>2021</b> , 1-18 |      | 3  |

|      |   |    |
|------|---|----|
| 1249 | Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19. <b>2021</b> , 39, 713-726  | 7  |
| 1248 | Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19. <b>2021</b> , 28, 3803-3824   | 7  |
| 1247 | Modular Evolution of Coronavirus Genomes. <b>2021</b> , 13,   | 5  |
| 1246 | Innovative Nanotechnology a Boon for Fight Against Pandemic COVID-19. <b>2021</b> , 3,  | 1  |
| 1245 | Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India. <b>2021</b> , 558, 13-21  | 11 |
| 1244 | Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation. <b>2021</b> , 24, 879-890   | 15 |
| 1243 | A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. <b>2021</b> , 58, 4535-4563                                  | 5  |
| 1242 | How and to What Extent Immunological Responses to SARS-CoV-2 Shape Pulmonary Function in COVID-19 Patients. <b>2021</b> , 12, 628288  | 2  |
| 1241 | Machine Learning Reveals the Critical Interactions for SARS-CoV-2 Spike Protein Binding to ACE2. <b>2021</b> , 12, 5494-5502  | 14 |
| 1240 | A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients. <b>2021</b> , 59, e0019321                               | 8  |
| 1239 | Interplays between human microbiota and microRNAs in COVID-19 pathogenesis: a literature review. <b>2021</b> , 25, 1-7  | 4  |
| 1238 | Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection. <b>2021</b> , 335, 584-595                                 | 9  |
| 1237 | SARS-CoV-2 Antiviral Therapy. <b>2021</b> , e0010921  | 12 |
| 1236 | Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. <b>2021</b> , 12, 701198 | 4  |
| 1235 | Susceptibility of Well-Differentiated Airway Epithelial Cell Cultures from Domestic and Wild Animals to Severe Acute Respiratory Syndrome Coronavirus 2. <b>2021</b> , 27, 1811-1820            | 5  |
| 1234 | Evolution trace of SARS-CoV-2 from January 19 to March 12, 2020, in the United States. <b>2021</b> , 93, 6595-6604  |    |
| 1233 | COVID-19: <del>2021</del> <b>2021</b> , 86, 964-984   |    |
| 1232 | Translating SARS-CoV-2 wastewater-based epidemiology for prioritizing mass vaccination: a strategic overview. <b>2021</b> , 28, 42975-42980   | 2  |

|      |  |     |
|------|--|-----|
| 1231 | Evolution-Based Protein Engineering for Antifungal Peptide Improvement. <b>2021</b> , 38, 5175-5189  | 1   |
| 1230 | Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. <b>2021</b> , 17, 67   | 2   |
| 1229 | Relevance of BET Family Proteins in SARS-CoV-2 Infection. <b>2021</b> , 11,  | 3   |
| 1228 | Marine Sulfated Polysaccharides as Promising Antiviral Agents: A Comprehensive Report and Modeling Study Focusing on SARS CoV-2. <b>2021</b> , 19,   | 9   |
| 1227 | SARS-CoV-2 receptor-binding mutations and antibody contact sites. <b>2021</b> , 4, 149-158   | 5   |
| 1226 | Correlative multi-scale cryo-imaging unveils SARS-CoV-2 assembly and egress. <b>2021</b> , 12, 4629  | 24  |
| 1225 | Emerging neurotropic features of SARS-CoV-2. <b>2021</b> ,   | 2   |
| 1224 | The SARS-CoV-2 pandemic is associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: A multi-centre study of the first COVID-19 wave. <b>2021</b> , 38, e14640 | 13  |
| 1223 | Interaction of selected terpenoids with two SARS-CoV-2 key therapeutic targets: An in silico study through molecular docking and dynamics simulations. <b>2021</b> , 134, 104538                     | 8   |
| 1222 | Therapeutic antibodies under development for SARS-CoV-2. <b>2021</b> , 20200178  | 2   |
| 1221 | Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. <b>2021</b> ,  | 4   |
| 1220 | A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2). <b>2021</b> , 183, 2248-2261                  | 1   |
| 1219 | Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. <b>2021</b> , 29, 1331-1346   | 4   |
| 1218 | Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak. <b>2021</b> , 37, e3186  | 4   |
| 1217 | V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. <b>2021</b> , 95, e0061721    | 44  |
| 1216 | SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <b>2021</b> , 29, 1124-1136.e11   | 147 |
| 1215 | Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). <b>2021</b> , 505, 108326   | 19  |
| 1214 | Regulation Mechanism for the Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II. <b>2021</b> , 12, 6252-6261   | 3   |

|      |  |     |
|------|--|-----|
| 1213 | Carbon Nanotube Mask Filters and Their Hydrophobic Barrier and Hyperthermic Antiviral Effects on SARS-CoV-2. <b>2021</b> , 4, 8135-8144  | 7   |
| 1212 | ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions. <b>2021</b> , 17, e1009723   | 2   |
| 1211 | Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection. <b>2021</b> , 10, | 0   |
| 1210 | Non-RBM Mutations Impaired SARS-CoV-2 Spike Protein Regulated to the ACE2 Receptor Based on Molecular Dynamic Simulation. <b>2021</b> , 8, 614443  | 2   |
| 1209 | The Role of Alveolar Edema in COVID-19. <b>2021</b> , 10,  | 6   |
| 1208 | CyDisCo production of functional recombinant SARS-CoV-2 spike receptor binding domain. <b>2021</b> , 30, 1983-1990   | 7   |
| 1207 | Differential Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern. <b>2021</b> ,  | 16  |
| 1206 | Ultrasound and Doppler findings in pregnant women with SARS-CoV-2 infection. <b>2021</b> , 58, 111-120   | 7   |
| 1205 | The extent of molecular variation in novel SARS-CoV-2 after the six-month global spread. <b>2021</b> , 91, 104800  | 2   |
| 1204 | Effect of clinical isolate or cleavage site mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion. <b>2021</b> , 297, 100902  | 9   |
| 1203 | SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. <b>2021</b> ,   | 33  |
| 1202 | Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor. <b>2021</b> , 26, 100982  | 3   |
| 1201 | Nucleation and Growth of Iron (II) Oxide Nanoparticles in Thermal Arc Plasma and Their Interaction Study With SARS-CoV-2: A Computational Approach. <b>2021</b> , 49, 2278-2285  | 0   |
| 1200 | The Spike of SARS-CoV-2: Uniqueness and Applications. <b>2021</b> , 12, 663912   | 2   |
| 1199 | SARS-Cov-2 spike protein fragment 674-685 protects mitochondria from releasing cytochrome c in response to apoptogenic influence. <b>2021</b> , 561, 14-18   | 3   |
| 1198 | A novel method for conserved sequence extraction with prospective mutation prediction for SARS-CoV-2 PCR primer design. <b>2021</b> , 293, 114146  | 0   |
| 1197 | Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection. <b>2021</b> , 17, e1009715  | 6   |
| 1196 | SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. <b>2021</b> , 9,  | 245 |

|      |   |    |
|------|---|----|
| 1195 | The molecular basis for SARS-CoV-2 binding to dog ACE2. <b>2021</b> , 12, 4195  | 17 |
| 1194 | Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. <b>2021</b> , 58, 530-545 | 2  |
| 1193 | Coronavirus Disease: Epidemiology, Aetiology, Pathophysiology and Involvement of the Cardiovascular System.   |    |
| 1192 | Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. <b>2021</b> , 7, 2546-2564   | 8  |
| 1191 | COVID-19: Myths and Reality. <b>2021</b> , 86, 800-817  | 2  |
| 1190 | A Fungal Defensin Targets the SARS-CoV-2 Spike Receptor-Binding Domain. <b>2021</b> , 7,  | 1  |
| 1189 | Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates. <b>2021</b> , 1, 100003  | 3  |
| 1188 | Preliminary Structural Data Revealed That the SARS-CoV-2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the Wild Type to Enhance the Infectivity. <b>2021</b> , 22, 2641-2649                                     | 26 |
| 1187 | Dual inhibition of COVID-19 spike glycoprotein and main protease 3CLpro by Withanone from. <b>2021</b> , 13, 359-369  | 6  |
| 1186 | A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. <b>2021</b> , 36, 109433  | 25 |
| 1185 | Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket. <b>2021</b> , 143, 11349-11360                                      | 13 |
| 1184 | Safety and Pharmacokinetics of Intranasally Administered Heparin.. <b>2022</b> ,  |    |
| 1183 | PDZ-containing proteins targeted by the ACE2 receptor.  | 4  |
| 1182 | Susceptibilities of human ACE2 genetic variants in coronavirus infection.   | 0  |
| 1181 | A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. <b>2021</b> , 12, 4635  | 15 |
| 1180 | Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents. <b>2021</b> , 18, 1281-1289   | 1  |
| 1179 | Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2. <b>2021</b> , 120, 2902-2913   | 9  |
| 1178 | Stroke Associated with SARS-CoV-2 Infection and its Pathogenesis: A Systematic Review.. <b>2021</b> , 12, 569-586   | 1  |



|      |   |    |
|------|---|----|
| 1177 | Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility. <b>2021</b> , 433, 167051  | 28 |
| 1176 | Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19. <b>2021</b> , 11, e046738 | 4  |
| 1175 | A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. <b>2021</b> , 21, 273-283   | 6  |
| 1174 | The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion?. <b>2021</b> , 12, 693579  | 0  |
| 1173 | The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications. <b>2021</b> , 13,  | 3  |
| 1172 | What can the neurological manifestations of COVID-19 tell us: a meta-analysis. <b>2021</b> , 19, 363  | 4  |
| 1171 | Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, M and PL of SARS-CoV-2: Protein-Protein Interactions, Dynamics Simulations and Free Energy Calculations. <b>2021</b> , 26,                         | 4  |
| 1170 | Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients. <b>2021</b> , 12, 700220  | 2  |
| 1169 | Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <b>2021</b> , 12, 699949   | 7  |
| 1168 | Lower Serum Angiotensin-Converting Enzyme Level in Relation to Hyperinflammation and Impaired Antiviral Immune Response Contributes to Progression of COVID-19 Infection. <b>2021</b> , 10, 2431-2446                               | 2  |
| 1167 | Spike protein mutational landscape in India during the complete lockdown phase: Could Muller's ratchet be a future game-changer for COVID-19?. <b>2021</b> , 92, 104874   | 1  |
| 1166 | Comprehensive analysis of SARS-COV-2 drug targets and pharmacological aspects in treating the COVID-19. <b>2021</b> ,   | 2  |
| 1165 | Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. <b>2021</b> , 11, 168   | 10 |
| 1164 | Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19. <b>2021</b> , 278, 119510  | 1  |
| 1163 | Investigation of nonsynonymous mutations in the spike protein of SARS-CoV-2 and its interaction with the ACE2 receptor by molecular docking and MM/GBSA approach. <b>2021</b> , 135, 104654   | 6  |
| 1162 | A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. <b>2021</b> , 12, 5000  | 7  |
| 1161 | An unexpected biomaterial against SARS-CoV-2: Bio-polyphosphate blocks binding of the viral spike to the cell receptor. <b>2021</b> , 51, 504-504   | 2  |
| 1160 | In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry. <b>2021</b> , 45, 442-458   | 0  |



|      |  |     |
|------|--|-----|
| 1159 | Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. <b>2021</b> , 21, 1107-1119                    | 145 |
| 1158 | The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. <b>2021</b> , 43, 177-196   | 1   |
| 1157 | Age and gender differences in ACE2 and TMPRSS2 expressions in oral epithelial cells. <b>2021</b> , 19, 358   | 3   |
| 1156 | Nervous System-Systemic Crosstalk in SARS-CoV-2/COVID-19: A Unique Dyshomeostasis Syndrome. <b>2021</b> , 15, 727060   | 0   |
| 1155 | Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics. <b>2021</b> , 12, 4887   | 8   |
| 1154 | Identification of Potent Small Molecule Inhibitors of SARS-CoV-2 Entry.  | 1   |
| 1153 | COVID-19 and metabolic comorbidities: An update on emerging evidences for optimal therapies. <b>2021</b> , 140, 111685   | 3   |
| 1152 | Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation. <b>2021</b> , 61, 4425-4441   | 17  |
| 1151 | Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets. <b>2021</b> , 1-11  | 0   |
| 1150 | Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. <b>2021</b> , 97, 107828  | 7   |
| 1149 | Probing the Allosteric Inhibition Mechanism of a Spike Protein Using Molecular Dynamics Simulations and Active Compound Identifications. <b>2021</b> ,   | 3   |
| 1148 | Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. <b>2021</b> , 12, 679841   | 6   |
| 1147 | Analysis of endogenous oxidative damage markers and association with pulmonary involvement severity in patients with SARS-CoV-2 pneumonia. <b>2021</b> , 51, 429-434   | 1   |
| 1146 | Conformational flexibility and structural variability of SARS-CoV2 S protein. <b>2021</b> , 29, 834-845.e5   | 11  |
| 1145 | MicroRNA-28-3p inhibits angiotensin-converting enzyme $\beta$ ectodomain shedding in 293T cells treated with the spike protein of severe acute respiratory syndrome coronavirus $\beta$ by targeting A disintegrin and metalloproteinase 17. <b>2021</b> , 48, | 0   |
| 1144 | Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility. <b>2021</b> , 135, 1805-1824   | 5   |
| 1143 | Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption.  | 0   |
| 1142 | The impact of high-resolution structural data on stemming the COVID-19 pandemic. <b>2021</b> , 49, 127-138   | 1   |

|      |   |    |
|------|---|----|
| 1141 | Performance assessment of seven SARS-CoV-2 IgG enzyme-linked immunosorbent assays. <b>2021</b> , 93, 6696-6702  | 1  |
| 1140 | Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. <b>2021</b> , 135, 104634   | 6  |
| 1139 | Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations. <b>2021</b> , 19, 113  | 4  |
| 1138 | Rarely Recognized Antibody Diversification in Covid-19 Evolution to Counteract Advanced SARS-CoV-2 Evasion Strategies, and Implications for Prophylactic Treatment. <b>2021</b> , 12, 624675                | 3  |
| 1137 | N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation. <b>2021</b> , 9, 697035  | 11 |
| 1136 | SARS-CoV-2 NSP12 Protein Is Not an Interferon- $\lambda$ Antagonist. <b>2021</b> , 95, e0074721   | 13 |
| 1135 | An in silico scientific basis for LL-37 as a therapeutic for Covid-19. <b>2021</b> , 11, 997  | 8  |
| 1134 | Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <b>2021</b> , 40, e107985   | 3  |
| 1133 | Binding Strength and Hydrogen Bond Numbers between COVID-19 RBD and HVR of Antibody. <b>2021</b> , 13, 1705-1716  | 19 |
| 1132 | Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. <b>2021</b> , 13, 2107-2119   | 24 |
| 1131 | SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <b>2021</b> , 7, 71  | 7  |
| 1130 | Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. <b>2021</b> , 95, e0040221                       | 22 |
| 1129 | Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice. <b>2021</b> , 11, 707194  | 2  |
| 1128 | The interaction of the severe acute respiratory syndrome coronavirus 2 spike protein with drug-inhibited angiotensin converting enzyme 2 studied by molecular dynamics simulation. <b>2021</b> , 11, 707194 | 7  |
| 1127 | Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. <b>2021</b> , 17, 2107-2119  | 4  |
| 1126 | A Computational Approach to Evaluate the Combined Effect of SARS-CoV-2 RBD Mutations and ACE2 Receptor Genetic Variants on Infectivity: The COVID-19 Host-Pathogen Nexus. <b>2021</b> , 17, 2107-2119       | 4  |
| 1125 | Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. <b>2021</b> , 17, 2107-2119  |    |

|      |   |     |
|------|---|-----|
| 1123 | A computational study of cooperative binding to multiple SARS-CoV-2 proteins. <b>2021</b> , 11, 16307   | 2   |
| 1122 | SARS-CoV-2 Antibody Testing: Where Are We Now?. <b>2021</b> ,   |     |
| 1121 | Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs. <b>2021</b> , 1179, 122862                                 | 1   |
| 1120 | Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era. <b>2021</b> , 3, 125-133  |     |
| 1119 | Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. <b>2021</b> ,  | 15  |
| 1118 | Mechanical activation of spike fosters SARS-CoV-2 viral infection. <b>2021</b> , 31, 1047-1060  | 4   |
| 1117 | SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. <b>2021</b> , 118,   | 106 |
| 1116 | Recombination and lineage-specific mutations linked to the emergence of SARS-CoV-2. <b>2021</b> , 13, 124   | 8   |
| 1115 | The Emergence and Spread of Novel SARS-CoV-2 Variants. <b>2021</b> , 9, 696664  | 5   |
| 1114 | Inactivation of SARS-CoV-2 by deep ultraviolet light emitting diode: A review. <b>2021</b> , 60, 090501   | 3   |
| 1113 | Expression pattern and function of SARS-CoV-2 Receptor ACE2. <b>2021</b> , 3, 312-312   | 1   |
| 1112 | Molecular simulation studies of the interactions between the human/pangolin/cat/bat ACE2 and the receptor binding domain of the SARS-CoV-2 spike protein. <b>2021</b> , 187, 1-13             | 7   |
| 1111 | Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. <b>2021</b> , 14, | 3   |
| 1110 | Structural Dissection of Viral Spike-Protein Binding of SARS-CoV-2 and SARS-CoV-1 to the Human Angiotensin-Converting Enzyme 2 (ACE2) as Cellular Receptor. <b>2021</b> , 9,                  | 1   |
| 1109 | Interaction between spike protein of SARS-CoV-2 and human virus receptor ACE2 using two-color fluorescence cross-correlation spectroscopy.  |     |
| 1108 | Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein. <b>2021</b> , 6, e0064721  | 13  |
| 1107 | "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry. <b>2021</b> , 22,  | 2   |
| 1106 | Sterically confined rearrangements of SARS-CoV-2 Spike protein control cell invasion. <b>2021</b> , 10,   | 3   |

|      |   |    |
|------|---|----|
| 1105 | Viral proteins recognized by different TLRs. <b>2021</b> , 93, 6116-6123  | 4  |
| 1104 | Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein. <b>2021</b> , 1-12                                    | 3  |
| 1103 | Refining the N-Termini of the SARS-CoV-2 Spike Protein and Its Discrete Receptor-Binding Domain. <b>2021</b> , 20, 4427-4434  | 1  |
| 1102 | Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications.. <b>2021</b> , 4, 215-230                            | 0  |
| 1101 | Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain. <b>2021</b> , 478, 3671-3684   | 3  |
| 1100 | The pH Effects on SARS-CoV and SARS-CoV-2 Spike Proteins in the Process of Binding to hACE2. <b>2021</b> ,  | 1  |
| 1099 | SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection. <b>2021</b> , 38, 611-623  | 3  |
| 1098 | The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. <b>2021</b> , 71, 103544                                      | 16 |
| 1097 | Development of a novel, pan-variant aerosol intervention for COVID-19. <b>2021</b> ,  | 2  |
| 1096 | Neutral evolution test of the spike protein of SARS-CoV-2 and its implications in the binding to ACE2. <b>2021</b> , 11, 18847  | 4  |
| 1095 | Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants. <b>2021</b> , 17, e1009380            | 5  |
| 1094 | S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. <b>2021</b> , 6, 343 | 3  |
| 1093 | Cutaneous manifestations in children with SARS-CoV-2 infection and/or COVID-19: what do we know after 10 months under this pandemic?. <b>2022</b> , 61, 39-45               | 1  |
| 1092 | Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis. <b>2021</b> , 12, 718136  | 4  |
| 1091 | Identifying Distinct Structural Features of the SARS-CoV-2 Spike Protein Fusion Domain Essential for Membrane Interaction. <b>2021</b> , 60, 2978-2986                      | 1  |
| 1090 | Lymphopenia in Covid-19: A single center retrospective study of 589 cases. <b>2021</b> , 69, 102816   | 2  |
| 1089 | Evolution of the SARS-CoV-2 proteome in three dimensions (3D) during the first 6 months of the COVID-19 pandemic. <b>2021</b> ,   | 14 |
| 1088 | In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. <b>2021</b> ,                    | 22 |

|      |  |    |
|------|--|----|
| 1087 | The Antiviral Roles of Hydrogen Sulfide by Blocking the Interaction between SARS-CoV-2 and Its Potential Cell Surface Receptors. <b>2021</b> , 2021, 7866992   | 4  |
| 1086 | Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2. <b>2021</b> , 9, e0119921   | 1  |
| 1085 | Reappraisal of Dietary Phytochemicals for Coronavirus Infection: Focus on Hesperidin and Quercetin.  |    |
| 1084 | Advances in understanding the formation and fate of B-cell memory in response to immunisation or infection.  | 2  |
| 1083 | Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics. <b>2021</b> , 164, 3-18  | 5  |
| 1082 | "SLC-omics" of the kidney: solute transporters along the nephron. <b>2021</b> , 321, C507-C518   | 1  |
| 1081 | The SARS-CoV-2 spike protein is vulnerable to moderate electric fields. <b>2021</b> , 12, 5407   | 5  |
| 1080 | Surface Engineering of Graphene through Heterobifunctional Supramolecular-Covalent Scaffolds for Rapid COVID-19 Biomarker Detection. <b>2021</b> , 13, 43696-43707   | 3  |
| 1079 | Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India). <b>2021</b> , 7, 100054 | 23 |
| 1078 | Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. <i>Cell</i> , <b>2021</b> , 184, 4713-4733; e622   | 54 |
| 1077 | Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. <b>2021</b> , 297, 101202  | 7  |
| 1076 | Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. <b>2021</b> , 11, 499  | 9  |
| 1075 | Interactive Mechanism of Potential Inhibitors with Glycosyl for SARS-CoV-2 by Molecular Dynamics Simulation. <b>2021</b> , 9, 1749   |    |
| 1074 | Therapeutic approaches in covid-19 followed before arrival of any vaccine. <b>2021</b> , 48, 1258-1258   | 1  |
| 1073 | Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. <b>2021</b> , 193, 105127  | 6  |
| 1072 | Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study. <b>2021</b> , 10,   | 11 |
| 1071 | Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2. <b>2021</b> , 147, 62-71  | 12 |
| 1070 | Structure, interface stability and hot-spots identification for RBD(SARS-CoV-2):hACE2 complex formation. 1-12  | 1  |

|      |  |    |
|------|--|----|
| 1069 | Antigenic sites in SARS-CoV-2 spike RBD show molecular similarity with pathogenic antigenic determinants and harbors peptides for vaccine development. <b>2021</b> , 226, 152091   | 5  |
| 1068 | Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. <b>2021</b> ,   | 4  |
| 1067 | Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms. <b>2021</b> , 6, 26354-26371  | 2  |
| 1066 | Curious Binding Energy Increase between the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein and Angiotensin-Converting Enzyme 2 Adsorbed on a Silane Monolayer from Molecular Dynamics Simulations. <b>2021</b> , 125, 11078-11090 | 3  |
| 1065 | Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. <b>2021</b> , 12, 752003   | 8  |
| 1064 | Exploring the Interaction between E484K and N501Y Substitutions of SARS-CoV-2 in Shaping the Transmission Advantage of COVID-19 in Brazil: A Modeling Study. <b>2021</b> ,   | 3  |
| 1063 | Structural and kinetic analyses of holothurian sulfated glycans suggest potential treatment for SARS-CoV-2 infection. <b>2021</b> , 297, 101207  | 7  |
| 1062 | Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics. <b>2021</b> , 8, e2100460   | 8  |
| 1061 | Competing Bioaerosols May Influence the Seasonality of Influenza-Like Illnesses, including COVID-19. The Chicago Experience. <b>2021</b> , 10,   | 4  |
| 1060 | A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding. <b>2021</b> , 571, 152-158   | 3  |
| 1059 | In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs. <b>2021</b> , 1  | 5  |
| 1058 | Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction. <b>2021</b> , 9, 740702   | 2  |
| 1057 | Development and Efficacy of Lateral Flow Point-of-Care Testing Devices for Rapid and Mass COVID-19 Diagnosis by the Detections of SARS-CoV-2 Antigen and Anti-SARS-CoV-2 Antibodies. <b>2021</b> , 11,                                     | 4  |
| 1056 | Impact of air pollution and smoking on COVID-19: a review. <b>2021</b> , 15,   |    |
| 1055 | Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. <b>2021</b> , 1-14   | 2  |
| 1054 | Molecular docking studies of Indian variants of pathophysiological proteins of SARS-CoV-2 with selected drug candidates. <b>2021</b> , 100, 1  | 1  |
| 1053 | Accommodating receptor flexibility and free energy calculation to reduce false positive binders in the discovery of natural products blockers of SARS-COV-2 spike RBD-ACE2 interface. <b>2021</b> , 27, 101024                             |    |
| 1052 | An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <b>2021</b> , 29, 1437-1453.e8   | 20 |

|      |   |         |
|------|---|---------|
| 1051 | Diabetes and COVID-19: Role of insulin resistance as a risk factor for COVID-19 severity. <b>2021</b> , 12, 1550-1562   | 1       |
| 1050 | Identification of RBD subdomain of spike protein from Pro-Thr for applications in vaccine development against SARS-CoV2. <b>2021</b> , 1240, 130534   | 2       |
| 1049 | Structural biology of SARS-CoV-2 and implications for therapeutic development. <b>2021</b> , 19, 685-700  | 38      |
| 1048 | ACE2 in the Gut: The Center of the 2019-nCoV Infected Pathology. <b>2021</b> , 8, 708336  | 3       |
| 1047 | Allosteric Control of Structural Mimicry and Mutational Escape in the SARS-CoV-2 Spike Protein Complexes with the ACE2 Decoys and Miniprotein Inhibitors: A Network-Based Approach for Mutational Profiling of Binding and Signaling. <b>2021</b> , 61, 5172-5191 | 2       |
| 1046 | Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <b>2021</b> , 33, 529-540  | 5       |
| 1045 | Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , <b>2021</b> , 184, 5432-5447.e16  | 56.2 34 |
| 1044 | Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque. <b>2021</b> , 9,  | 1       |
| 1043 | SARS-CoV-2, COVID-19 and the Ageing Immune System. <b>2021</b> , 1, 769-782   | 34      |
| 1042 | Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. <b>2021</b> , 118,  | 20      |
| 1041 | Wave-wise comparative genomic study for revealing the complete scenario and dynamic nature of COVID-19 pandemic in Bangladesh. <b>2021</b> , 16, e0258019   | 5       |
| 1040 | Antiviral and antibacterial activity of hand sanitizer and surface disinfectant formulations. <b>2021</b> , 609, 121139   | 0       |
| 1039 | The Role of Spike Protein Mutations in the Infectious Power of SARS-COV-2 Variants: A Molecular Interaction Perspective. <b>2021</b> ,  | 4       |
| 1038 | Host proviral and antiviral factors for SARS-CoV-2. <b>2021</b> , 57, 475-488   | 3       |
| 1037 | Featuring ACE2 binding SARS-CoV and SARS-CoV-2 through a conserved evolutionary pattern of amino acid residues. <b>2021</b> , 1-10  | 1       |
| 1036 | Human genetic basis of coronavirus disease 2019. <b>2021</b> , 6, 344   | 4       |
| 1035 | [Impact of SARS-CoV-2 on fertility, gametes' quality and Assisted Reproduction Technology]. <b>2021</b> ,   |         |
| 1034 | Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. <b>2021</b> , 44, 688-695  | 0       |



|      |   |    |
|------|---|----|
| 1033 | Computational studies reveal Fluorine based quinolines to be potent inhibitors for proteins involved in SARS-CoV-2 assembly. <b>2021</b> , 250, 109865                            | 2  |
| 1032 | Proteases and variants: context matters for SARS-CoV-2 entry assays. <b>2021</b> , 50, 49-58  | 5  |
| 1031 | Cell entry by SARS-CoV-2. <b>2021</b> , 46, 848-860   | 34 |
| 1030 | Nanomedicine based approaches for combating viral infections. <b>2021</b> , 338, 80-104   | 6  |
| 1029 | Design and synthesis of pyrazolone-based compounds as potent blockers of SARS-CoV-2 viral entry into the host cells. <b>2021</b> , 1241, 130665                                   | 6  |
| 1028 | Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases.. <b>2022</b> , 12, 1126-1147   | 2  |
| 1027 | Structure of SARS-CoV-2 spike protein. <b>2021</b> , 50, 173-182  | 19 |
| 1026 | Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry. <b>2021</b> , 172, 105820          | 9  |
| 1025 | Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents. <b>2021</b> , 278, 114303                  | 3  |
| 1024 | Structure-based study of immune receptors as eligible binding targets of coronavirus SARS-CoV-2 spike protein. <b>2021</b> , 108, 107997  | 2  |
| 1023 | The Science of Frailty: Sex Differences. <b>2021</b> , 37, 625-638  | 0  |
| 1022 | A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <b>2021</b> , 100, 108162  | 17 |
| 1021 | Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization. <b>2021</b> , 226, 113863                   | 4  |
| 1020 | SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. <b>2021</b> , 1867, 166264 | 0  |
| 1019 | DCs-based therapies: potential strategies in severe SARS-CoV-2 infection. <b>2021</b> , 18, 406-418   | 7  |
| 1018 | Host-shift as the cause of emerging infectious diseases: Experimental approaches using Drosophila-virus interactions. <b>2020</b> , 44, e20200197                                 | 2  |
| 1017 | Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study. <b>2021</b> , 1  | 7  |
| 1016 | Comparisons of the immunological landscape between COVID-19, influenza, and respiratory syncytial virus patients by clustering analysis. <b>2021</b> , 19, 2347-2355              | 0  |



|      |   |    |
|------|---|----|
| 1015 | Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. <b>2021</b> , 19, 4684-4701  | 6  |
| 1014 | Probing conformational hotspots for the recognition and intervention of protein complexes by lysine reactivity profiling. <b>2020</b> , 12, 1451-1457   | 7  |
| 1013 | Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. <b>2021</b> , 10, 1574-1588   | 3  |
| 1012 | ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV. <b>2021</b> , 57, 5949-5952   | 6  |
| 1011 | Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients. <b>2021</b> , 31, 1-12   | 22 |
| 1010 | Dynamic Network Modeling of Allosteric Interactions and Communication Pathways in the SARS-CoV-2 Spike Trimer Mutants: Differential Modulation of Conformational Landscapes and Signal Transmission via Cascades of Regulatory Switches. <b>2021</b> , 125, 850-873 | 18 |
| 1009 | No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. <b>2021</b> , 11, 413  | 77 |
| 1008 | Human SARS CoV-2 spike protein mutations. <b>2021</b> , 89, 569-576   | 67 |
| 1007 | Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. <b>2021</b> , 19, 2806-2818   | 10 |
| 1006 | Pharmacotherapeutics of SARS-CoV-2 Infections. <b>2021</b> , 16, 12-37  | 3  |
| 1005 | Nicotinic cholinergic system and COVID-19: evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions. <b>2021</b> , 8, 73-83   | 18 |
| 1004 | Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. <b>2021</b> , 11,  | 0  |
| 1003 | Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. <b>2021</b> , 21, e8  | 2  |
| 1002 | Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate. <b>2021</b> , 9,   | 12 |
| 1001 | COVID-19 Diagnostics: State-of-the-Art and Challenges for Rapid, Scalable, and High-Accuracy Screening. <b>2020</b> , 8, 605702   | 12 |
| 1000 | Could Dermaseptin Analogue be a Competitive Inhibitor for ACE2 Towards Binding with Viral Spike Protein Causing COVID19?: Computational Investigation. <b>2021</b> , 27, 1-14   | 4  |
| 999  | Development and application of therapeutic antibodies against COVID-19. <b>2021</b> , 17, 1486-1496   | 16 |
| 998  | Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2. <b>2021</b> , 22, 714-725   | 12 |

|     |   |     |
|-----|---|-----|
| 997 | Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. <b>2021</b> , 16, e0245382 | 4   |
| 996 | Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein. <b>2021</b> , 9, 61                     | 10  |
| 995 | Proposing high-affinity inhibitors from Glycyrrhiza glabra L. against SARS-CoV-2 infection: virtual screening and computational analysis. <b>2021</b> , 45, 15977-15995       | 5   |
| 994 | Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol. <b>2020</b> , 7, 618651  | 24  |
| 993 | Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. <b>2021</b> , 12, 250  | 45  |
| 992 | The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis. <b>2021</b> , 22,                                  | 35  |
| 991 | Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme <sup>®</sup> a medical device mouth spray against the common cold. <b>2021</b> , 93, 1792-1795                  | 6   |
| 990 | An Overview of the Crystallized Structures of the SARS-CoV-2. <b>2020</b> , 39, 600-618   | 17  |
| 989 | Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. <b>2020</b> , 63, 1833-1849   | 13  |
| 988 | Asthma-associated risk for COVID-19 development. <b>2020</b> , 146, 1295-1301   | 50  |
| 987 | ACE2 and gut amino acid transport. <b>2020</b> , 134, 2823-2833   | 33  |
| 986 | Covid-19: the renin-angiotensin system imbalance hypothesis. <b>2020</b> , 134, 1259-1264   | 49  |
| 985 | ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. <b>2020</b> , 134, 2851-2871  | 19  |
| 984 | ACE2: from protection of liver disease to propagation of COVID-19. <b>2020</b> , 134, 3137-3158   | 15  |
| 983 | Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin. <b>2020</b> , 120, 1700-1715 | 116 |
| 982 | Cross-species recognition of SARS-CoV-2 to bat ACE2. <b>2021</b> , 118,   | 32  |
| 981 | The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. <b>2021</b> , 22, 742-768                                      | 16  |
| 980 | Evolutionary and codon usage preference insights into spike glycoprotein of SARS-CoV-2. <b>2021</b> , 22, 1006-1022   | 7   |

|     |  |    |
|-----|--|----|
| 979 | SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia. <b>2021</b> , 162, 243-252  | 70 |
| 978 | Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. <b>2021</b> , 30, 252-263   | 2  |
| 977 | Identification of a SARS-like bat coronavirus that shares structural features with the spike glycoprotein receptor-binding domain of SARS-CoV-2. <b>2020</b> , 2, acmi000166 | 2  |
| 976 | Recombination and lineage-specific mutations linked to the emergence of SARS-CoV-2. <b>2021</b> ,  | 15 |
| 975 | Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Viruses Reveal Mosaic Pattern of Phylogeographical Distribution.   | 4  |
| 974 | Recombination and purifying selection preserves covariant movements of mosaic SARS-CoV-2 protein S.  | 2  |
| 973 | Biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and implications for infectivity.  | 15 |
| 972 | Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2.  | 2  |
| 971 | Multidrug treatment with nelfinavir and cepharanthine against COVID-19.  | 35 |
| 970 | Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy.   | 6  |
| 969 | Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.  | 1  |
| 968 | Computational Electrostatics Predict Variations in SARS-CoV-2 Spike and Human ACE2 Interactions.   | 1  |
| 967 | Molecular Architecture of Early Dissemination and Evolution of the SARS-CoV-2 Virus in Metropolitan Houston, Texas.  | 12 |
| 966 | A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.   | 13 |
| 965 | Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission.  | 3  |
| 964 | Missense variants in ACE2 are predicted to encourage and inhibit interaction with SARS-CoV-2 Spike and contribute to genetic risk in COVID-19.                               | 8  |
| 963 | Computational analysis on the ACE2-derived peptides for neutralizing the ACE2 binding to the spike protein of SARS-CoV-2.  | 3  |
| 962 | Global Spread of SARS-CoV-2 Subtype with Spike Protein Mutation D614G is Shaped by Human Genomic Variations that Regulate Expression of TMPRSS2 and MX1 Genes.               | 63 |

|     |  |    |
|-----|--|----|
| 961 | Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients.  | 16 |
| 960 | Neutralization of SARS-CoV-2 by destruction of the prefusion Spike.  | 4  |
| 959 | Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin Converting Enzyme 2 Receptor.  | 5  |
| 958 | A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability.                                | 29 |
| 957 | Comparison of SARS-CoV-2 spike protein binding to human, pet, farm animals, and putative intermediate hosts ACE2 and ACE2 receptors.                             | 5  |
| 956 | SARS-CoV-2 Spike Glycoprotein and ACE2 interaction reveals modulation of viral entry in wild and domestic animals.   | 1  |
| 955 | Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas. <b>2020,</b>  | 19 |
| 954 | ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. <b>2020,</b>                                      | 19 |
| 953 | Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.  | 41 |
| 952 | Infection Groups Differential (IGD) Score Reveals Infection Ability Difference between SARS-CoV-2 and Other Coronaviruses.                                       | 2  |
| 951 | COVID-19 genomic susceptibility: Definition of ACE2 variants relevant to human infection with SARS-CoV-2 in the context of ACMG/AMP Guidance.                    | 3  |
| 950 | COVID-19: age, Interleukin-6, C-Reactive Protein and lymphocytes as key clues from a multicentre retrospective study in Spain.                                   | 3  |
| 949 | Distribution of ACE2, CD147, cyclophilins, CD26 and other SARS-CoV-2 associated molecules in human tissues and immune cells in health and disease.               | 7  |
| 948 | Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein. <b>2020,</b>                                      | 18 |
| 947 | Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?.  | 6  |
| 946 | High Throughput Designing and Mutational Mapping of RBD-ACE2 Interface Guide Non-Conventional Therapeutic Strategies for COVID-19.                               | 6  |
| 945 | A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. <b>2020,</b>                          | 9  |
| 944 | Immunization with the receptorBinding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. | 4  |

|     |   |     |
|-----|---|-----|
| 943 | Systemic Effects of Missense Mutations on SARS-CoV-2 Spike Glycoprotein Stability and Receptor Binding Affinity.  | 4   |
| 942 | Structural basis of SARS-CoV-2 spike protein induced by ACE2.   | 0   |
| 941 | Plasmin cascade mediates thrombolytic events in SARS-CoV-2 infection via complement and platelet-activating systems.  | 1   |
| 940 | Closing coronavirus spike glycoproteins by structure-guided design. <b>2020,</b>  | 7   |
| 939 | SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.                                     | 8   |
| 938 | Insights on cross-species transmission of SARS-CoV-2 from structural modeling. <b>2020,</b>   | 7   |
| 937 | D936Y and Other Mutations in the Fusion Core of the SARS-Cov-2 Spike Protein Heptad Repeat 1 Undermine the Post-Fusion Assembly.                                  | 8   |
| 936 | SARS-CoV-2 nucleocapsid protein undergoes liquid-liquid phase separation stimulated by RNA and partitions into phases of human ribonucleoproteins. <b>2020,</b>   | 18  |
| 935 | Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region.            | 5   |
| 934 | Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein. <b>2020,</b>  | 27  |
| 933 | Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. <b>2020,</b>   | 15  |
| 932 | The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. <b>2020,</b>  | 294 |
| 931 | Cell entry of SARS-CoV-2 conferred by angiotensin-converting enzyme 2 (ACE2) of different species.  | 3   |
| 930 | Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike. <b>2020,</b>  | 25  |
| 929 | Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <b>2020,</b> | 4   |
| 928 | Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and correlation to tissue damage.  | 9   |
| 927 | High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. <b>2020,</b>   | 6   |
| 926 | Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19. <b>2020,</b>                           | 19  |

|     |  |    |
|-----|--|----|
| 925 | Which animals are at risk? Predicting species susceptibility to Covid-19. <b>2020,</b>   | 7  |
| 924 | Robust three-dimensional expansion of human adult alveolar stem cells and SARS-CoV-2 infection.  | 1  |
| 923 | Lethality of SARS-CoV-2 infection in K18 human angiotensin converting enzyme 2 transgenic mice.  | 9  |
| 922 | On the molecular mechanism of SARS-CoV-2 retention in the upper respiratory tract. <b>2020,</b>  | 1  |
| 921 | An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation. <b>2020,</b>   | 20 |
| 920 | Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients: in vitro and in vivo preliminary evidences.   | 9  |
| 919 | Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. <b>2020,</b>   | 10 |
| 918 | Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction. <b>2020,</b>          | 4  |
| 917 | Spike protein mutational landscape in India: Could Muller's ratchet be a future game-changer for COVID-19?.  | 3  |
| 916 | Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies. <b>2020,</b>                      | 18 |
| 915 | Determinants of SARS-CoV-2 receptor gene expression in upper and lower airways. <b>2020,</b>   | 8  |
| 914 | Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction. <b>2020,</b>   | 1  |
| 913 | Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins.  | 2  |
| 912 | Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2. <b>2020,</b> | 12 |
| 911 | Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.   | 1  |
| 910 | Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells. <b>2020,</b>  | 8  |
| 909 | The flexibility of ACE2 in the context of SARS-CoV-2 infection. <b>2020,</b>   | 6  |
| 908 | Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein. <b>2020,</b>  | 4  |

|     |   |    |
|-----|---|----|
| 907 | Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution.  | 1  |
| 906 | Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. <b>2020,</b>  | 11 |
| 905 | In silico identification and validation of inhibitors of the interaction between neuropilin receptor 1 and SARS-CoV-2 Spike protein. <b>2020,</b>                                       | 11 |
| 904 | Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2. <b>2020,</b>   | 4  |
| 903 | Design, expression, purification and characterization of a YFP-tagged 2019-nCoV spike receptor-binding domain construct.  | 1  |
| 902 | SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro.      | 14 |
| 901 | A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.   | 6  |
| 900 | Extremely potent human monoclonal antibodies from convalescent Covid-19 patients.   | 6  |
| 899 | Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.   | 2  |
| 898 | Transferrin receptor is another receptor for SARS-CoV-2 entry.  | 18 |
| 897 | A computational approach to evaluate the combined effect of SARS-CoV-2 RBD mutations and ACE2 receptor genetic variants on infectivity: The COVID-19 host-pathogen nexus.               | 3  |
| 896 | Susceptibility of well-differentiated airway epithelial cell cultures from domestic and wildlife animals to SARS-CoV-2.   | 4  |
| 895 | N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation.  | 7  |
| 894 | A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2. <b>2020,</b>  | 8  |
| 893 | Role of Long-range Allosteric Communication in Determining the Stability and Disassembly of SARS-COV-2 in Complex with ACE2. <b>2020,</b>   | 7  |
| 892 | Evolution of the SARS-CoV-2 proteome in three dimensions (3D) during the first six months of the COVID-19 pandemic. <b>2020,</b>  | 15 |
| 891 | A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations. | 8  |
| 890 | Ca <sup>2+</sup> -dependent mechanism of membrane insertion and destabilization by the SARS-CoV-2 fusion peptide. <b>2021,</b>  | 1  |

|     |  |     |
|-----|--|-----|
| 889 | Thiol drugs decrease SARS-CoV-2 lung injury and disrupt SARS-CoV-2 spike complex binding to ACE2. <b>2021,</b>   | 11  |
| 888 | Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2.   | 6   |
| 887 | SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. <b>2020,</b>  | 153 |
| 886 | Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. <b>2020, 130, 6141-6150</b>                         | 239 |
| 885 | Molecular-level Anatomy of SARS-CoV-2 for the Battle against COVID-19 Pandemic.  | 7   |
| 884 | Computational screening for potential drug candidates against the SARS-CoV-2 main protease. <b>2020, 9,</b>  | 9   |
| 883 | Computational screening for potential drug candidates against the SARS-CoV-2 main protease. <b>2020, 9, 514</b>  | 7   |
| 882 | Immunopathology of galectin-3: an increasingly promising target in COVID-19. <b>2020, 9, 1078</b>  | 22  |
| 881 | Immunopathology of galectin-3: an increasingly promising target in COVID-19. <b>2020, 9, 1078</b>  | 27  |
| 880 | The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. <b>2020, 18, e3001016</b>  | 90  |
| 879 | Insights on cross-species transmission of SARS-CoV-2 from structural modeling. <b>2020, 16, e1008449</b>   | 31  |
| 878 | In silico mutagenesis of human ACE2 with S protein and translational efficiency explain SARS-CoV-2 infectivity in different species. <b>2020, 16, e1008450</b> | 15  |
| 877 | Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. <b>2020, 15, e0240647</b>                                | 17  |
| 876 | Genetic diversity of SARS-CoV-2 and clinical, epidemiological characteristics of COVID-19 patients in Hanoi, Vietnam. <b>2020, 15, e0242537</b>                | 12  |
| 875 | SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs. <b>2020, 39, e106478</b>   | 83  |
| 874 | From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate, Then Clot Blood Cells in Pulmonary and Systemic Microvasculature.   | 2   |
| 873 | Proteome Organization of COVID-19: Illustrating Targets for Vaccine Development. <b>2020, 14, 831-840</b>  | 2   |
| 872 | Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). <b>2020, 91, 137-145</b>  | 37  |



|     |  |     |
|-----|--|-----|
| 871 | Coronavirus infections in children: from SARS and MERS to COVID-19, a narrative review of epidemiological and clinical features. <b>2020</b> , 91, e2020032              | 2   |
| 870 | Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important?. <b>2020</b> , 41, 213-219  | 50  |
| 869 | COVID-19 and Central Nervous System: Entry Routes And. <b>2020</b> , 11, 217-224   | 6   |
| 868 | SARS-CoV-2 and COVID-19: A Brief Review for Family Physicians. <b>2020</b> , 20-27   | 1   |
| 867 | Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation. <b>2020</b> , 12,                                      | 10  |
| 866 | Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19. <b>2020</b> , 21,  | 21  |
| 865 | Multiple Recombination Events and Strong Purifying Selection at the Origin of SARS-CoV-2 Spike Glycoprotein Increased Correlated Dynamic Movements. <b>2020</b> , 22,    | 9   |
| 864 | Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign. <b>2020</b> , 22,   | 1   |
| 863 | Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2). <b>2020</b> , 11, 157-178  | 7   |
| 862 | COVID-19 in China: From epidemiology to treatment (Review). <b>2020</b> , 20, 223  | 2   |
| 861 | An integrative look at SARS-CoV-2 (Review). <b>2021</b> , 47, 415-434  | 12  |
| 860 | Dealing with lung cancer in the COVID-19 scenario (A review). <b>2021</b> , 14, 27   | 3   |
| 859 | Bioengineered probiotics to control SARS-CoV-2 infection. 6,   | 7   |
| 858 | Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection. <b>2020</b> , 12, 731-751 | 11  |
| 857 | Mutations Observed in the SARS-CoV-2 Spike Glycoprotein and Their Effects in the Interaction of Virus with ACE-2 Receptor. <b>2020</b> , 35, 253-260                     | 12  |
| 856 | Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?. <b>2020</b> , 14, 256-258   | 6   |
| 855 | Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2. <b>2020</b> , 18, e43                         | 5   |
| 854 | Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?. <b>2020</b> , 9,   | 145 |

|     |  |     |
|-----|--|-----|
| 853 | Neuropathogenesis of SARS-CoV-2 infection. <b>2020</b> , 9,  | 24  |
| 852 | ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. <b>2020</b> , 9,  | 143 |
| 851 | Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. <b>2020</b> , 9,   | 76  |
| 850 | Positive selection within the genomes of SARS-CoV-2 and other Coronaviruses independent of impact on protein function. <b>2020</b> , 8, e10234   | 24  |
| 849 | A potential role for Galectin-3 inhibitors in the treatment of COVID-19. <b>2020</b> , 8, e9392  | 43  |
| 848 | Computational perspectives revealed prospective vaccine candidates from five structural proteins of novel SARS corona virus 2019 (SARS-CoV-2). <b>2020</b> , 8, e9855                    | 5   |
| 847 | Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection. <b>2021</b> , 23, 22957-22971   | 4   |
| 846 | Current Status of COVID-19 Diagnostics.  |     |
| 845 | The evaluation of potential global impact of the N501Y mutation in SARS-COV-2 positive patients. <b>2021</b> ,   | 6   |
| 844 | SARS-CoV-2 spike protein harnesses SNX27-mediated endocytic recycling pathway.. <b>2021</b> ,  | 5   |
| 843 | Imaging and visualizing SARS-CoV-2 in a new era for structural biology.. <b>2021</b> , 11, 20210019  | 1   |
| 842 | Immunotherapy in the Treatment of COVID-19. <b>2021</b> , 20, 158-168  |     |
| 841 | Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <b>2021</b> , 11, 20274                                 | 8   |
| 840 | The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. <b>2021</b> , 49, 647   | 3   |
| 839 | Targeting SARS-CoV-2 with Chaga mushroom: An in silico study toward developing a natural antiviral compound.. <b>2021</b> , 9, 6513-6523   | 3   |
| 838 | A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. <b>2021</b> , 13, | 6   |
| 837 | Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. <b>2021</b> , 6, e0009521   | 8   |
| 836 | Mechanisms of SARS-CoV-2 entry into cells. <b>2021</b> ,   | 228 |

|     |  |    |
|-----|--|----|
| 835 | AI-driven prediction of SARS-CoV-2 variant binding trends from atomistic simulations. <b>2021</b> , 44, 123  | 1  |
| 834 | Human Cell Receptors and Downstream Cascades: A Review of Molecular Aspects and Potential Therapeutic Targets against COVID-19. <b>2021</b> , In Press,  |    |
| 833 | Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. <b>2021</b> , 13, e14544  | 1  |
| 832 | Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. <b>2021</b> , 37, 109928   | 21 |
| 831 | Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. <b>2021</b> , 12, e0181321                                      | 8  |
| 830 | Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19. <b>2021</b> ,   | 2  |
| 829 | Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. <b>2021</b> , 6, 369  | 3  |
| 828 | Variations in cell-surface ACE2 levels alter direct binding of SARS-CoV-2 Spike protein and viral infectivity: Implications for measuring Spike protein interactions with animal ACE2 orthologs. <b>2021</b> , |    |
| 827 | Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. <b>2021</b> , 9, e0135221  | 2  |
| 826 | The acid sphingomyelinase/ceramide system in COVID-19. <b>2021</b> ,   | 18 |
| 825 | Fluorescent glycan fingerprinting of SARS2 spike proteins. <b>2021</b> , 11, 20428   | 0  |
| 824 | Current treatment strategies for COVID-19 (Review). <b>2021</b> , 24,  | 2  |
| 823 | SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury.   | 1  |
| 822 | Identification of Hotspot Residues in Binding of SARS-CoV-2 Spike and Human ACE2 Proteins. <b>2021</b> , 20, 729-739   | 0  |
| 821 | Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. <b>2021</b> , 12, 6103  | 24 |
| 820 | Molecular Insights into the Differential Dynamics of SARS-CoV-2 Variants of Concern (VOC).   | 0  |
| 819 | SMOG 2 and OpenSMOG: Extending the limits of structure-based models. <b>2021</b> ,   | 3  |
| 818 | The Omic Insights on Unfolding Saga of COVID-19. <b>2021</b> , 12, 724914  | 0  |

|     |   |    |
|-----|---|----|
| 817 | Post-Translational Modifications of Proteins Exacerbate Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2).  |    |
| 816 | Accurate detection and quantification of SARS-CoV-2 genomic and subgenomic mRNAs by ddPCR and meta-transcriptomics analysis. <b>2021</b> , 4, 1215  | 2  |
| 815 | Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2. <b>2021</b> , 64, 14955-14967  | 5  |
| 814 | A Mechanistic Review on Plant-derived Natural Inhibitors of Human Coronaviruses with Emphasis on SARS-COV-1 and SARS-COV-2. <b>2021</b> ,   |    |
| 813 | Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex. <b>2021</b> , 9, 55  | 3  |
| 812 | Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach. <b>2021</b> , 11, 765039                       | 13 |
| 811 | Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2.. <b>2021</b> , 28, 201-218   | 1  |
| 810 | Activity of THC, CBD, and CBN on Human ACE2 and SARS-CoV1/2 Main Protease to Understand Antiviral Defense Mechanism. <b>2021</b> ,  | 2  |
| 809 | Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals. <b>2021</b> , 13,   | 12 |
| 808 | Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. <b>2021</b> , 20, 126                                    | 3  |
| 807 | Bioinformatics analysis of the differences in the binding profile of the wild-type and mutants of the SARS-CoV-2 spike protein variants with the ACE2 receptor. <b>2021</b> , 138, 104936 | 5  |
| 806 | The COVID-19 Pandemic: Theories to Therapies. <b>2020</b> , 10, 16-28   | 1  |
| 805 | Defining the Pandemic at the State Level: Sequence-Based Epidemiology of the SARS-CoV-2 virus by the Arizona COVID-19 Genomics Union (ACGU).  | 5  |
| 804 | Broad-spectrum virucidal activity of bacterial secreted lipases against flaviviruses, SARS-CoV-2 and other enveloped viruses.   | 3  |
| 803 | A Review of COVID-19 in Children. <b>2020</b> , 11,   | 1  |
| 802 | In Silico Screening of Traditional Herbal Medicine Derived Chemical Constituents for Possible Potential Inhibition against SARS-CoV-2. <b>2020</b> , 20, 79-88                            | 2  |
| 801 | Hidden in plain sight: The effects of BCG vaccination in COVID-19 pandemic.   |    |
| 800 | Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review. <b>2020</b> , 3, 90-102   | 1  |

|     |   |    |
|-----|---|----|
| 799 | Stereotypic Neutralizing VH Clonotypes Against SARS-CoV-2 RBD in COVID-19 Patients and the Healthy Population.  | 4  |
| 798 | Nicotinic receptors atlas in the adult human lung.  | 1  |
| 797 | Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2. <b>2020</b> ,   | 1  |
| 796 | Associations of Medications With Lower Odds of Typical COVID-19 Symptoms: Cross-Sectional Symptom Surveillance Study (Preprint).  |    |
| 795 | SARS-CoV-2 Infection with Associated Rhabdomyolysis and Probable Myocarditis. <b>2020</b> , 7, 001867   | 2  |
| 794 | Structural and Functional Analysis of Female Sex Hormones against SARS-CoV-2 Cell Entry. <b>2021</b> , 22,  | 5  |
| 793 | A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses. <b>2021</b> , 26,  | 11 |
| 792 | study of potential anti-SARS cell entry phytoligands from : a promising avenue for prophylaxis. <b>2021</b> ,   | 1  |
| 791 | Therapeutic potential of targeting LSD1/ KDM1A in cancers. <b>2021</b> , 105958   | 4  |
| 790 | Metallo drug Profiling against SARS-CoV-2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain-like Protease PL. <b>2021</b> ,  | 7  |
| 789 | SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. <b>2021</b> ,   | 3  |
| 788 | Human semen quality as affected by SARS-CoV-2 infection: An up-to-date review. <b>2021</b> , e14295   | 4  |
| 787 | QUASISPECIES FEATURE IN SARS-CoV-2. <b>2021</b> , 9, 591-597  |    |
| 786 | ACE2 peptide fragment interacts with several sites on the SARS-CoV-2 spike protein S1.  |    |
| 785 | A framework for predicting potential host ranges of pathogenic viruses based on receptor ortholog analysis.   |    |
| 784 | The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities. <b>2020</b> , 26,   | 0  |
| 783 | SARS-CoV-2 Infection is Protease-Dependent and Induces Neutrophils Proteolytic Storm Triggering Clinical Worsening and Viral Sepsis. Proteolysis and Inhibitors of Neutrophil Release Can Prevent and Treat Covid-19. <b>2020</b> , 67-73 |    |
| 782 | A molecular dynamic study on the ability of phosphorene for designing new sensor for SARS-CoV-2 detection. <b>2022</b> , 345, 117852  | 4  |

|     |  |    |
|-----|--|----|
| 781 | Atomistic insight into 2D COFs as antiviral agents against SARS-CoV-2. <b>2022</b> , 276, 125382   | 0  |
| 780 | SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Gene. <b>2021</b> , 21, e32   | 15 |
| 779 | Unbiased Local Sequencing Similarity Analysis for SARS-CoV-2 Worldwide.  |    |
| 778 | Neurological impairments in COVID-19 pandemic. <b>2020</b> , 61, 71-77   |    |
| 777 | Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <b>2020</b> , 3639618 | 3  |
| 776 | Evidence of SARS-CoV-2 infection in gallbladder and aggravating cholecystitis to septic shock: a case report.. <b>2021</b> , 9, 1631                                       | 2  |
| 775 | Arq Ajb a wonder Unani formulation for inhibiting SARS-CoV-2 spike glycoprotein and main protease an approach. <b>2021</b> ,   | 1  |
| 774 | Computational insights into differential interaction of mammalian angiotensin-converting enzyme 2 with the SARS-CoV-2 spike receptor binding domain. <b>2021</b> , 105017  | 6  |
| 773 | Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <b>2021</b> ,   | 23 |
| 772 | Using animal models for studying SARS-CoV-2. <b>2021</b> , 1-17  | 2  |
| 771 | Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption. <b>2021</b> , 17, e1010053                           | 6  |
| 770 | Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2. <b>2021</b> , 145, 105024   | 7  |
| 769 | Nanomedicine for the Diagnosis and Therapy of COVID-19. <b>2021</b> , 9, 758121  |    |
| 768 | Fighting COVID-19 with Artificial Intelligence. <b>2022</b> , 2390, 103-112  | 0  |
| 767 | Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations. <b>2021</b> , 11, 21735  | 2  |
| 766 | Genomic diversity and molecular dynamics interaction on mutational variances among RB domains of SARS-CoV-2 interplay drug inactivation. <b>2021</b> , 105128              | 1  |
| 765 | A high-throughput pipeline for design and selection of peptides targeting the SARS-Cov-2 Spike protein. <b>2021</b> , 11, 21768  | 1  |
| 764 | A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <b>2021</b> , 6, 378                           | 5  |

|     |  |   |
|-----|--|---|
| 763 | ACE2 : S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics. <b>2021</b> , 2021, 1828792  | 0 |
| 762 | Pharmacotherapy of COVID-19: confine to existential drugs or search for new ones? (Preprint).  |   |
| 761 | Possibility of SARS-CoV-2 infection and transmission through the digestive tract. <b>2020</b> , 28, 563-569  | 0 |
| 760 | Wide variabilities identified among spike proteins of SARS Cov2 globally-dominant variant identified.  | 1 |
| 759 | Obesity alters and expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19. <b>2020</b> ,  | 2 |
| 758 | Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain. <b>2020</b> ,   | 2 |
| 757 | Coronavirus and Homo Sapiens.  |   |
| 756 | Identifying zoonotic origin of SARS-CoV-2 by modeling the binding affinity between Spike receptor-binding domain and host ACE2. <b>2020</b> ,  |   |
| 755 | Positive selection within the genomes of SARS-CoV-2 and other Coronaviruses independent of impact on protein function.   |   |
| 754 | Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry.  |   |
| 753 | Mechanism of ligand recognition by human ACE2 receptor. <b>2020</b> ,  | 2 |
| 752 | Temporal patterns in the evolutionary genetic distance of SARS-CoV-2 during the COVID-19 pandemic.   |   |
| 751 | Human cardiac stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression. |   |
| 750 | Recombinant ACE2 Expression is Required for SARS-CoV-2 to Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.   |   |
| 749 | The Rhinolophus affinis bat ACE2 and multiple animal orthologs are functional receptors for bat coronavirus RaTG13 and SARS-CoV-2.   |   |
| 748 | An in silico LLPS perturbation approach in the design of a novel SARS-CoV-2 spike receptor-binding domain inhibitor. <b>2020</b> , 21,   |   |
| 747 | Case Report: Unusual presentation of concomitant gastric outlet obstruction and jaundice complicating giant hepatic angioma. 9, 1355   |   |
| 746 | COVID-19' Hastalar 'n Mezenkimal K' H're Tedavisi.   |   |

|     |  |    |
|-----|--|----|
| 745 | Mechanisms of COVID-19 thrombosis in an inflammatory environment and new anticoagulant targets. <b>2021</b> , 13, 3925-3941  | 4  |
| 744 | Working goal of Brazilein sappan wood as a candidate for SARS-coV-2 antivirus drug against spike (S) glycoprotein, papain-like proteinase, and main protease: study. <b>2021</b> , 12, 298-304 | 1  |
| 743 | Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. <b>2021</b> , 8, 54-60   |    |
| 742 | Machine Learning Approach Effectively Predicts Binding Between SARS-CoV-2 Spike and ACE2 Across Mammalian Species - Worldwide, 2021. <b>2021</b> , 3, 967-972                                  | 0  |
| 741 | Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations. <b>2021</b> , 97, 105153  | 2  |
| 740 | Disulfide Bonds Play a Critical Role in the Structure and Function of the Receptor-binding Domain of the SARS-CoV-2 Spike Antigen. <b>2021</b> , 434, 167357                                   | 7  |
| 739 | Basic virological aspects of SARS-CoV-2. <b>2022</b> , 1-30  |    |
| 738 | Fundamental aspects of the structural biology of coronaviruses. <b>2022</b> , 31-52  |    |
| 737 | Susceptibilities of human ACE2 genetic variants in coronavirus infection. <b>2021</b> , JVI0149221   | 2  |
| 736 | Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System. <b>2021</b> , 12, 689065                           | 2  |
| 735 | Antiviral drugs suppress infection of 2019-nCoV spike pseudotyped virus by interacting with ACE2 protein. <b>2021</b> , e22948   | 1  |
| 734 | A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. <b>2021</b> , e2103240  | 3  |
| 733 | Skin Aging, Cellular Senescence and Natural Polyphenols. <b>2021</b> , 22,   | 9  |
| 732 | Brought to Light: How Ultraviolet Disinfection Can Prevent the Nosocomial Transmission of COVID-19 and Other Infectious Diseases. <b>2021</b> , 1, 537-556                                     | 2  |
| 731 | PDZ-Containing Proteins Targeted by the ACE2 Receptor. <b>2021</b> , 13,   | 1  |
| 730 | SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape. <b>2021</b> , 22,   | 2  |
| 729 | Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <b>2021</b> , 101533   | 11 |
| 728 | Insights into the conformation changes of SARS-CoV-2 spike receptor-binding domain on graphene. <b>2021</b> , 151934   | 3  |



|     |   |   |
|-----|---|---|
| 727 | Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes, and half-dead lymphocytes. <b>2021</b> ,   | 5 |
| 726 | A 3D structural SARS-CoV-2-human interactome to explore genetic and drug perturbations. <b>2021</b> , 18, 1477-1488   | 3 |
| 725 | Plasma gp96 is a Novel Predictive Biomarker for Severe COVID-19. <b>2021</b> , e0059721   |   |
| 724 | LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry. <b>2021</b> ,  | 0 |
| 723 | Mutation-Induced Long-Range Allosteric Interactions in the Spike Protein Determine the Infectivity of SARS-CoV-2 Emerging Variants. <b>2021</b> , 6, 31312-31327  | 2 |
| 722 | Identification of potential inhibitors of SARS-CoV-2 S protein ACE2 interaction by in silico drug repurposing. 10, 358  | 0 |
| 721 | Comparative genomic analysis reveals varying levels of mammalian adaptation to coronavirus infections. <b>2021</b> , 17, e1009560   | 1 |
| 720 | Nanotechnology: A Potential Weapon to Fight against COVID-19.. <b>2022</b> , 39, 2100159  | 1 |
| 719 | Site-Specific and Stable Conjugation of the SARS-CoV-2 Receptor-Binding Domain to Liposomes in the Absence of Any Other Adjuvants Elicits Potent Neutralizing Antibodies in BALB/c Mice. <b>2021</b> ,          | 0 |
| 718 | Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations. <b>2021</b> , 12, 730099 | 3 |
| 717 | Emerging roles for endogenous retroviruses in immune epigenetic regulation. <b>2021</b> ,   | 3 |
| 716 | Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization. <b>2021</b> , 12, 772511  | 1 |
| 715 | A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies. <b>2021</b> , 1,  | 1 |
| 714 | Interaction between Spike Protein of SARS-CoV-2 and Human Virus Receptor ACE2 Using Two-Color Fluorescence Cross-Correlation Spectroscopy. <b>2021</b> , 11, 10697  | 0 |
| 713 | Pathogenesis of Respiratory Viral and Fungal Coinfections. <b>2021</b> , e0009421   | 4 |
| 712 | E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody.. <b>2021</b> , 102, 108424  | 3 |
| 711 | Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.. <b>2021</b> , 96, 107613   | 2 |
| 710 | Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses. <b>2021</b> ,  | 3 |

|     |   |    |
|-----|---|----|
| 709 | Tracking the amino acid changes of spike proteins across diverse host species of severe acute respiratory syndrome coronavirus 2. <b>2021</b> , 103560                                      | 1  |
| 708 | Penta-peptide ATN-161 based neutralization mechanism of SARS-CoV-2 spike protein. <b>2021</b> , 28, 101170  | 3  |
| 707 | Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern. <b>2021</b> ,   | 20 |
| 706 | Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders.  | 1  |
| 705 | Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <b>2021</b> ,  | 5  |
| 704 | ACE2 Peptide Fragment Interaction with Different S1 Protein Sites. <b>2022</b> , 28, 7  | 3  |
| 703 | A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. <b>2021</b> , 74, 103729   | 7  |
| 702 | It Takes Two to Tango: Secondary Entry Pathway for SARS-CoV-2 Induces Analgesia. <b>2021</b> ,  |    |
| 701 | Emergence, virology, immune response after SARS-CoV-2 infection, and role of immunopathology behind vaccination. <b>2021</b> , 5, 45  |    |
| 700 | Nicotinic receptors as SARS-CoV-2 spike co-receptors?. <b>2022</b> , 158, 110741  | 3  |
| 699 | Molecular Aspects of Spike-ACE2 Interaction. <b>2022</b> , 2, 96-108  | 0  |
| 698 | Yeast surface display-based identification of ACE2 mutations that modulate SARS-CoV-2 spike binding across multiple mammalian species.. <b>2022</b> , 35,                                   | 0  |
| 697 | Molecular basis of SARS-CoV-2 Omicron variant receptor engagement and antibody evasion and neutralization.  | 4  |
| 696 | Two-step fitness selection for intra-host variations in SARS-CoV-2.. <b>2021</b> , 110205   | 9  |
| 695 | Probing the Formation, Structure and Free Energy Relationships of M Protein Dimers of SARS-CoV-2.. <b>2022</b> , 20, 573-573  | 0  |
| 694 | Computational modelling of potentially emerging SARS-CoV-2 spike protein RBDs mutations with higher binding affinity towards ACE2: A structural modelling study.. <b>2021</b> , 141, 105163 | 3  |
| 693 | Scanning the RBD-ACE2 molecular interactions in Omicron variant.. <b>2022</b> , 592, 18-23  | 8  |
| 692 | Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking.. <b>2021</b> , 301, 114424  | 3  |

|     |   |    |
|-----|---|----|
| 691 | Bioactive peptides produced by engineered probiotics and other food-grade bacteria: A review.. <b>2022</b> , 13, 100196   | 3  |
| 690 | The Importance of Glycosylation in COVID-19 Infection. <b>2021</b> , 1325, 239-264  | 3  |
| 689 | Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning.  |    |
| 688 | SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues.. <b>2021</b> , 21, e38   | 7  |
| 687 | Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. <b>2021</b> , 8, 54-60  | 0  |
| 686 | Scanning the RBD-ACE2 molecular interactions in Omicron variant.  | 0  |
| 685 | SARS-CoV-2-host cell surface interactions and potential antiviral therapies.. <b>2022</b> , 12, 20200081  | 0  |
| 684 | Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs.. <b>2022</b> , 28, 275-289  | 2  |
| 683 | Conformational Flexibility and Local Frustration in the Functional States of the SARS-CoV-2 Spike B.1.1.7 and B.1.351 Variants: Mutation-Induced Allosteric Modulation Mechanism of Functional Dynamics and Protein Stability.. <b>2022</b> , 23, | 0  |
| 682 | A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon.. <b>2022</b> , 1-28  | 0  |
| 681 | Exploration of nanozymes in viral diagnosis and therapy.  | 13 |
| 680 | Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses.. <b>2022</b> ,  | 1  |
| 679 | Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.. <b>2021</b> , 1-51   | 4  |
| 678 | An insight into SARS-CoV2 structure, Pathogenesis, target hunting for drug development and vaccine initiatives.   | 0  |
| 677 | Photodynamic Inactivation of Human Coronaviruses.. <b>2022</b> , 14,  | 2  |
| 676 | A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.. <b>2022</b> , 13, 155  | 6  |
| 675 | Experimental Models of COVID-19.. <b>2021</b> , 11, 792584  | 2  |
| 674 | The impact of calcitriol and estradiol on the SARS-CoV-2 biological activity: a molecular modeling approach.. <b>2022</b> , 12, 717   | 1  |

|     |  |    |
|-----|--|----|
| 673 | Peptide-Integrated Superparamagnetic Nanoparticles for the Identification of Epitopes from SARS-CoV-2 Spike and Nucleocapsid Proteins.. <b>2022</b> , 5, 642-653                                 | 1  |
| 672 | Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19.. <b>2022</b> ,   | 9  |
| 671 | Importance of Negatively Charged Residues in the Membrane Ordering Activity of SARS-CoV-1 and -2 Fusion Peptides.. <b>2021</b> ,   | 0  |
| 670 | The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour.. <b>2021</b> ,   | 2  |
| 669 | Trypsin enhances SARS-CoV-2 infection by facilitating viral entry.. <b>2022</b> ,  | 2  |
| 668 | Angiotensin-Converting Enzyme 2 Expression Is Detectable in Keratinocytes, Cutaneous Appendages, and Blood Vessels by Multiplex RNA in Situ Hybridization.. <b>2022</b> ,                        | 1  |
| 667 | A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of <i>Thermothelomyces heterothallica</i> induces a functional immune response in mice.. <b>2022</b> , | 3  |
| 666 | Neutralizing SARS-CoV-2 by dimeric side chain-to-side chain cross-linked ACE2 peptide mimetics.. <b>2022</b> ,   |    |
| 665 | Genomic perspectives on the emerging SARS-CoV-2 omicron variant.. <b>2022</b> ,  | 12 |
| 664 | Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.. <b>2022</b> , 375, eabm8143 23  |    |
| 663 | In Silico Analysis Of The Effects Of Omicron Spike Amino Acid Changes On The Interactions With Human ACE2 Receptor And Structurally Characterized Complexes With Human Antibodies.               |    |
| 662 | COVID-19 and its clinical severity are associated with alterations of plasma sphingolipids and enzyme activities of sphingomyelinase and ceramidase.   | 0  |
| 661 | SARS-CoV-2 and the Host Cell: A Tale of Interactions. <b>2022</b> , 1,   | 3  |
| 660 | Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19.. <b>2022</b> , 12,              | 4  |
| 659 | Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems.. <b>2022</b> , 10,                       | 5  |
| 658 | A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2.. <b>2022</b> , 74, 425  | 1  |
| 657 | Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants .. <b>2021</b> , 12, 755600                       | 6  |
| 656 | Role of Genetic Variants and Host Polymorphisms on COVID-19: From Viral Entrance Mechanisms to Immunological Reactions.. <b>2022</b> ,   | 1  |

|     |  |      |    |
|-----|--|------|----|
| 655 | Structural Insights into the Cofactor Role of Heparin/Heparan Sulfate in Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II.. <b>2022</b> ,    |      | 1  |
| 654 | SNX27 suppresses SARS-CoV-2 infection by inhibiting viral lysosome/late endosome entry.. <b>2022</b> , 119,  |      | 7  |
| 653 | Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis.. <b>2022</b> ,      |      | 8  |
| 652 | Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.. <b>2022</b> ,  |      | 12 |
| 651 | Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.. <b>2022</b> , 14, 2021601                                 |      | 1  |
| 650 | Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2.. <i>Cell</i> , <b>2022</b> ,   | 56.2 | 48 |
| 649 | Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron.. <i>Cell</i> , <b>2022</b> ,  | 56.2 | 39 |
| 648 | Plastic Antibodies Mimicking the ACE2 Receptor for Selective Binding of SARS-CoV-2 Spike.. <b>2022</b> , 9, 2101925  |      | 5  |
| 647 | Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.. <b>2022</b> , 23, 2 |      | 4  |
| 646 | Rapid de novo discovery of peptidomimetic affinity reagents for human angiotensin converting enzyme 2. <b>2022</b> , 5,  |      | 2  |
| 645 | In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.. <b>2021</b> ,   |      | 1  |
| 644 | Aptamers-Diagnostic and Therapeutic Solution in SARS-CoV-2.. <b>2022</b> , 23,   |      | 0  |
| 643 | The effect of coronavirus disease 2019 immunity on frozen-thawed embryo transfer cycles outcome.. <b>2022</b> ,  |      | 3  |
| 642 | SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress granules to impair host stress response.. <b>2022</b> , 25, 103562  |      | 15 |
| 641 | ELISA-Based Analysis Reveals an Anti-SARS-CoV-2 Protein Immune Response Profile Associated with Disease Severity.. <b>2022</b> , 11,   |      | 2  |
| 640 | Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.. <b>2022</b> ,  |      | 2  |
| 639 | Mechanisms contributing to adverse outcomes of COVID-19 in obesity.. <b>2022</b> , 477, 1155   |      | 2  |
| 638 | Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor.. <b>2021</b> , 590, 34-41  |      | 39 |

- 637 Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
- 636 Evolution of Viral Pathogens Follows a Linear Order.. **2022**, e0165521
- 635 Palladium-Catalysed Intermolecular Direct C-H Bond Arylation of Heteroarenes with Reagents Alternative to Aryl Halides: Current State of the Art. **2022**, 26,
- 634 Inhibition of ACE2-Spike interaction by an ACE2 binder suppresses SARS-CoV-2 entry.. **2022**, 1
- 633 The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study.. **2022**, 7
- 632 A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges.. **2022**, 1-22 4
- 631 Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor.. **2022**, 1-14 1
- 630 Mitochondrial hijacking: a potential mechanism for SARS-CoV-2 to impair female fertility.. **2022**, 110778 0
- 629 The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione.. **2022**, 597, 30-36 3
- 628 Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition.. **2022**, 231, 114121 6
- 627 Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes.. **2021**, 15, 103631
- 626 The Diagnostic Accuracy of Xpert Xpress to SARS-CoV-2: a systematic review.. **2022**, 114460 1
- 625 Synthetic nanobody-functionalized nanoparticles for accelerated development of rapid, accessible detection of viral antigens.. **2022**, 202, 113971 0
- 624 Versatile role of ACE2-based biosensors for detection of SARS-CoV-2 variants and neutralizing antibodies.. **2022**, 203, 114034 2
- 623 Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant.. **2022**, 4, 33-37 12
- 622 Aerosolized Nanobodies Prevent Infections of SARS-CoV-2 in PrEP and PEP Settings in Mice and are Effective to Variants.
- 621 Mutations in human SARS-CoV-2 spike proteins, potential drug binding and epitope sites for COVID-19 therapeutics development.. **2022**, 4, 41-50 4
- 620 Accelerating the discovery of the beyond rule of five compounds that have high affinities toward SARS-CoV-2 spike RBD.. **2022**, 1-10

|     |   |    |
|-----|---|----|
| 619 | Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.. <b>2022</b> , 13, 817905             | 2  |
| 618 | The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic.. <b>2022</b> , 13, 789882   | 3  |
| 617 | Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2.. <b>2022</b> , 101710   | 4  |
| 616 | Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review.. <b>2022</b> , 14,  | 1  |
| 615 | Expression, purification and characterization of SARS-CoV-2 spike RBD in ExpiCHO cells.. <b>2022</b> , 106071   | 1  |
| 614 | Cryo-EM structure of the SARS-CoV-2 Omicron spike.. <b>2022</b> , 110428  | 12 |
| 613 | Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody.. <b>2022</b> , 375, eabn8863   | 36 |
| 612 | Latex Microsphere-Based Bicolor Immunochromatography for Qualitative Detection of Neutralizing Antibody against SARS-CoV-2.. <b>2022</b> , 12,              | 1  |
| 611 | Mechanistic origin of different binding affinities of SARS-CoV and SARS-CoV-2 spike RBDs to human ACE2.   | 1  |
| 610 | The Concept Of Repurposing In Covid-19 Infection. <b>2022</b> , 03,   |    |
| 609 | Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management.. <b>2022</b> , 14,   | 3  |
| 608 | SARS-CoV-2-Specific Vaccine Candidates; the Contribution of Structural Vaccinology.. <b>2022</b> , 10,  | 5  |
| 607 | Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches.. <b>2022</b> , e2334                                  | 4  |
| 606 | The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review.. <b>2021</b> ,   | 5  |
| 605 | Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM.. <b>2021</b> , 12, 7345 | 13 |
| 604 | The emergence, genomic diversity and global spread of SARS-CoV-2. <b>2021</b> ,   | 42 |
| 603 | SARS-CoV-2 spreads through cell-to-cell transmission.. <b>2022</b> , 119,   | 20 |
| 602 | A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. <b>2021</b> , 118,  | 4  |

|     |   |    |
|-----|---|----|
| 601 | Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.. <b>2022</b> , 14, 2002236                        | 2  |
| 600 | SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.. <b>2021</b> , 17, e1010175                                      | 4  |
| 599 | Nanomaterials as Promising Theranostic Tools in Nanomedicine and Their Applications in Clinical Disease Diagnosis and Treatment.. <b>2021</b> , 11,         | 5  |
| 598 | Structural Analysis of the SARS-CoV-2 Omicron Variant Proteins.. <b>2021</b> , 2021, 9769586  | 8  |
| 597 | Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor.. <b>2021</b> , 10,                                    | 2  |
| 596 | Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data. <b>2020</b> ,     |    |
| 595 | Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through analysis of Viral Genomics and Structure. <b>2021</b> ,                                |    |
| 594 | The expression of interleukin-1 $\beta$ and nuclear factor erythroid-2 in the periodontitis after treatment of liquid smoke rice hull. <b>2022</b> , 13, 95 | 1  |
| 593 | Anticoronavirus Activity of Water-Soluble Pristine C Fullerenes: In Vitro and In Silico Screenings.. <b>2021</b> , 1352, 159-172                            | 1  |
| 592 | Optical biosensors for SARS-CoV-2 detection. <b>2022</b> , 155-166  |    |
| 591 | Significance of the RBD mutations in the SARS-CoV-2 omicron: from spike opening to antibody escape and cell attachment.. <b>2022</b> ,                      | 3  |
| 590 | AI-powered drug repurposing for developing COVID-19 treatments. <b>2022</b> ,   |    |
| 589 | Macrophages in respiratory system. <b>2022</b> , 299-333  |    |
| 588 | Neurological manifestations of long-COVID syndrome: a narrative review.. <b>2022</b> , 13, 20406223221076890  | 14 |
| 587 | Computational Design of Miniprotein Binders.. <b>2022</b> , 2405, 361-382   | 0  |
| 586 | SARS-CoV-2???ACE2????????????/?????. <b>2022</b> ,  |    |
| 585 | A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern.. <b>2022</b> ,                      | 3  |
| 584 | SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy.. <b>2022</b> , e0322721                             | 3  |



|     |  |    |
|-----|--|----|
| 583 | Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque.. <b>2022,</b>                                  | 0  |
| 582 | A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody.. <b>2022, 23,</b>                | 2  |
| 581 | Targeting Angiotensin-Converting Enzyme 2 (ACE2) for the Discovery of Anticoronaviral Drugs. <b>2022, 03,</b>  |    |
| 580 | Bat coronaviruses related to SARS-CoV-2 and infectious for human cells.. <b>2022,</b>  | 36 |
| 579 | Molecular basis of receptor binding and antibody neutralization of Omicron.. <b>2022,</b>  | 13 |
| 578 | Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.. <b>2022, 13, 835136</b>   | 1  |
| 577 | Inhibitory mechanism of clioquinol and its derivatives at the exopeptidase site of human angiotensin-converting enzyme-2 and receptor binding domain of SARS-CoV-2 viral spike.. <b>2022, 1-10</b> | 0  |
| 576 | Neuropilin-1-Mediated SARS-CoV-2 Infection in Bone Marrow-Derived Macrophages Inhibits Osteoclast Differentiation.. <b>2022, e2200007</b>  | 1  |
| 575 | Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein.. <b>2022, 10,</b>   | 0  |
| 574 | Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies.. <b>2022, 13, 871</b>  | 13 |
| 573 | The counter-regulatory arm of the renin-angiotensin system and COVID-19: insights from Gitelman's and Bartter's syndromes.. <b>2022, 40,</b>   | 0  |
| 572 | A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19.. <b>2022, 28, e936292</b>             | 2  |
| 571 | The pH Effects on SARS-CoV and SARS-CoV-2 Spike Proteins in the Process of Binding to hACE2.. <b>2022, 11,</b>   | 1  |
| 570 | An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission.. <b>2022, 7, 24</b>  | 3  |
| 569 | Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.. <b>2022, 23,</b>               | 0  |
| 568 | Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <b>2022, 2, 3-22</b>   | 0  |
| 567 | PWM2Vec: An Efficient Embedding Approach for Viral Host Specification from Coronavirus Spike Sequences.. <b>2022, 11,</b>  | 3  |
| 566 | Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.   | 6  |

|     |   |   |
|-----|---|---|
| 565 | mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.. <b>2022</b> , 18, 2040330   | 1 |
| 564 | Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.. <b>2022</b> , 23,                               | 0 |
| 563 | Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in Silico Approach.. <b>2022</b> , 27,  | 0 |
| 562 | Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation.. <b>2022</b> , 1   | 2 |
| 561 | Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants.. <b>2022</b> ,   | 1 |
| 560 | Safety and Pharmacokinetics of Intranasally Administered Heparin.. <b>2022</b> , 39, 541  | 0 |
| 559 | COVID-19-Associated Myocarditis: An Evolving Concern in Cardiology and Beyond.. <b>2022</b> , 11,   | 3 |
| 558 | SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease.. <b>2022</b> , 19, 48   | 4 |
| 557 | Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. <b>2022</b> ,   | 0 |
| 556 | Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2.. <b>2022</b> , e2100360   | 1 |
| 555 | Theoretical Investigation of the Coronavirus SARS-CoV-2 (COVID-19) Infection Mechanism and Selectivity.. <b>2022</b> , 27,  |   |
| 554 | E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces.. <b>2022</b> , 10, e13099                |   |
| 553 | Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization.. <b>2022</b> , 119, e2122954119  | 1 |
| 552 | Moderately hyperglycemia as an independent prognostic factor for the worse outcome of COVID-19.. <b>2022</b> ,  |   |
| 551 | Towards an Electrochemical Immunosensor for the Detection of Antibodies against SARS-CoV-2 Spike Protein. <b>2022</b> , 169, 037523   | 5 |
| 550 | Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.. <b>2022</b> , | 1 |
| 549 | A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates.. <b>2022</b> , 1-39  | 5 |
| 548 | A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions.. <b>2022</b> , 119, e2114397119  | 0 |

|     |  |   |
|-----|--|---|
| 547 | Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction.. <b>2022</b> , 5, 262            | 1 |
| 546 | The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes.. <b>2022</b> ,  | 6 |
| 545 | Antibody escape and global spread of SARS-CoV-2 lineage A.27.. <b>2022</b> , 13, 1152  | 5 |
| 544 | Structures of a deltacoronavirus spike protein bound to porcine and human receptors.. <b>2022</b> , 13, 1467   | 2 |
| 543 | Structural basis of nanobodies neutralizing SARS-CoV-2 variants.. <b>2022</b> ,  | 0 |
| 542 | Cannabidiol and SARS-CoV-2 Infection.. <b>2022</b> , 13, 870787  | 1 |
| 541 | The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae and Vaccines.. <b>2022</b> ,  | 0 |
| 540 | Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions.. <b>2022</b> , 25, 103939 | 2 |
| 539 | Antigen-Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD.. <b>2022</b> , 9, 797132                               | 0 |
| 538 | Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes.. <b>2022</b> , 17, e0263671  | 0 |
| 537 | SARS-CoV-2 Spike Glycoprotein and ACE2 Interaction Reveals Modulation of Viral Entry in Wild and Domestic Animals.. <b>2021</b> , 8, 775572                                      | 0 |
| 536 | 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope.. <b>2022</b> ,  | 1 |
| 535 | Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19.. <b>2022</b> , 22, 211                         | 5 |
| 534 | Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike.. <b>2022</b> , 11,  | 3 |
| 533 | Neuroimmunology and Neurological Manifestations of COVID-19.   |   |
| 532 | A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues.. <b>2022</b> ,  |   |
| 531 | Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.. <b>2022</b> , 13, 840136          | 2 |
| 530 | The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein.. <b>2022</b> , 11,   | 3 |

|     |   |    |
|-----|---|----|
| 529 | In Silico Multi-Target Approach Revealed Potential Lead Compounds as Scaffold for the Synthesis of Chemical Analogues Targeting SARS-CoV-2.. <b>2022</b> , 11,      | 1  |
| 528 | A spike protein S2 antibody efficiently neutralizes the Omicron variant.. <b>2022</b> ,   | 1  |
| 527 | Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection.. <b>2022</b> , 12, 3446   | 3  |
| 526 | MutateX: an automated pipeline for in silico saturation mutagenesis of protein structures and structural ensembles.. <b>2022</b> ,                                  | 1  |
| 525 | The Traditional Chinese Medicine Formula Jing Guan Fang for Preventing SARS-CoV-2 Infection: From Clinical Observation to Basic Research.. <b>2022</b> , 13, 744439 | 1  |
| 524 | Methylxanthines as Potential Inhibitor of SARS-CoV-2: an In Silico Approach.. <b>2022</b> , 8, 1-22   | 2  |
| 523 | Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.. <b>2022</b> , 17, 377-391                                    | 6  |
| 522 | Unbinding of hACE2 and inhibitors from the receptor binding domain of SARS-CoV-2 spike protein.. <b>2022</b> , 1-20   |    |
| 521 | Critical role of nitric oxide in impeding COVID-19 transmission and prevention: a promising possibility.. <b>2022</b> , 1   | 1  |
| 520 | Molecular Virology of SARS-CoV-2 and Related Coronaviruses.. <b>2022</b> , e0002621   | 2  |
| 519 | Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.. <b>2022</b> , e0181421   | 1  |
| 518 | FURIN gene variants (rs6224/rs4702) as potential markers of deat hand cardiovascular traits in severe COVID-19.. <b>2022</b> ,                                      | 0  |
| 517 | A network biology approach to identify crucial host targets for COVID-19.. <b>2022</b> ,  | 0  |
| 516 | Computational Modeling of T Cell Hypersensitivity during Coronavirus Infections Leading to Autoimmunity and Lethality.. <b>2022</b> , 2022, 9444502                 | 0  |
| 515 | ACE2-independent infection of T lymphocytes by SARS-CoV-2.. <b>2022</b> , 7, 83   | 11 |
| 514 | In silico design of ACE2 mutants for competitive binding of SARS-CoV-2 receptor binding domain with hACE2. <b>2022</b> ,  |    |
| 513 | Nitric Oxide in the Management of Respiratory Consequences in COVID-19: A Scoping Review of a Different Treatment Approach.. <b>2022</b> , 14, e23852               | 0  |
| 512 | Genetic Landscape of the ACE2 Coronavirus Receptor.. <b>2022</b> ,  | 0  |

|     |  |   |
|-----|--|---|
| 511 | Mutant EK1 with Q1004E/N1006I: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2.. <b>2021,</b>  |   |
| 510 | Fighting SARS-CoV-2 with structural biology methods.. <b>2022,</b>   |   |
| 509 | Natural Compounds as Potential Anti-COVID Agent. <b>2022,</b> 20,  |   |
| 508 | Discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery.. <b>2022,</b>   | 0 |
| 507 | The basis of mink susceptibility to SARS-CoV-2 infection.. <b>2022,</b> 1  | 1 |
| 506 | Omicron: Understanding the latest variant of SARS-CoV-2 and strategies for tackling the infection.. <b>2022,</b>   | 0 |
| 505 | Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.. <b>2022,</b> 200, 105290  | 1 |
| 504 | Evaluation of binding performance of bioactive compounds against main protease and mutant model spike receptor binding domain of SARS-CoV-2: Docking, ADMET properties and molecular dynamics simulation study. <b>2022,</b> 99, 100417  | 2 |
| 503 | Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allostery as Energetic Drivers of Highly Transmissible Spike Variants.. <b>2022,</b> | 0 |
| 502 | David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.. <b>2022,</b> 14, 2057832   | 2 |
| 501 | Rare genetic tubulopathies Gitelman's and Bartter's syndromes and their naturally occurring protection from COVID-19.. <b>2022,</b>  |   |
| 500 | Unique peptide signatures of SARS-CoV-2 virus against human proteome reveal variants' immune escape and infectiveness.. <b>2022,</b> 8, e09222   |   |
| 499 | Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein.. <b>2022,</b>   | 0 |
| 498 | Mechanistic Origin of Different Binding Affinities of SARS-CoV and SARS-CoV-2 Spike RBDs to Human ACE2.. <b>2022,</b> 11,  | 1 |
| 497 | NO in Viral Infections: Role and Development of Antiviral Therapies.. <b>2022,</b> 27,   | 0 |
| 496 | A Cell-Free Assay for Rapid Screening of Inhibitors of hACE2-Receptor-SARS-CoV-2-Spike Binding.. <b>2022,</b>  |   |
| 495 | The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech).. <b>2022,</b> 12, 5999   | 0 |
| 494 | The spike glycoproteins of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape.. <b>2022,</b>  | 4 |

|     |   |   |
|-----|---|---|
| 493 | Evolutionary Shift from Purifying Selection towards Divergent Selection of SARS-CoV2 Favors its Invasion into Multiple Human Organs.. <b>2022</b> , 198712                            | 2 |
| 492 | Computational studies on the interaction of SARS-CoV-2 Omicron SGP RBD with human receptor ACE2, limonin and glycyrrhizic acid.. <b>2022</b> , 144, 105367                            | 2 |
| 491 | The accessible promoter-mediated supplementary effect of host factors provides new insight into the tropism of SARS-CoV-2.. <b>2022</b> ,   | 0 |
| 490 | Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity.. <b>2022</b> , 155181   | 0 |
| 489 | SARS-CoV-2 gained a novel spike protein S1-N-Terminal Domain (S1-NTD).. <b>2022</b> , 211, 113047   | 0 |
| 488 | Millisecond dynamic of SARS-CoV-2 spike and its interaction with ACE2 receptor and small extracellular vesicles. <b>2021</b> , 10, e12170   | 5 |
| 487 | The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. <b>2021</b> , 1, 216-234  | 0 |
| 486 | Computational Electrostatics Predict Variations in SARS-CoV-2 Spike and Human ACE2 Interactions. <b>2021</b> ,  |   |
| 485 | Next Generation Sequence Prediction Intelligent System for SARS-COV-2 Using Deep Learning Neural Network. <b>2021</b> ,   | 0 |
| 484 | COMPARATIVE ANALYSIS OF HUMAN AND LIVESTOCK $\alpha$ -RECEPTORS FOR SARS-COV-2. 62, 120-129   |   |
| 483 | Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection.. <b>2021</b> , 27, 162  | 3 |
| 482 | Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2.. <b>2021</b> , 6, 156   | 2 |
| 481 | RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor.. <b>2021</b> , 14,                                   | 2 |
| 480 | Antigenic characterization of influenza and SARS-CoV-2 viruses.. <b>2021</b> ,  | 1 |
| 479 | Advances in Magnetic Microbead Affinity Selection Screening: Discovery of Natural Ligands to the SARS-CoV-2 Spike Protein.. <b>2021</b> ,   | 1 |
| 478 | Use of simplified models for theoretical prediction of the interactions between available antibodies and the receptor-binding domain of SARS-CoV-2 spike protein.. <b>2021</b> , 1-10 | 0 |
| 477 | In silico bioprospecting of antiviral compounds from marine fungi and mushroom for rapid development of nutraceuticals against SARS-CoV-2.. <b>2021</b> , 1-12                        | 1 |
| 476 | Investigation of SARS-CoV-2 on Ocular Surface of Coronavirus Disease 2019 Patients Using One-Step Reverse-Transcription Droplet Digital PCR.. <b>2021</b> , 14, 5395-5401             | 2 |

|     |  |   |
|-----|--|---|
| 475 | Computational Study of SARS-CoV-2 RNA Dependent RNA Polymerase Allosteric Site Inhibition.. <b>2021</b> , 27,  | 5 |
| 474 | Unifying the Efforts of Medicine, Chemistry, and Engineering in Biosensing Technologies to Tackle the Challenges of the COVID-19 Pandemic. <b>2021</b> ,   | 0 |
| 473 | Angiotensin-Converting Enzyme 2 (ACE2) As a Novel Biorecognition Element in A Cell-Based Biosensor for the Ultra-Rapid, Ultra-Sensitive Detection of the SARS-CoV-2 S1 Spike Protein Antigen. <b>2021</b> , 9, 341                             | 0 |
| 472 | Neuropsychiatric symptoms associated with the COVID-19 and its potential nervous system infection mechanism: the role of imaging in the study. <b>2021</b> , 1, 199-211  | 0 |
| 471 | How Does COVID-19 Pandemic Impact on Incidence of Infection and Exacerbation of Its Gastrointestinal Symptoms?. <b>2021</b> , 8, 775063  | 1 |
| 470 | Bioinorganic Chemistry of Zinc in relation to the Immune system. <b>2021</b> ,   | 0 |
| 469 | Is there impact of the SARS-CoV-2 pandemic on steroidogenesis and fertility?. <b>2021</b> , 70, S161-S175  | 1 |
| 468 | The Development of SARS-CoV-2 Variants: The Gene Makes the Disease.. <b>2021</b> , 9,  | 6 |
| 467 | Critical Negatively Charged Residues Are Important for the Activity of SARS-CoV-1 and SARS-CoV-2 Fusion Peptides.. <b>2021</b> ,   |   |
| 466 | Phage Display-Derived Peptide for the Specific Binding of SARS-CoV-2.. <b>2022</b> , 7, 3203-3211  | 2 |
| 465 | Drug discovery to treat COVID-19 two years after its outbreak.. <b>2021</b> , 15, 281-288  | 2 |
| 464 | Protein-Based Nanoparticle Vaccines for SARS-CoV-2.. <b>2021</b> , 22,   | 2 |
| 463 | Allosteric Modulation of Small Molecule Drugs on ACE2 Conformational Change upon Binding to SARS-CoV-2 Spike Protein. <b>2021</b> ,  | 1 |
| 462 | Effect of Cysteine Oxidation in SARS-CoV-2 Receptor-Binding Domain on Its Interaction with Two Cell Receptors: Insights from Atomistic Simulations.. <b>2021</b> ,   | 2 |
| 461 | Interpretable and Predictive Deep Modeling of the SARS-CoV-2 Spike Protein Sequence.   | 3 |
| 460 | Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations.. <b>2022</b> , 23, | 1 |
| 459 | Immunoinformatics approach of epitope prediction for SARS-CoV-2.. <b>2022</b> , 20, 60   | 0 |
| 458 | Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis.. <b>2022</b> , 12, 6241  | 1 |

|     |   |   |
|-----|---|---|
| 457 | Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides.. <b>2022</b> , 198769                 | 1 |
| 456 | Amomum tsao-ko essential oil, a Novel Anti-COVID-19 Omircon Spike Protein Natural Products: A Computational Study.. <b>2022</b> , 103916    | 0 |
| 455 | COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response. <b>2022</b> , 2, 115-144 |   |
| 454 | Peptide-Based Vaccines and Therapeutics for COVID-19.. <b>2022</b> , 28, 94   | 2 |
| 453 | Variant Analysis and Strategic Clustering to Sub-Lineage of Double Mutant Strain B.1.617 of SARS-CoV-2. <b>2022</b> , 2, 513-531            |   |
| 452 | Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines.. <b>2022</b> , e2346         | 3 |
| 451 | ACE2, BAT1, and SARS-CoV-2 spike protein: Structural and functional implications.. <b>2022</b> , 74, 102388                                 | 0 |
| 450 | The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines.. <b>2022</b> , 10,     | 4 |
| 449 | Multimodal Benefits of Exercise in Patients With Multiple Sclerosis and COVID-19.. <b>2022</b> , 13, 783251                                 | 0 |
| 448 | The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects.. <b>2022</b> ,   | 0 |
| 447 | Development of a Novel Human CD147 Knock-in NSG Mouse Model to Test SARS-CoV-2 Viral Infection.. <b>2022</b> ,                              | 0 |
| 446 | SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response.. <b>2022</b> , 15, eabg8744      | 5 |
| 445 | Molecular insights into the differential dynamics of SARS-CoV-2 variants of concern.. <b>2022</b> , 114, 108194                             | 2 |
| 444 | Data_Sheet_1.docx. <b>2020</b> ,  |   |
| 443 | Data_Sheet_1.pdf. <b>2020</b> ,   |   |
| 442 | Table_1.pdf. <b>2020</b> ,  |   |
| 441 | Data_Sheet_1.PDF. <b>2020</b> ,   |   |
| 440 | Image_1.PNG. <b>2020</b> ,  |   |



439 Table\_1.XLS. **2020**,

438 Table\_2.XLSX. **2020**,

437 Table\_3.DOCX. **2020**,

436 Table\_4.DOCX. **2020**,

435 Table\_5.XLSX. **2020**,

434 Table\_6.DOCX. **2020**,

433 Table\_7.XLSX. **2020**,

432 Image\_1.TIF. **2020**,

431 Image\_1.pdf. **2020**,

430 Table\_1.XLSX. **2020**,

429 Table\_2.XLSX. **2020**,

428 Table\_3.XLSX. **2020**,

427 Table\_4.XLSX. **2020**,

426 Table\_5.XLSX. **2020**,

425 Table\_6.XLSX. **2020**,

424 Table\_1.docx. **2020**,

423 Data\_Sheet\_1.pdf. **2020**,

422 Presentation\_1.pdf. **2020**,

421 Video\_1.mp4. **2020**,

420 Video\_2.mp4. **2020**,

419 Video\_3.mp4. **2020**,

418 Video\_4.mp4. **2020**,

417 Video\_5.mp4. **2020**,

416 Table\_1.DOCX. **2020**,

415 Table\_1.DOCX. **2020**,

414 Performance evaluation of four rapid antibody tests for the detection of severe acute respiratory syndrome coronavirus 2.. **2022**, e24374

413 Probing the competitive inhibitor efficacy of frog-skin alpha helical AMPs identified against ACE2 binding to SARS-CoV-2 S1 spike protein as therapeutic scaffold to prevent COVID-19.. **2022**, 28, 128

412 Advances in COVID-19 mRNA vaccine development.. **2022**, 7, 94

411 Epidemiology and Genomic Characterization of Two Novel SARS-Related Coronaviruses in Horseshoe Bats from Guangdong, China.. **2022**, e0046322

410 Measurement of SARS-CoV-2-Specific Humoral and Cellular Immunity in Coronavirus Disease 2019 Convalescent Health Care Workers in Iraq.. **2021**, 76, 1255-2127

409 [Efficacy of black cohosh extracts for improving low estrogen status induced by postoperative GnRHa treatment in patients with endometriosis: a systematic review]. **2020**, 49, 397-405

408 [Replication and transmission mechanisms of highly pathogenic human coronavirus]. **2020**, 49, 324-339

407 Implementation of level-2 biosafety for a macromolecular crystallography beamline at SSRF.. **2021**, 11, 529-536

406 Antiviral Strategies Against SARS-CoV-2: A Systems Biology Approach.. **2022**, 2452, 317-351

405 Subacute thyroiditis after SARS-CoV-2 BNT162b2 vaccine in a multiple myeloma patient.. **2022**, 10, 2050313X221091392

404 Novel Insights Into the Sulfated Glucuronic Acid-Based Anti-SARS-CoV-2 Mechanism of Exopolysaccharides From Halophilic Archaeon .. **2022**, 10, 871509

|     |   |        |
|-----|---|--------|
| 403 | Cell surface detection of vimentin, ACE2 and SARS-CoV-2 Spike proteins reveals selective colocalization at primary cilia.. <b>2022</b> , 12, 7063 | 1      |
| 402 | Photonics enabled intelligence system to identify SARS-CoV 2 mutations.. <b>2022</b> ,  | 1      |
| 401 | Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent.. <b>2022</b> ,                    | 2      |
| 400 | 2D MXenes for Combatting COVID-19 Pandemic: A Perspective on Latest Developments and Innovations. <b>2022</b> , 100377                            | 3      |
| 399 | Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions.. <b>2022</b> , 7, 143                    | 5      |
| 398 | SARS-CoV-2 Susceptibility and Gene Variations Within Diverse Ethnic Backgrounds.. <b>2022</b> , 13, 888025  | 0      |
| 397 | SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance.. <b>2022</b> , 13, 877101            | 3      |
| 396 | Structure and Orientation of the SARS-Coronavirus-2 Spike Protein at Air-Water Interfaces.. <b>2022</b> ,   | 1      |
| 395 | Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.. <i>Cell</i> , <b>2022</b> ,                          | 56.2 8 |
| 394 | effect of COVID-19 on micro RNA and therefore gene expression. 5056-5062  |        |
| 393 | Comprehensive Role of SARS-CoV-2 Spike Glycoprotein in Regulating Host Signaling Pathway.. <b>2022</b> ,  | 0      |
| 392 | Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen.. <b>2022</b> ,                        | 0      |
| 391 | Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants.. <b>2022</b> ,            | 1      |
| 390 | An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).. <b>2022</b> , 27, 38                             | 0      |
| 389 | Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component. <b>2022</b> , 10, 772                  | 3      |
| 388 | Polygoni multiflori radix extracts inhibit SARS-CoV-2 pseudovirus entry in HEK293T cells and zebrafish larvae.. <b>2022</b> , 102, 154154         | 1      |
| 387 | Emerging clinically tested detection methods for COVID-19.. <b>2022</b> ,   |        |
| 386 | Antiviral Drug Discovery for the Treatment of COVID-19 Infections. <b>2022</b> , 14, 961  | 3      |

|     |   |   |
|-----|---|---|
| 385 | Emerging SARS-CoV-2 variants: why, how, and what's next?. <b>2022</b> , 100029  | 3 |
| 384 | The Pathophysiology of Long COVID throughout the Renin-Angiotensin System.. <b>2022</b> , 27,   | 3 |
| 383 | Activity of a Carbohydrate-Binding Module Therapy, Neumifil, against SARS-CoV-2 Disease in a Hamster Model of Infection. <b>2022</b> , 14, 976  | 1 |
| 382 | Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. <b>2022</b> , 14, 1029  | 1 |
| 381 | Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2.. <b>2022</b> , 114, 108201 | 1 |
| 380 | Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.. <b>2022</b> , 105332                            | 1 |
| 379 | Constructing high-accuracy theoretical Raman spectra of SARS-CoV-2 spike proteins based on a large fragment method.. <b>2022</b> , 800, 139663  | 1 |
| 378 | Propagation and Quantification of SARS-CoV-2.. <b>2022</b> , 2452, 111-129  |   |
| 377 | Evolution and Epidemiology of SARS-CoV-2 Virus.. <b>2022</b> , 2452, 3-18   |   |
| 376 | IgG targeting distinct seasonal coronavirus OC43-conserved SARS-CoV-2 spike subdomains correlate with differential COVID-19 disease outcomes. <b>2022</b> , 110904  | 0 |
| 375 | Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region. <b>2022</b> , 105625  | 1 |
| 374 | A Class of Shark-Derived Single-Domain Antibodies can Broadly Neutralize SARS-Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape.. <b>2022</b> , e2200387                        | 0 |
| 373 | Bioinformatics for the Origin and Evolution of Viruses.. <b>2022</b> , 1368, 53-71  | 1 |
| 372 | Inhibition of IRAK4 dysregulates SARS-CoV-2 spike protein-induced macrophage inflammatory and glycolytic reprogramming.. <b>2022</b> , 79, 301  | 1 |
| 371 | The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients.. <b>2022</b> ,  | 2 |
| 370 | Structure-guided affinity maturation of a novel human antibody targeting the SARS-CoV-2 nucleocapsid protein.. <b>2022</b> , 12, 8469   |   |
| 369 | Pyrazolone-type compounds: synthesis and in silico assessment of antiviral potential against key viral proteins of SARS-CoV-2. <b>2022</b> , 12, 16054-16070  | 2 |
| 368 | A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding. <b>2022</b> , 13,  | 0 |

|     |  |        |
|-----|--|--------|
| 367 | Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein. <b>2022</b> , 59, 107986   | 0      |
| 366 | Freeze-dried plasma: From damage control resuscitation to coronavirus disease 2019 therapy.  | 0      |
| 365 | Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes. <b>2022</b> , 9,  | 0      |
| 364 | Genome similarities between human-derived and mink-derived SARS-CoV-2 make mink a potential reservoir of the virus.  |        |
| 363 | Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.  | 1      |
| 362 | Protective neutralizing epitopes in SARS-CoV-2.  | 3      |
| 361 | Changing Dynamics of SARS-CoV-2: A Global Challenge. <b>2022</b> , 12, 5546  | 0      |
| 360 | Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages.                          |        |
| 359 | Principles of SARS-CoV-2 Glycosylation. <b>2022</b> , 102402   | 0      |
| 358 | Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins.   | 5      |
| 357 | Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.  | 2      |
| 356 | Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate. <b>2022</b> , 10, 897                     | 0      |
| 355 | Mutations of the SARS-CoV-2 Spike Glycoprotein Detected in Cats and Their Effect on Its Structure and Function. <b>2022</b> , 12,  | 0      |
| 354 | Therapeutic significance of nano- and biosensor technology in combating SARS-CoV-2: a review.  | 0      |
| 353 | Cutaneous Manifestations of COVID-19 in Critical Care. <b>2022</b> , 33, 186-195   |        |
| 352 | The soluble N-terminal autoinhibitory module of the A1 domain in von Willebrand factor partially suppresses its catch bond with glycoprotein Ib in a sandwich complex. <b>2022</b> , 24, 14857-14865 | 1      |
| 351 | Proteolysis and deficiency of H-proteinase inhibitor in SARS-CoV-2 infection. <b>2022</b> , 68, 157-176  | 1      |
| 350 | Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. <i>Cell</i> , <b>2022</b> ,   | 56.2 7 |

|     |   |   |
|-----|---|---|
| 349 | The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.   | 0 |
| 348 | Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein. <b>2022</b> , 26,  | 1 |
| 347 | Detection of SARS-CoV-2 in tissue: the comparative roles of RT-qPCR, in situ RNA hybridization, and immunohistochemistry. 1-16  | 0 |
| 346 | Cross-species recognition and molecular basis of SARS-CoV-2 and SARS-CoV binding to ACE2s of marine animals.  | 1 |
| 345 | Singular Interface Dynamics of the SARS-CoV-2 Delta Variant Explained with Contact Perturbation Analysis.   | 1 |
| 344 | Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms. |   |
| 343 | Different Binding Modes of SARS-CoV-1 and SARS-CoV-2 Fusion Peptides to Cell Membranes: The Influence of Peptide Helix Length.  | 0 |
| 342 | Venetoclax Decreases the Expression of the Spike Protein through Amino Acids Q493 and S494 in SARS-CoV-2. <b>2022</b> , 11, 1924  | 0 |
| 341 | Atlas of currently-available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. <b>2022</b> ,   | 2 |
| 340 | Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.  | 1 |
| 339 | Ionization of D571 Is Coupled with SARS-CoV-2 Spike Up/Down Equilibrium Revealing the pH-Dependent Allosteric Mechanism of Receptor-Binding Domains.  | 1 |
| 338 | Molecular mechanisms highlighting the potential role of COVID-19 in the development of neurodegenerative diseases. <b>2022</b> , 109, 135-162   | 1 |
| 337 | The Extracts of Polygonum cuspidatum Root and Rhizome Block the Entry of SARS-CoV-2 Wild-Type and Omicron Pseudotyped Viruses via Inhibition of the S-Protein and 3CL Protease. <b>2022</b> , 27, 3806  | 1 |
| 336 | SARS-CoV-2 Omicron Variant Binds to Human Cells More Strongly than the Wild Type: Evidence from Molecular Dynamics Simulation.  | 2 |
| 335 | Development of Metal Complexes for Treatment of Coronaviruses. <b>2022</b> , 23, 6418   | 2 |
| 334 | Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.   | 0 |
| 333 | Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <b>2022</b> , 14, 1255   | 1 |
| 332 | Binding and structural basis of equine ACE2 to RBDs from SARS-CoV, SARS-CoV-2 and related coronaviruses. <b>2022</b> , 13,  | 1 |

- 331 Evolutionary trajectory of the physicochemical mechanism of interaction of SARS-CoV-2 spike protein with ACE2.
- 330 Lymphocyte count and A-DROP score in COVID-19 patients: A retrospective observational study. **2022**, 11, 115
- 329 Genomic, proteomic and metabolomic profiling of severe acute respiratory syndrome-Coronavirus-2. **2022**, 49-76
- 328 Experimental Models of SARS-COV-2 Infection in the Central Nervous System. **2022**, 14, 117957352211022
- 327 Frustration-driven allosteric regulation and signal transmission in the SARS-CoV-2 spike omicron trimer structures: a crosstalk of the omicron mutation sites allosterically regulates tradeoffs of protein stability and conformational adaptability. 2
- 326 A Visual Immunochromatographic Assay for Rapid Detection of SARS-CoV-2 Neutralizing Antibody.
- 325 Databases, DrugBank, and virtual screening platforms for therapeutic development. **2022**, 291-334
- 324 Nanogram-scale silver particles potentially combat SARS-CoV-2 infection by suppressing the ACE2 expression and inflammatory responses. 1
- 323 Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. **2022**, 12, 0
- 322 Chromosomal-level reference genome assembly of the North American wolverine (*Gulo gulo luscus*): a resource for conservation genomics. 0
- 321 Probing the Conformational States of Thimet Oligopeptidase in Solution. **2022**, 23, 7297
- 320 Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A single or double-edged effect?. **2022**, 23, 0
- 319 A Game of Infection: Song of Respiratory Viruses and Interferons. 12,
- 318 An RBD-Based Diagnostic Method Useful for the Surveillance of Protective Immunity against SARS-CoV-2 in the Population. **2022**, 12, 1629 0
- 317 Broader-species receptor binding and structural bases of Omicron SARS-CoV-2 to both mouse and palm-civet ACE2s. **2022**, 8, 2
- 316 Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders. **2022**, 2, 0
- 315 In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding. **2022**, 18, e1010733 1
- 314 A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. 13, 4

|     |   |   |
|-----|---|---|
| 313 | Creation of transgenic mice susceptible to coronaviruses: a platform for studying viral pathogenesis and testing vaccines. <b>2022</b> , 26, 402-408  |   |
| 312 | Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. <b>2022</b> , 14, 1560   | 2 |
| 311 | Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms. <b>2022</b> , 12, 964 |   |
| 310 | Clinical grade ACE2 as a universal agent to block SARS-CoV -2 variants.   | 4 |
| 309 | Trimeric Receptor Binding Domain of SARS-CoV-2 Acts as a Potent Inhibitor of ACE2 Receptor-Mediated Viral Entry. <b>2022</b> , 104716   | 0 |
| 308 | Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. 1-21  | 0 |
| 307 | Animal models for COVID-19: advances, gaps and perspectives. <b>2022</b> , 7,   | 4 |
| 306 | NMR Experiments Provide Insights into Ligand-Binding to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.   | 0 |
| 305 | Impact of the temperature on the interactions between common variants of the SARS-CoV-2 receptor binding domain and the human ACE2. <b>2022</b> , 12,   |   |
| 304 | Identification of Surface Glycoprotein Mutations of SARS-CoV-2 in Isolated Strains from Iraq. <b>2022</b> , 24, 729-740   | 0 |
| 303 | SARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites. <b>2022</b> , 2022, 1-14   | 1 |
| 302 | Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells.   | 0 |
| 301 | Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. <b>2022</b> , 17, e0271066  | 1 |
| 300 | Painless Subacute Thyroiditis in a Patient With Acute COVID-19 Infection: A Transient Event. <b>2022</b> ,  | 0 |
| 299 | Potential autonomic nervous system dysfunction in COVID-19 patients detected by heart rate variability is a sign of SARS-CoV-2 neurotropic features.  | 0 |
| 298 | A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant. <b>2022</b> , 96,   |   |
| 297 | Therapeutic potential of P2X7 purinergic receptor modulation in the main organs affected by the COVID-19 cytokine storm. <b>2022</b> , 28,  | 1 |
| 296 | Vascular Endothelial Growth Factor Receptor, fms-Like Tyrosine Kinase-1 (Flt-1), as a Novel Binding Partner for SARS-CoV-2 Spike Receptor-Binding Domain. 13,   | 0 |



|     |   |   |
|-----|---|---|
| 295 | Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2. <b>2022</b> , 17, e0271112 | 3 |
| 294 | Analysis of ACE2 and TMPRSS2 coding variants as a risk factor for SARS-CoV-2 from 946 whole exome sequencing data in the Turkish Population.  | 0 |
| 293 | Lineage-specific positive selection on ACE2 contributes to the genetic susceptibility of COVID-19.  |   |
| 292 | Significance of chlorine dioxide-based oral rinses in preventing SARS-CoV -2 cell entry.  |   |
| 291 | Kidney organoid research: current status and applications. <b>2022</b> , 75, 101944   | 2 |
| 290 | Cell tropism and viral clearance during SARS-CoV-2 lung infection. <b>2022</b> , 236, 154000  |   |
| 289 | Allosteric inhibitors of the main protease of SARS-CoV-2. <b>2022</b> , 205, 105381   | 6 |
| 288 | Immunization with 674885 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice. <b>2022</b> , 622, 57-63   | 1 |
| 287 | Coronaviruses. <b>2023</b> , 277-306  |   |
| 286 | Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis. <b>2022</b> , 17, e0270627  | 1 |
| 285 | N- glycoproteomic profiling revealing novel coronavirus therapeutic targets potentially involved in Cepharanthine intervention. <b>2022</b> , 100156  | 0 |
| 284 | Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. <b>2022</b> , 10, 1731  | 1 |
| 283 | Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies. <b>2022</b> , 28,  | 0 |
| 282 | Immunopathology of COVID-19 and its implications in the development of rhino-orbital-cerebral mucormycosis: a major review. 1-10  |   |
| 281 | Hydroxytyrosol Recovers SARS-CoV-2-PLpro-Dependent Impairment of Interferon Related Genes in Polarized Human Airway, Intestinal and Liver Epithelial Cells. <b>2022</b> , 11, 1466  | 2 |
| 280 | Imaging Techniques: Essential Tools for the Study of SARS-CoV-2 Infection. 12,  | 0 |
| 279 | In Silico Analysis of the Effects of Omicron Spike Amino Acid Changes on the Interactions with Human Proteins. <b>2022</b> , 27, 4827   | 0 |
| 278 | Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. <b>2022</b> , 23, 8485  | 1 |

|     |  |   |
|-----|--|---|
| 277 | SARS-CoV-2 infection threatening intestinal health: A review of potential mechanisms and treatment strategies. 1-19  | 1 |
| 276 | Sequence Similarity Network Analysis Provides Insight into the Temporal and Geographical Distribution of Mutations in SARS-CoV-2 Spike Protein. <b>2022</b> , 14, 1672                                 |   |
| 275 | Good Practices to Counteract Epidemic Emergency in Mining Companies in Poland. <b>2022</b> , 15, 5500  | 0 |
| 274 | Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs. <b>2022</b> , 12, 1060                     | 0 |
| 273 | A potent virucidal activity of functionalized TiO <sub>2</sub> nanoparticles adsorbed with flavonoids against SARS-CoV-2.  | 0 |
| 272 | Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test. <b>2022</b> , 12, 1924                                       | 2 |
| 271 | Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines. <b>2022</b> , 2,   | 1 |
| 270 | Identification of antiviral peptide inhibitors for $\alpha$ receptor binding domain of SARS-CoV-2 omicron and its sub-variants: an in-silico approach. <b>2022</b> , 12,                               | 0 |
| 269 | Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. <b>2022</b> , 3,   | 2 |
| 268 | Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape. <b>2022</b> , 13,   | 7 |
| 267 | Density functional theory computation of the binding free energies between various mutations of SARS-CoV-2 RBD and human ACE2: molecular level roots of the contagiousness. <b>2022</b> , 8, e10128    | 1 |
| 266 | Role of the Pangolin in Origin of SARS-CoV-2: An Evolutionary Perspective. <b>2022</b> , 23, 9115  |   |
| 265 | Co-existence and co-infection of influenza A viruses and coronaviruses: public health challenges. <b>2022</b> , 100306   | 0 |
| 264 | An engineered SARS-CoV-2 receptor-binding domain produced in <i>Pichia pastoris</i> as a candidate vaccine antigen. <b>2022</b> ,  | 1 |
| 263 | Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. | 0 |
| 262 | Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants.  | 2 |
| 261 | MR-proADM Biomarker Predicts COVID-19 Clinical Outcomes: a US-based Cohort Study.  | 1 |
| 260 | Viral Dynamic Surveillance in COVID-19 Patients: A Cohort Study. <b>2022</b> , 2022, 1-10  |   |

259 Phytoncides could potentially inhibit the spike protein of SARS-CoV -2 variants.

258 Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis. 1

257 Bilateral Psoas Haematoma Following Extracorporeal Membranous Oxygenation in a Patient with Severe COVID-19 (SARS CoV-2). A Rare Case Report and Literature Review..

256 Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. **2022**, 15, 1002 0

255 Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2. **2022**, 167, 1931-1946 2

254 In vitro high-content tissue models to address precision medicine challenges. **2022**, 101108

253 Screening of cell-virus, cell-cell, gene-gene crosstalk among animal kingdom at single cell resolution. **2022**, 12,

252 Detection of COVID-19-related biomarkers by electrochemical biosensors and potential for diagnosis, prognosis, and prediction of the course of the disease in the context of personalized medicine. 1

251 Humanized mice for investigating SARS-CoV-2 lung infection and associated human immune responses. 0

250 An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection. 3

249 Recognition in the Domain of Molecular Chirality: From Noncovalent Interactions to Separation of Enantiomers. **2022**, 122, 13235-13400 7

248 Structural and Phylogenetic Analysis of SARS-CoV-2 Spike Glycoprotein from the Most Widespread Variants. **2022**, 12, 1245 2

247 Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs.

246 Core fucose-specific Pholiota squarrosa lectin ( PhoSL ) as a potent broad-spectrum inhibitor of SARS-CoV -2 infection.

245 Genome Similarities between Human-Derived and Mink-Derived SARS-CoV-2 Make Mink a Potential Reservoir of the Virus. **2022**, 10, 1352 0

244 Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2. **2022**, 3

243 Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. **2022**, 25, 104935 2

242 Decoding molecular factors shaping human angiotensin converting enzyme 2 receptor usage by spike glycoprotein in lineage B beta-coronaviruses. **2022**, 1868, 166514

|     |  |   |
|-----|--|---|
| 241 | Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2. <b>2023</b> , 251, 123813  | 0 |
| 240 | Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <b>2022</b> , 8, | 1 |
| 239 | SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. <b>2022</b> , 19,   | 5 |
| 238 | A Positron Emission Tomography Tracer Targeting the S2 Subunit of SARS-CoV-2 in Extrapulmonary Infections.   | 0 |
| 237 | Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening. <b>2022</b> , 321, 198915   | 0 |
| 236 | Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection. <b>2022</b> , 367, 110179                         | 1 |
| 235 | RBD spatial orientation of the spike protein and its binding to ACE2: insight into the high infectivity of the SARS-CoV-2 Delta variant from MD simulations.                                 | 0 |
| 234 | Development of optical biosensors for the diagnosis of pathogens. <b>2022</b> , 137-168  | 0 |
| 233 | In silico investigation and identification of bioactive compounds from medicinal plants as potential inhibitors against SARS-CoV-2 cellular entry. <b>2022</b> , 355-376                     | 0 |
| 232 | Covid-19, nervous system pathology, and Parkinson's disease: Bench to bedside. <b>2022</b> , 17-34   | 0 |
| 231 | Omicron Coronavirus Variant: pH-Dependent Electrostatic Potentials and Energy of Association of S-Protein to ACE2 Receptor.  | 0 |
| 230 | Systematic Review of the SARS-CoV-2 Viral Vector Vaccine AstraZeneca (Azd1222). <b>2022</b> , 4,   | 0 |
| 229 | Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome. <b>2022</b> , 14, 596   | 1 |
| 228 | Structural Insights into Binding of Remdesivir Triphosphate within the Replication-Transcription Complex of SARS-CoV-2. <b>2022</b> , 61, 1966-1973  | 0 |
| 227 | A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery. <b>2022</b> , 7,  | 1 |
| 226 | Redox stress in COVID-19: Implications for hematologic disorders. <b>2022</b> , 101373   | 0 |
| 225 | Nanoparticle assembled structures for matter assays in human flowing systems. <b>2022</b> , 5, 2760-2786   | 0 |
| 224 | Time evolution of cytokine profiles associated with mortality in COVID-19 hospitalized patients. 13,   | 0 |

|     |  |   |
|-----|--|---|
| 223 | Title: BEYOND COVID-19 AND SARS-CoV-2, CARDIOVASCULAR OUTCOMES OF [LONG COVID] FROM A PATHOLOGICAL PERSPECTIVE [A LOOK BACK AND ROAD AHEAD. <b>2022</b> , 154144   | 1 |
| 222 | Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2. 9,  | 0 |
| 221 | Host adaptation of codon usage in SARS-CoV-2 from mammals indicates potential natural selection and viral fitness.   | 1 |
| 220 | Electrostatic Features for the Receptor Binding Domain of SARS-COV-2 Wildtype and Its Variants. Compass to the Severity of the Future Variants with the Charge-Rule. <b>2022</b> , 126, 6835-6852  | 1 |
| 219 | Atomistic Simulations and Network-Based Energetic Profiling of Binding and Allostery in the SARS-CoV-2 Spike Omicron BA.1, BA.1.1, BA.2 and BA.3 Subvariant Complexes with the Host Receptor: Revealing Hidden Functional Roles of the Binding Hotspots in Mediating Epistatic Effects and Long-Range Communication with Allosteric Pockets. | 0 |
| 218 | Probing Mechanisms of Binding and Allostery in the SARS-CoV-2 Spike Omicron Variant Complexes with the Host Receptor: Revealing Functional Roles of the Binding Hotspots in Mediating Epistatic Effects and Communication with Allosteric Pockets. <b>2022</b> , 23, 11542   | 2 |
| 217 | SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages.  | 4 |
| 216 | Immunogenicity of two doses of BNT162b2 and mRNA -1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV -2 infection.   | 0 |
| 215 | The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. <b>2022</b> , 25, 105016  | 0 |
| 214 | Designing In-House SARS-CoV-2 RT-qPCR Assay for Variant of Concerns. <b>2022</b> , 09, 252-257   | 1 |
| 213 | Identification and characterization of a novel cell binding and cross-reactive region on spike protein of SARS-CoV-2. <b>2022</b> , 12,  | 0 |
| 212 | Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. 1-30  | 0 |
| 211 | Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells.   | 0 |
| 210 | Diffusion-Induced Ingress of Angiotensin-Converting Enzyme 2 into the Charge Conducting Path of a Pentacene Channel for Efficient Detection of SARS-CoV-2 in Saliva Samples.   | 0 |
| 209 | Atorvastatin efficacy in the management of mild to moderate hospitalized COVID-19: a pilot randomized triple-blind placebo-controlled clinical trial. <b>2022</b> , 17,  | 3 |
| 208 | Electrostatics in Computational Biophysics and Its Implications for Disease Effects. <b>2022</b> , 23, 10347   | 0 |
| 207 | Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea. <b>2022</b> ,   | 0 |
| 206 | Computation of the Binding Energies between Human ACE2 and Spike RBDs of the Original Strain, Delta and Omicron Variants of the SARS-CoV-2: A DFT Simulation Approach. 2200337   | 0 |

|     |  |   |
|-----|--|---|
| 205 | Severe Acute Respiratory Syndrome Coronavirus 2 Associated Blepharconjunctivitis and Erythema Multiforme-Like Rash in a Young Man. <b>2022</b> , Publish Ahead of Print,                 | 0 |
| 204 | RBD-ACE2 binding properties in five SARS-CoV-2 variants of concern with new perspectives in the design of pan-coronavirus peptide inhibitors. <b>2022</b> ,                              | 0 |
| 203 | Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2. <b>13</b> , | 0 |
| 202 | Epistatic Variations in the Omicron Receptor Binding Domain Can Enhance Host Recognition: An In Silico Assessment and Prediction. <b>2022</b> , <b>13</b> , 8808-8815                    | 0 |
| 201 | The COVID-19 pandemic and Alzheimer's disease: mutual risks and mechanisms. <b>2022</b> , <b>11</b> ,  | 2 |
| 200 | Delta variant: Partially sensitive to vaccination, but still worth global attention. <b>2022</b> , <b>10</b> , 227-235   | 0 |
| 199 | Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case.                                | 0 |
| 198 | Recent advances in small-molecular therapeutics for COVID-19.  | 0 |
| 197 | Subtyping of major SARS-CoV-2 variants reveals different transmission dynamics based on 10 million genomes.  | 0 |
| 196 | SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. <b>4</b> ,  | 0 |
| 195 | The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis. <b>2022</b> , <b>17</b> , e0267423                            | 0 |
| 194 | Effect of Disulfide Bridge on the Binding of SARS-CoV-2 Fusion Peptide to Cell Membrane: A Coarse-Grained Study.   | 1 |
| 193 | Molecular-Level Targets for the Development of Therapies Against Coronavirus Diseases. <b>2021</b> , 69-84   | 0 |
| 192 | Biological effect of black phosphorus nanosheets to the interaction between SARS-CoV-2 S protein and ACE2.   | 0 |
| 191 | COVID-19 mitigation: Nanotechnological intervention, perspective, and future scope.  | 0 |
| 190 | Multidistrict Host-Pathogen Interaction during COVID-19 and the Development Post-Infection Chronic Inflammation. <b>2022</b> , <b>11</b> , 1198  | 0 |
| 189 | A snapshot of protein trafficking in SARS-CoV-2 infection.   | 1 |
| 188 | Proviral role of human respiratory epithelial cell-derived small extracellular vesicles in SARS-CoV-2 infection. <b>2022</b> , <b>11</b> ,   | 2 |

|     |   |   |
|-----|---|---|
| 187 | Cell Entry and Unusual Replication of SARS-CoV2. <b>2022</b> , 24,  | 0 |
| 186 | The SARS-CoV-2 S1 Spike Protein Promotes MAPK and NF- $\kappa$ B Activation in Human Lung Cells and Inflammatory Cytokine Production in Human Lung and Intestinal Epithelial Cells. <b>2022</b> , 10, 1996              | 0 |
| 185 | Atomistic insights into the binding of SARS-CoV-2 spike receptor binding domain with the human ACE2 receptor: The importance of residue 493. <b>2022</b> , 108360   | 0 |
| 184 | Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods. <b>2022</b> , 14, 1109-1140  | 0 |
| 183 | SARS-CoV-2 downregulates ACE2 through lysosomal degradation.  | 1 |
| 182 | SARS-CoV-2 Spike Protein (RBD) Subunit Adsorption at Abiotic Surfaces and Corona Formation at Polymer Particles. <b>2022</b> , 23, 12374  | 0 |
| 181 | Single-Cell Immunobiology of the Maternal-Fetal Interface. <b>2022</b> , 209, 1450-1464   | 3 |
| 180 | COVID-19 and hepatorenal syndrome. 28, 5666-5678  | 0 |
| 179 | Antiviral drug design based on structural insights into the N-terminal domain and C-terminal domain of the SARS-CoV-2 nucleocapsid protein. <b>2022</b> ,   | 0 |
| 178 | Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection. <b>2022</b> , 7,  | 2 |
| 177 | An Update on Detection Technologies for SARS-CoV-2 Variants of Concern. <b>2022</b> , 14, 2324  | 2 |
| 176 | Effects of a Shift of the Signal Peptide Cleavage Site in Signal Peptide Variant on the Synthesis and Secretion of SARS-CoV-2 Spike Protein. <b>2022</b> , 27, 6688   | 1 |
| 175 | A Deletion Encompassing the Furin Cleavage Site in the Spike Encoding Gene Does Not Alter SARS-CoV-2 Replication in Lung Tissues of Mink and Neutralization by Convalescent Human Serum Samples. <b>2022</b> , 11, 1152 | 0 |
| 174 | LRRC15 inhibits SARS-CoV-2 cellular entry in trans. <b>2022</b> , 20, e3001805  | 1 |
| 173 | Vimentin is an important ACE2 co-receptor for SARS-CoV-2 in epithelial cells. <b>2022</b> , 105463  | 1 |
| 172 | COVID-19 Vaccination in Kidney Transplant Candidates and Recipients. <b>2022</b> , 10, 1808   | 0 |
| 171 | Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of SARS-CoV -2. <b>2022</b> , 31,  | 0 |
| 170 | Stability and expression of SARS-CoV-2 spike-protein mutations.   | 0 |

|     |  |   |
|-----|--|---|
| 169 | Investigation of SARS-CoV-2 lineages and mutations circulating in a university-affiliated hospital in South Korea analyzed using Oxford Nanopore MinION sequencing. <b>2022</b> , 13, 360-369  | 0 |
| 168 | Cheminformatics Bioprospection of Broad Spectrum Plant Secondary Metabolites Targeting the Spike Proteins of Omicron Variant and Wild-Type SARS-CoV-2. <b>2022</b> , 12, 982   | 0 |
| 167 | SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact. <b>2022</b> , 5,  | 3 |
| 166 | High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2. <b>2022</b> , 10, 2779 | 0 |
| 165 | A peptide array pipeline for the development of Spike-ACE2 interaction inhibitors. <b>2022</b> , 158, 170898   | 1 |
| 164 | Novel coronavirus mutations: Vaccine development and challenges. <b>2022</b> , 173, 105828   | 1 |
| 163 | In silico study identifies peptide inhibitors that negate the effect of non-synonymous mutations in major drug targets of SARS-CoV-2 variants. 1-11  | 0 |
| 162 | Infrared spectra of the SARS-CoV-2 spike receptor-binding domain: Molecular dynamics simulations. <b>2022</b> , 140176   | 0 |
| 161 | Proteolysis and Deficiency of $\beta$ -Proteinase Inhibitor in SARS-CoV-2 Infection. <b>2022</b> , 16, 271-291   | 0 |
| 160 | Efficient SARS-CoV-2 detection utilizing chitin-immobilized nanobodies synthesized in <i>Ustilago maydis</i> .   | 0 |
| 159 | Correlation between structural heart disease and cardiac SARS-CoV-2 manifestations. <b>2022</b> , 2,   | 1 |
| 158 | The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study. <b>2022</b> , 23, 13502                         | 0 |
| 157 | Modeling studies on the role of vitamins B1 (thiamin), B3 (nicotinamide), B6 (pyridoxamine), and caffeine as potential leads for the drug design against COVID-19. <b>2022</b> , 28,   | 0 |
| 156 | Structural Effects of Spike Protein D614G Mutation in SARS-CoV-2. <b>2022</b> ,  | 0 |
| 155 | Towards potent Covid-19 spike protein inhibitors and catecholase activity agents: Synthesis, ADME-Tox analysis and molecular docking of new 1,2,4- triazole-based molecules.   | 0 |
| 154 | SARS-CoV-2 variants of concerns in animals: An unmonitored rising health threat.   | 0 |
| 153 | Micro-second Time-resolved X-ray Single-molecule Internal Motions of SARS-CoV-2 Spike Variants.  | 0 |
| 152 | Computational search for potential COVID-19 drugs from ayurvedic medicinal plants to identify potential inhibitors against SARS-CoV-2 targets. <b>2022</b> , 19,   | 1 |



|     |   |   |
|-----|---|---|
| 151 | Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery.   | 2 |
| 150 | Alcohol use disorder as a potential risk factor for COVID -19 severity: A narrative review.   | 0 |
| 149 | Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. <b>2022</b> , 17, e0277745   | 0 |
| 148 | A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant.  | 1 |
| 147 | Effect of N343 glycosylation and N501Y mutation on the SARS-CoV-2 spike protein: Modeling and MD Simulations. <b>2022</b> ,   | 0 |
| 146 | Pyroptosis in the lung and spleen of patients died from COVID-19. <b>2022</b> , 20, 1721727X2211406   | 0 |
| 145 | Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2. <b>2023</b> , 87, 104401  | 0 |
| 144 | Mutation and SARS-CoV-2 strain competition under vaccination in a modified SIR model. <b>2023</b> , 166, 112964   | 0 |
| 143 | Inhibitory activities of alginate phosphate and sulfate derivatives against SARS-CoV-2 in vitro. <b>2023</b> , 227, 316-328   | 0 |
| 142 | Polymer modification of SARS-CoV-2 spike protein impacts its ability to bind key receptor. <b>2023</b> , 184, 111767  | 0 |
| 141 | Development of receptor binding domain-based double-antigen sandwich lateral flow immunoassay for the detection and evaluation of SARS-CoV-2 neutralizing antibody in clinical sera samples compared with the conventional virus neutralization test. <b>2023</b> , 255, 124200           | 0 |
| 140 | A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. <b>2022</b> , 37, 1  | 0 |
| 139 | Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study. <b>2022</b> ,   | 0 |
| 138 | Photoacoustic Detection of Nuclei Acid-Containing Water Droplets. <b>2022</b> ,   | 0 |
| 137 | Prevalence of Human Coronaviruses in Children and Phylogenetic Analysis of HCoV-OC43 during 2016-2022 in Riyadh, Saudi Arabia. <b>2022</b> , 14, 2592   | 0 |
| 136 | An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. 13, | 0 |
| 135 | An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. 13,   | 1 |
| 134 | A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. 13,  | 0 |

- 133 Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants. **2022**, 23, 14796 1
- 132 COVID-19 and neurological complications: A review. **2021**, 10, 0
- 131 Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. **2022**, 10, 2035 0
- 130 Secondary conformation of MERS-CoV, SARS-CoV and SARS-CoV-2 Spike Proteins revealed by Infrared Vibrational Spectroscopy. 0
- 129 Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen. 1
- 128 Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. 10, 0
- 127 In silico study of SARS-CoV-2 Spike protein RBD and human ACE-2 affinity dynamics across variants and Omicron sub-variants. 0
- 126 The SARS-CoV-2 spike protein binds and modulates estrogen receptors. **2022**, 8, 2
- 125 Inhalable SARS-CoV-2 vaccines for single-dose dry-powder aerosol immunization and orchestrated mucosal/systemic immune responses. 0
- 124 Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. 0
- 123 Development of Electrochemical Biosensor Platforms for Determination of Environmental Viral Structures. **2022**, 12, 12971 0
- 122 Precise Detection on Cell-Cell Fusion by a Facile Molecular Beacon-Based Method. **2022**, 94, 17334-17340 0
- 121 Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel $\square$  85 Protects K18-hACE2 Mice against Lethal Virus Challenge. **2022**, 10, 2119 0
- 120 Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases. **2022**, 12, 1226 0
- 119 HBD-2 variants and SARS-CoV-2: New insights into inter-individual susceptibility. 13, 0
- 118 Development of Fluorescence-Tagged SARS-CoV-2 Virus-like Particles by a Tri-Cistronic Vector Expression System for Investigating the Cellular Entry of SARS-CoV-2. **2022**, 14, 2825 0
- 117 Dengue and COVID-19 co-infections: an important consideration in the tropics. 0
- 116 IRAA : A statistical tool for investigating a protein-protein interaction interface from multiple structures. **2023**, 32, 0

|     |  |   |
|-----|--|---|
| 115 | Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2. <b>2022</b> , 13,  | 1 |
| 114 | Network analysis uncovers the communication structure of SARS-CoV-2 Spike protein identifying sites for immunogen design. <b>2022</b> , 105855   | 0 |
| 113 | Plant production of high affinity nanobodies that block SARS-CoV-2 spike protein binding with its receptor, human angiotensin converting enzyme. 10,   | 0 |
| 112 | The third inactivated vaccine booster dramatically enhanced SARS-CoV-2 antibody responses and did not influence the profile of prothrombotic antibody. <b>2023</b> , 95,   | 0 |
| 111 | Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment. <b>2022</b> , 12, 2117   | 0 |
| 110 | Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017. <b>2022</b> , 41, 111831  | 0 |
| 109 | Clinical features of elderly patients with COVID-19 in Wuhan, China. 10, 12890-12898   | 0 |
| 108 | Polymorphisms in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2 Genes Are Associated with Worse Clinical Outcomes in COVID-19. <b>2023</b> , 14, 29  | 2 |
| 107 | Potential antiviral peptides targeting the SARS-CoV-2 spike protein. <b>2022</b> , 23,   | 1 |
| 106 | Preclinical Toxicity and Immunogenicity of a COVID-19 Vaccine (ZF2001) in Cynomolgus Monkeys. <b>2022</b> , 10, 2080   | 0 |
| 105 | Near-Native Visualization of SARS-CoV-2 Induced Membrane Remodeling and Virion Morphogenesis. <b>2022</b> , 14, 2786   | 0 |
| 104 | Host range and structural analysis of bat-origin RshSTT182 /200 coronavirus binding to human ACE2 and its animal orthologs.  | 0 |
| 103 | Identification of anti-SARS-CoV-2 agents based on flavor/fragrance compositions that inhibit the interaction between the virus receptor binding domain and human angiotensin converting enzyme 2. <b>2022</b> , 17, e0279182 | 0 |
| 102 | Drug Repurposing: a Shortcut to New Biological Entities. <b>2022</b> , 56, 1203-1214   | 0 |
| 101 | Thermodynamic analysis of the interactions between human ACE2 and spike RBD of Betacoronaviruses ( SARS-CoV -1 and SARS-CoV -2).   | 0 |
| 100 | A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. <b>2022</b> , 8,                                | 0 |
| 99  | The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD-ACE2 Binding Interface. <b>2022</b> , 27, 8938  | 0 |
| 98  | Molecular mechanisms implicated in SARS-CoV-2 liver tropism. 28, 6875-6887   | 0 |

- 97 Targeting SARS-CoV-2 and host cell receptor interactions. **2022**, 105514 ○
- 96 COVID Vaccination for Children: A Literature Review. **2022**, 4, 13-17 ○
- 95 Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. **2023**, 100918 ○
- 94 Use of Antiviral Agents and other Therapies for COVID-19. **2023**, 44, 118-129 ○
- 93 COVID-19 and hepatic injury: Diversity and risk assessment. 29, 425-449 ○
- 92 Artemisia argyi potentially prevents the infections with SARS-CoV-2 variants. ○
- 91 Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. **2023**, 8, 121-134 1
- 90 Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease. ○
- 89 Discovery of Novel Chinese Medicine Compounds Targeting 3CL Protease by Virtual Screening and Molecular Dynamics Simulation. **2023**, 28, 937 ○
- 88 Intensive Care during the COVID-19 Pandemic. **2023**, 11, 125 ○
- 87 A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics. ○
- 86 A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants. **2023**, 95, 1
- 85 Penetration of Cell Surface Glycocalyx by Enveloped Viruses Is Aided by Weak Multivalent Adhesive Interaction. ○
- 84 Covalent Organic Frameworks (COFs) as Multi-Target Multifunctional Frameworks. **2023**, 15, 267 1
- 83 Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions. **2023**, e12890 ○
- 82 Spatiotemporal changes of tissue glycans depending on localization in cardiac aging. **2023**, 22, 68-78 ○
- 81 From Challenges to Opportunities and Open Questions. **2023**, 87-130 ○
- 80 Safeguarding Against the Analog of Antimicrobial-Resistance Development. **2023**, 163-176 ○

- 79 Viral infection and its management. **2023**, 189-207
- 78 Design of hACE2-based small peptide inhibitors against spike protein of SARS-CoV-2: a computational approach.
- 77 Potential of Lactoferrin in the Treatment of Lung Diseases. **2023**, 16, 192
- 76 A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?.
- 75 A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. **2023**, 19, e1011085
- 74 Synthesis and Characterization of New Mixed-Ligand Complexes; Density Functional Theory, Hirshfeld, and In Silico Assays Strengthen the Bioactivity Performed In Vitro. **2023**, 8, 4220-4233
- 73 Tutorial review on the processing and performance of fabrics with antipathogenic inorganic agents.
- 72 A High-throughput screening system for SARS-CoV-2 entry inhibition, syncytia formation and cell toxicity
- 71 Omics approaches in COVID-19: An overview. **2023**, 3-21
- 70 Hybrid data mining based breast prediction of COVID-19. **2023**,
- 69 Rapidly Progressive Emphysematous Pancreatitis With Massive Hemorrhage and Multi-Organ Failure: A Severe Sequela of COVID-19. **2023**,
- 68 Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. **2023**, 15, 451
- 67 The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells. **2023**, 15, 332
- 66 Magnetic Resonance Imaging of Cardiovascular Manifestations Following COVID -19.
- 65 SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?. **2023**, 21,
- 64 Adaptive evolution of the Spike protein in coronaviruses.
- 63 In silico targeting of SARS-CoV-2 spike receptor-binding domain from different variants with chaga mushroom terpenoids. 1-9
- 62 Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RABD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus. **2023**, 9, e15032

- 61 Zebrafish-based platform for emerging bio-contaminants and virus inactivation research. **2023**, 872, 162197 ○
- 60 Identification of natural peptides from PlantPepDB database as anti-SARS-CoV-2 agents: A protein-protein docking approach. **2023**, 3, 100446 ○
- 59 The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2. **2023**, 213, 105590 ○
- 58 Gold-silver alloy hollow nanoshells-based lateral flow immunoassay for colorimetric, photothermal, and SERS tri-mode detection of SARS-CoV-2 neutralizing antibody. **2023**, 1255, 341102 ○
- 57 The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex. ○
- 56 SARS-CoV-2 Spike Protein Post-Translational Modification Landscape and Its Impact on Protein Structure and Function via Computational Prediction. **2023**, 6, ○
- 55 Radiological Evidence of Testicular Damage in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Sonoelastography's Potential Role. Publish Ahead of Print, ○
- 54 Interactions between Humans and Dogs during the COVID-19 Pandemic: Recent Updates and Future Perspectives. **2023**, 13, 524 ○
- 53 Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. ○
- 52 On the Sensitivity and Affinity of Gold, Silver, and Platinum Surfaces against the SARS-CoV-2 Virus: A Comparative Computational Study. **2023**, 63, 1276-1292 ○
- 51 Urological complications of COVID-19: a systematic review. **2023**, 49, 24-40 ○
- 50 Comparison of truncated human angiotensin-converting enzyme 2 (hACE2) expression in pET28a(+) versus pET-SUMO vector and two Escherichia coli strains. **2023**, 68, 61-70 ○
- 49 Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome. **2023**, 12, 393 ○
- 48 A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site. **2023**, 11, 371 ○
- 47 Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern. **2023**, 95, ○
- 46 Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs. **2023**, 21, e3001967 2
- 45 Aloidin A inhibits SARS CoV-2 replication by targeting its binding with ACE2 - Evidence from modeling-supported molecular dynamics simulation. 1-10 ○
- 44 SARSMutOnto: An Ontology for SARS-CoV-2 Lineages and Mutations. **2023**, 15, 505 ○

- 43 Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. **2023**, 18, e0281689 ○
- 42 Distinct Conformations of SARS-CoV-2 Omicron Spike Protein and Its Interaction with ACE2 and Antibody. **2023**, 24, 3774 ○
- 41 Development and characterization of a multimeric recombinant protein based on the spike protein receptor binding domain of SARS-CoV-2 that can neutralize virus infection. ○
- 40 Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave. **2023**, 20, 3665 ○
- 39 Mutation-driven parallel evolution in emergence of ACE2-utilizing sarbecoviruses. 14, ○
- 38 Analysis of the SARS-CoV-2 spike protein revealed that blocked receptor-binding domain antigenicity decreases the production of neutralizing antibodies in vivo. ○
- 37 Antiviral activity of Humulus lupulus (HOP) aqueous extract against MERS-CoV and SARS-CoV-2: in-vitro and in-silico study. **2023**, 37, 167-179 ○
- 36 Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2. **2023**, 19, ○
- 35 Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. **2023**, 11, 545 ○
- 34 COVID-19 Biogenesis and Intracellular Transport. **2023**, 24, 4523 2
- 33 An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations. **2023**, 117, 109934 ○
- 32 Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. **2023**, 19, 177-184 ○
- 31 Multiple functions of stress granules in viral infection at a glance. 14, ○
- 30 The renin-angiotensin system in the eye. **2023**, 419-447 ○
- 29 Triterpene Derivatives as Potential Inhibitors of the RBD Spike Protein from SARS-CoV-2: An In Silico Approach. **2023**, 28, 2333 ○
- 28 Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 Spike Trimers : Balancing Stability and Adaptability in BA.1, BA.2 and BA.2.75 Variants. ○
- 27 Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells. **2023**, 13, 472 ○
- 26 Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial. **2023**, 15, 1285 ○

- 25 SIM imaging resolves endocytosis of SARS-CoV-2 spike RBD in living cells. **2023**, 30, 248-260.e4 ○
- 24 Cigarette smoke preferentially induces full length ACE2 expression in differentiated primary human airway cultures but does not alter the efficiency of cellular SARS-CoV-2 infection. **2023**, 9, e14383 ○
- 23 Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential. **2023**, 252, 115272 ○
- 22 Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2. **2023**, 95, ○
- 21 Acid sphingomyelinase (ASM) and COVID-19: A review of the potential use of ASM inhibitors against SARS-CoV-2. **2023**, 41, 284-295 ○
- 20 Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. **2023**, 21, 2339-2351 ○
- 19 The Role of Folic Acid in SARS-CoV-2 Infection: An Intriguing Linkage under Investigation. **2023**, 13, 561 ○
- 18 Balancing Functional Tradeoffs between Protein Stability and ACE2 Binding in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB Lineages : Dynamics-Based Network Models Reveal Epistatic Effects Modulating Compensatory Dynamic and Energetic Changes. ○
- 17 An Oral Galectin Inhibitor in COVID-19 Phase II Randomized Controlled Trial. **2023**, 11, 731 ○
- 16 Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants. **2023**, 17, 7017-7034 ○
- 15 Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine. **2023**, 107, 2983-2995 ○
- 14 Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle. ○
- 13 Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. 1-12 ○
- 12 A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB. **2023**, 11, 778 ○
- 11 Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System. **2023**, 11, 771 ○
- 10 Biomimetic SARS-CoV-2 Spike Protein Nanoparticles. ○
- 9 Whole Sequencing and Detailed Analysis of SARS-CoV-2 Genomes in Southeast Spain: Identification of Recurrent Mutations in the 20E (EU1) Variant with Some Clinical Implications. **2023**, 11, 54 ○
- 8 Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 Spike Trimers: Balancing Stability and Adaptability in BA.1, BA.2 and BA.2.75 Variants. **2023**, 24, 6642 ○



- 7 Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection. **2023**, 14, ○
- 6 SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. **2024**, 24-51 ○
- 5 Spatial Distribution of SARS-CoV-2 Receptors and Proteases in Testicular Cells. 002215542311689 ○
- 4 COVID-19: Molecular Pathogenesis and Prospective Therapeutic Interventions. **2023**, 269-294 ○
- 3 High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2. **2023**, 9, ○
- 2 Potent Immunogenicity and Broad-Spectrum Protection Potential of Microneedle Array Patch-Based COVID-19 DNA Vaccine Candidates Encoding Dimeric RBD Chimera of SARS-CoV and SARS-CoV-2 Variants. ○
- 1 Sex affects immune response capacity against COVID-19 infection. ○